

Official Protocol Title:	A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy
NCT number:	NCT04725188
Document Date:	19 December 2022

Title Page

THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME LLC, RAHWAY, NJ, USA (MSD).

Protocol Title: A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

Protocol Number: 002-02

Compound Number: MK-7684A

Sponsor Name:

Merck Sharp & Dohme LLC
(hereafter called the Sponsor or MSD)

Legal Registered Address:

126 East Lincoln Avenue

P.O. Box 2000

Rahway, NJ 07065 USA

Regulatory Agency Identifying Number(s):

IND	147424
EudraCT	2020-004034-38
EU CT	2022-500420-30-00

Approval Date: 19 December 2022

Sponsor Signatory

Typed Name:
Title:

Date

Protocol-specific Sponsor contact information can be found in the Investigator Study File Binder (or equivalent).

Investigator Signatory

I agree to conduct this clinical study in accordance with the design outlined in this protocol and to abide by all provisions of this protocol.

Typed Name:
Title:

Date

DOCUMENT HISTORY

Document	Date of Issue	Overall Rationale
Amendment 02	19-DEC-2022	Merck Sharp & Dohme Corp. underwent an entity name and address change to Merck Sharp & Dohme LLC, Rahway, NJ, USA. This conversion resulted in an entity name change and update to the address. Additional changes were made throughout to align with the EU CTR and for clarification of study procedures.
Amendment 01	28-FEB-2021	The Dose Modification and Toxicity Management Guidelines for irAEs and table were updated to align with the USPI as requested by the FDA. Also, per FDA's request, added polysorbate 80 as an example of severe hypersensitivity to study treatment.
Original Protocol	19-OCT-2020	Not applicable

PROTOCOL AMENDMENT SUMMARY OF CHANGES

Amendment: 02

Overall Rationale for the Amendments:

Sponsor underwent an entity name change and update to the address. Additional changes were made throughout to align with the EU CTR and for clarification of study procedures.

Summary of Changes Table:

Section # and Name	Description of Change	Brief Rationale
Title Page 10.1.1 Code of Conduct for Clinical Trials Throughout	Sponsor entity name and address change.	Merck Sharp & Dohme Corp. underwent an entity name and address change to Merck Sharp & Dohme LLC, Rahway, NJ, USA. This conversion resulted only in an entity name change and update to the address.
Title Page	Added EU CT number.	Alignment with the EU CTR.
1.3.1 Initial Treatment Phase	Corrected the time window for assessment of ECOG performance status during the screening period before randomization of the participant.	Participants should have ECOG performance status of 0 to 1 assessed within 7 days prior to randomization.
1.3.1 Initial Treatment Phase	Added predose PK samples at Safety Follow-up visit.	Pharmacokinetics samples should be collected for all participants during the Safety Follow-up visit (30 days post last dose).

Section # and Name	Description of Change	Brief Rationale
4.4 Beginning and End of Study Definition	Added statements regarding when the study ends for purposes of analysis and reporting and the EEA local start of study definition.	Alignment with the EU CTR.
5 Study Population	Added text to clarify the collection, use, and confidentiality of demographic data provided by participants.	Alignment with the EU CTR.
5.4 Screen Failures	Deleted the requirement of consultation between the investigator and Sponsor and written documentation for rescreening after screen failure.	Participants may be rescreened after initially failing to meet the inclusion/exclusion criteria.
6.1 Study Intervention(s) Administered	Replaced “NIMP” with “NIMP/AxMP.” In the “Use” column, “Experimental” was replaced with “Test Product.”	Alignment with the EU CTR.
6.5.1 Rescue Medications and Supportive Care	Clarified that participants in the docetaxel arm should receive premedication with corticosteroids for 3 days starting 1 day before docetaxel administration.	Consistency with Section 8.1.8.1.
8.3.2 Vital Signs	Corrected the frequency of BP measurements by removing the requirement for 3 consecutive BP readings at each visit.	Only 1 BP measurement is needed for participants at each visit (unless additional BP measurements are medically indicated by the investigator or medically qualified designee [consistent with local requirements]).

Section # and Name	Description of Change	Brief Rationale
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety Events	Added that investigators need to document if an SAE was associated with a medication error, misuse, or abuse.	Alignment with the EU CTR.
10.3 Appendix 3 Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting	Added a new section with definitions of medication error, misuse, and abuse.	Alignment with the EU CTR.
Throughout Document	Minor administrative, formatting, grammatical, and typographical changes were made throughout the document.	To ensure clarity and accurate interpretation of the intent of the protocol.

Table of Contents

DOCUMENT HISTORY	3
PROTOCOL AMENDMENT SUMMARY OF CHANGES.....	4
1 PROTOCOL SUMMARY	15
1.1 Synopsis.....	15
1.2 Schema	19
1.2.1 Initial Treatment Phase	19
1.2.2 Second Course Treatment Phase.....	20
1.3 Schedule of Activities	21
1.3.1 Initial Treatment Phase	21
1.3.2 Second Course Treatment Phase (Arms 1 and 2 Only)	26
2 INTRODUCTION.....	29
2.1 Study Rationale	29
2.2 Background	31
2.2.1 Pharmaceutical and Therapeutic Background	31
2.2.1.1 MK-7684 Background	31
2.2.1.2 Pembrolizumab Background.....	32
2.2.2 Preclinical and Clinical Studies	32
2.2.2.1 MK-7684A Preclinical Studies	32
2.2.2.2 Pembrolizumab Preclinical and Clinical Studies.....	35
2.2.3 Ongoing Clinical Studies	35
2.2.3.1 MK-7684 Ongoing Clinical Studies	35
2.2.3.2 Pembrolizumab Ongoing Clinical Studies.....	36
2.3 Benefit/Risk Assessment	37
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS	37
4 STUDY DESIGN.....	39
4.1 Overall Design	39
4.2 Scientific Rationale for Study Design.....	41
4.2.1 Rationale for Endpoints	41
4.2.1.1 Efficacy Endpoints.....	41
4.2.1.2 Safety Endpoints	41
4.2.1.3 Pharmacokinetic Endpoints	42
4.2.1.4 Planned Exploratory Biomarker Research.....	42
4.2.1.5 Future Biomedical Research	43
4.2.2 Rationale for the Use of Comparator/Placebo	44
4.3 Justification for Dose	44

4.3.1	MK-7684A	44
4.3.2	Pembrolizumab	45
4.3.3	Maximum Dose/Exposure for This Study	45
4.4	Beginning and End of Study Definition	46
4.4.1	Clinical Criteria for Early Study Termination	46
5	STUDY POPULATION	46
5.1	Inclusion Criteria	47
5.2	Exclusion Criteria	52
5.3	Lifestyle Considerations	54
5.3.1	Meals and Dietary Restrictions	54
5.3.2	Caffeine, Alcohol, and Tobacco Restrictions	54
5.3.3	Activity Restrictions	54
5.4	Screen Failures	54
5.5	Participant Replacement Strategy	54
6	STUDY INTERVENTION	55
6.1	Study Intervention(s) Administered	55
6.2	Preparation/Handling/Storage/Accountability	58
6.2.1	Dose Preparation	58
6.2.2	Handling, Storage, and Accountability	58
6.3	Measures to Minimize Bias: Randomization and Blinding	59
6.3.1	Intervention Assignment	59
6.3.2	Stratification	59
6.3.3	Blinding	59
6.4	Study Intervention Compliance	59
6.5	Concomitant Therapy	60
6.5.1	Rescue Medications and Supportive Care	61
6.6	Dose Modification (Escalation/Titration/Other)	62
6.6.1	Immune-Related Events and Dose Modification (Withhold, Treat, Discontinue)	62
6.6.2	Initial Treatment or First Course	69
6.6.3	Second Course	70
6.7	Intervention After the End of the Study	70
6.8	Clinical Supplies Disclosure	70
6.9	Standard Policies	71
7	DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT WITHDRAWAL	71
7.1	Discontinuation of Study Intervention	71
7.2	Participant Withdrawal From the Study	72

7.3	Lost to Follow-up	72
8	STUDY ASSESSMENTS AND PROCEDURES	73
8.1	Administrative and General Procedures	74
8.1.1	Informed Consent.....	74
8.1.1.1	General Informed Consent.....	74
8.1.1.2	Consent and Collection of Specimens for Future Biomedical Research	74
8.1.2	Inclusion/Exclusion Criteria	75
8.1.3	Participant Identification Card.....	75
8.1.4	Medical History	75
8.1.5	Prior and Concomitant Medications Review	75
8.1.5.1	Prior Medications.....	75
8.1.5.2	Concomitant Medications	75
8.1.6	Assignment of Screening Number	76
8.1.7	Assignment of Treatment/Randomization Number	76
8.1.8	Study Intervention Administration	76
8.1.8.1	Timing of Dose Administration	76
8.1.9	Discontinuation and Withdrawal	77
8.1.9.1	Withdrawal From Future Biomedical Research	77
8.1.10	Participant Blinding/Unblinding.....	77
8.1.11	Calibration of Equipment.....	78
8.1.12	Tumor Tissue for Biomarker Status.....	78
8.2	Efficacy Assessments	78
8.2.1	Tumor Imaging and Assessment of Disease.....	78
8.2.1.1	Initial Tumor Imaging.....	79
8.2.1.2	Tumor Imaging During the Study.....	80
8.2.1.3	End-of-Treatment and Follow-up Tumor Imaging	80
8.2.1.4	Second Course (Retreatment) Tumor Imaging	81
8.2.1.5	RECIST 1.1 Assessment of Disease	81
8.3	Safety Assessments.....	83
8.3.1	Physical Examinations	84
8.3.1.1	Full Physical Examination	84
8.3.1.2	Directed Physical Examination.....	84
8.3.2	Vital Signs.....	84
8.3.3	Electrocardiograms	85
8.3.4	Clinical Safety Laboratory Assessments	85
8.3.4.1	Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis).....	85

8.3.5	Pregnancy Testing.....	85
8.3.6	Eastern Cooperative Oncology Group Performance Status.....	86
8.4	Adverse Events, Serious Adverse Events, and Other Reportable Safety Events	86
8.4.1	Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information	87
8.4.2	Method of Detecting AEs, SAEs, and Other Reportable Safety Events.....	89
8.4.3	Follow-up of AE, SAE, and Other Reportable Safety Event Information...	89
8.4.4	Regulatory Reporting Requirements for SAE	89
8.4.5	Pregnancy and Exposure During Breastfeeding	89
8.4.6	Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or SAEs	90
8.4.7	Events of Clinical Interest.....	90
8.5	Treatment of Overdose.....	90
8.6	Pharmacokinetics.....	91
8.6.1	Blood Collection for Plasma MK-7684 and Pembrolizumab	91
8.6.1.1	Blood Collection for PK	91
8.6.1.2	Blood Collection for Antidrug Antibodies	91
8.7	Pharmacodynamics.....	91
8.8	Biomarkers	91
8.8.1	Planned Genetic Analysis Sample Collection.....	92
8.9	Future Biomedical Research Sample Collection.....	92
8.10	Health Economics Medical Resource Utilization and Health Economics.....	92
8.11	Visit Requirements.....	92
8.11.1	Screening.....	93
8.11.2	Initial Treatment Period	93
8.11.3	Second Course Treatment Phase.....	93
8.11.4	Discontinued Participants Continuing to be Monitored in the Study	93
8.11.5	Posttreatment Visit.....	94
8.11.5.1	Safety Follow-up Visit.....	94
8.11.5.2	Efficacy Follow-up Visits	94
8.11.5.3	Survival Follow-up Contacts	94
8.11.6	Survival Status	95
9	STATISTICAL ANALYSIS PLAN	95
9.1	Statistical Analysis Plan Summary.....	95
9.2	Responsibility for Analyses/In-house Blinding	96
9.3	Hypotheses/Estimation	97
9.4	Analysis Endpoints.....	97

9.4.1	Efficacy Endpoints.....	97
9.4.2	Safety Endpoints	97
9.5	Analysis Populations	98
9.5.1	Efficacy Analysis Populations	98
9.5.2	Safety Analysis Populations	98
9.6	Statistical Methods.....	98
9.6.1	Statistical Methods for Efficacy Analyses	98
9.6.1.1	Progression-free Survival (PFS)	98
9.6.1.2	Objective Response Rate (ORR)	100
9.6.1.3	Overall Survival (OS)	100
9.6.1.4	Duration of Response (DOR).....	101
9.6.1.5	Analysis Strategy for Key Efficacy Variables	101
9.6.2	Statistical Methods for Safety Analyses	102
9.6.3	Demographic and Baseline Characteristics	104
9.7	Interim Analyses	104
9.8	Multiplicity	105
9.9	Sample Size and Power Calculations	105
9.10	Subgroup Analyses.....	106
9.11	Compliance (Medication Adherence).....	106
9.12	Extent of Exposure.....	106
10	SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS	107
10.1	Appendix 1: Regulatory, Ethical, and Study Oversight Considerations	107
10.1.1	Code of Conduct for Clinical Trials.....	107
10.1.2	Financial Disclosure.....	109
10.1.3	Data Protection.....	109
10.1.3.1	Confidentiality of Data	110
10.1.3.2	Confidentiality of Participant Records.....	110
10.1.3.3	Confidentiality of IRB/IEC Information.....	110
10.1.4	Committees Structure.....	111
10.1.4.1	Steering Committee	111
10.1.4.2	Executive Oversight Committee	111
10.1.4.3	External Data Monitoring Committee	111
10.1.5	Publication Policy	111
10.1.6	Compliance with Study Registration and Results Posting Requirements	112
10.1.7	Compliance with Law, Audit, and Debarment	112
10.1.8	Data Quality Assurance	113
10.1.9	Source Documents	114

10.1.10	Study and Site Closure.....	114
10.2	Appendix 2: Clinical Laboratory Tests.....	115
10.3	Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.....	117
10.3.1	Definitions of Medication Error, Misuse, and Abuse	117
10.3.2	Definition of AE	117
10.3.3	Definition of SAE	118
10.3.4	Additional Events Reported in the Same Manner as SAE.....	120
10.3.5	Recording AE and SAE	120
10.3.6	Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor	123
10.4	Appendix 4: Medical Device and Drug-device Combination Products: Product Quality Complaints/Malfunctions: Definitions, Recording, and Follow-up	125
10.5	Appendix 5: Contraceptive Guidance.....	126
10.5.1	Definitions.....	126
10.5.2	Contraception Requirements.....	127
10.6	Appendix 6: Collection and Management of Specimens for Future Biomedical Research.....	128
10.7	Appendix 7: Country-specific Requirements	133
10.7.1	Argentina-specific Requirements.....	133
10.7.2	France-specific Requirements.....	133
10.7.3	Germany-specific Requirements.....	134
10.8	Appendix 8: Eastern Cooperative Oncology Group Performance Status....	135
10.9	Appendix 9: Abbreviations	136
11	REFERENCES.....	141

LIST OF TABLES

Table 1	Study Schedule of Activities – Initial Treatment Phase	21
Table 2	Study Schedule of Activities - Second Course Treatment Phase	26
Table 3	Adequate Organ Function Laboratory Values	51
Table 4	Study Interventions	56
Table 5	Dose Modification and Toxicity Management Guidelines for Immune-related Adverse Events Associated with Pembrolizumab Monotherapy, Coformulations or IO Combinations	64
Table 6	MK-7684A Infusion Reaction Dose Modification and Treatment Guidelines	68
Table 7	Reporting Time Periods and Time Frames for Adverse Events and Other Reportable Safety Events.....	88
Table 8	Censoring Rules for Primary and Sensitivity Analyses of PFS	100
Table 9	Censoring Rules for DOR.....	101
Table 10	Analysis Strategy for Key Efficacy Variables	102
Table 11	Analysis Strategy for Safety Parameters.....	104
Table 12	Protocol-required Safety Laboratory Assessments	115

LIST OF FIGURES

Figure 1 Initial Treatment Schema.....19

Figure 2 Second Course Schema.....20

Figure 3 Results of a Dose Titration Study of Anti-TIGIT 18G10-IgG2a in the
MC38 Colon Carcinoma Mouse Model.....33

Figure 4 Antitumor Efficacy of Anti-TIGIT 18G10-IgG2a as a Single Agent
and in Combination With Anti-PD-1(muDX400) Therapy in the
Murine Subcutaneous CT26 Colon Carcinoma Tumor-bearing Model34

Figure 5 Decision-Making Process When Progression Observed by Investigator ..83



1 PROTOCOL SUMMARY

1.1 Synopsis

Protocol Title: A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

Short Title: MK-7684A or MK-7684A plus docetaxel versus docetaxel for metastatic NSCLC after platinum doublet chemotherapy and immunotherapy

Acronym: MK-7684A-002

Hypotheses, Objectives, and Endpoints:

Male/female participants with metastatic NSCLC with progressive disease after treatment with a platinum doublet chemotherapy and immunotherapy who are 18 years of age or older may be enrolled in this study.

Primary Objectives	Primary Endpoints
<ul style="list-style-type: none">- Objective: To compare MK-7684A + docetaxel to normal saline placebo + docetaxel with respect to PFS per RECIST 1.1 by BICR.- Hypothesis (H1): MK-7684A + docetaxel is superior to normal saline placebo + docetaxel with respect to PFS per RECIST 1.1 by BICR.- Objective: To compare MK-7684A to normal saline placebo + docetaxel with respect to PFS per RECIST 1.1 as assessed by BICR.- Hypothesis (H2): MK-7684A is superior to normal saline placebo + docetaxel with respect to PFS per RECIST 1.1 by BICR.	<ul style="list-style-type: none">- PFS: The time from randomization to the first documented disease progression or death due to any cause, whichever occurs first.
Secondary Objectives	Secondary Endpoints
<ul style="list-style-type: none">- To evaluate ORR in participants treated with MK-7684A + docetaxel, MK-7684A, or normal saline placebo + docetaxel per RECIST 1.1 by BICR.	<ul style="list-style-type: none">- Objective response: defined as a confirmed CR or PR.

- To evaluate OS in participants treated with MK-7684A + docetaxel, MK-7684A, or normal saline placebo + docetaxel.	- OS: defined as the time from randomization to the date of death due to any cause.
- To evaluate DOR per RECIST 1.1 as assessed by BICR in participants treated with MK-7684A + docetaxel, MK-7684A, or normal saline placebo + docetaxel.	- DOR: for participants who demonstrate confirmed CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
- To evaluate the safety and tolerability in participants treated with MK-7684A + docetaxel, MK-7684A, or normal saline placebo + docetaxel.	- AEs. - Discontinuations of study intervention due to an AE.

Overall Design:

Study Phase	Phase 2
Primary Purpose	Treatment
Indication	Metastatic NSCLC
Population	Participants with metastatic NSCLC who have experienced PD after platinum doublet chemotherapy and immunotherapy
Study Type	Interventional
Intervention Model	Parallel This is a multi-site study.
Type of Control	Placebo- and active-control
Study Blinding	Arm 1 and Arm 3: Double-blind with in-house blinding Arm 2: Unblinded Open-label
Blinding Roles	Participants or Subjects Investigator Sponsor
Estimated Duration of Study	The Sponsor estimates that the study will require approximately 5 years from the time the first participant (or their legally acceptable representative) provides documented informed consent until the last participant's last study-related contact.

Number of Participants:

Approximately 240 participants will be randomized in the study, as described in Section 9.1.

Intervention Groups and Duration:

Intervention Groups	Inter- vention Group Name	Drug	Dose Strength	Dose Frequency	Route of Administra- tion	Regimen/ Treatment Period	Use
	Arm 1	MK-7684A	200 mg/ 200 mg ^a	Q3W	IV	Up to 35 cycles	Test Product
		Docetaxel	75 mg/m ²	Q3W	IV	Until a discontinuation criterion is met or as per approved local label	
	Arm 2	MK-7684A	200 mg/ 200 mg ^a	Q3W	IV	Up to 35 cycles	Test Product
	Arm 3	Normal saline placebo	0 mg	Q3W	IV	Up to 35 cycles	Placebo
		Docetaxel	75 mg/m ²	Q3W	IV	Until a discontinuation criterion is met or as per approved local label	Test Product
	Abbreviations: IV = Intravenous; Q3W = Every 3 weeks. a. MK-7684A = coformulated as 200 mg MK-7684 and 200 mg pembrolizumab.						
Total Number of Intervention Groups/ Arms	3						

Duration of Participation	<p>Each participant will participate in the study for approximately 3 years from the time the participant provides documented informed consent through the final contact.</p> <p>After a screening phase of up to 28 days, each participant will be assigned to receive study intervention until disease progression is radiographically documented, per RECIST 1.1 and verified by BICR, confirmed by the site when clinically appropriate, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to discontinue the participant, or administrative reasons requiring cessation of treatment, or until the participant has received 35 administrations of MK-7684A (approximately 2 years). Participants randomized to study intervention with docetaxel may receive docetaxel until a discontinuation criterion is met or as per approved local label. Participants who stop study intervention after receiving 35 administrations of MK-7684A for reasons other than disease progression or intolerability, or participants who attain a complete response and stop study intervention may be eligible for up to 17 additional administrations of MK-7684A (approximately 1 year) upon experiencing disease progression (Section 6.6.3).</p> <p>After the end of treatment, each participant will be followed for the occurrence of adverse events and spontaneously reported pregnancy as described under Section 8.4.</p> <p>Participants who discontinue for reasons other than radiographic disease progression will have post-treatment follow-up imaging for disease status until disease progression is documented radiographically per RECIST 1.1 and verified by BICR, the start of a new anti-cancer treatment, withdrawal of consent, pregnancy, death, or loss to follow-up. All participants will be followed by telephone for overall survival until death, withdrawal of consent, or the end of the study.</p>
---------------------------	---

Study Governance Committees:

Steering Committee	Yes
Executive Oversight Committee	Yes
Data Monitoring Committee	Yes
Clinical Adjudication Committee	No
Study governance considerations are outlined in Appendix 1.	

Study Accepts Healthy Volunteers: No


A list of abbreviations used in this document can be found in Appendix 9.

1.2 Schema

1.2.1 Initial Treatment Phase

The Initial Treatment study design is depicted in Figure 1.

Figure 1 Initial Treatment Schema




Abbreviations: ALK=anaplastic lymphoma kinase; ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor; IV=intravenous; NSCLC=non-small cell lung cancer; PD=progressive disease; PD-1=programmed cell death 1; PD-L1=programmed cell death ligand 1; Q3W=every 3 weeks; Q12W=every 12 weeks; Rand=randomization; RECIST 1.1=Response Evaluation Criteria in Solid Tumors 1.1; ROS1=reactive oxygen species; TPS=tumor proportion score.

1.2.2 Second Course Treatment Phase

The Second Course study design is depicted in [Figure 2](#).

Figure 2 Second Course Schema




Abbreviations: IV=intravenous; PD=progressive disease; Q3W=every 3 weeks; Q12W=every 12 weeks.

1.3 Schedule of Activities

1.3.1 Initial Treatment Phase

Table 1 Study Schedule of Activities – Initial Treatment Phase

									Posttreatment			Notes
Study Period	Screening	Treatment Cycle = 21 Days						EOT	Safety Follow-up	Efficacy Follow-up	Survival Follow-up	All procedures are to be performed before study intervention administration unless otherwise indicated. Refer to Section 8.11 for visit details.
Visit Timing/Cycle Number	-28 to -1	1	2	3	4	5	6 to 35	At DC	30 Days post last dose	Every 12 weeks	Every 12 weeks	
Cycle Day		1	1	1	1	1	1	–				
Scheduling Window (Days)		+3	±3	±3	±3	±3	±3		+14	±7	±14	
Administrative Procedures												
Informed consent	X											Documented informed consent must be obtained before any protocol-specific screening procedures are performed. Reconsent required to continue study intervention after PD.
Informed consent for FBR	X											This is optional for the participant.
Inclusion/exclusion criteria	X											
Participant identification card	X	X										Update with randomization number at C1D1.
Demographic and medical history	X											
Prior and concomitant medications review	X	X	X	X	X	X	X	X	X			Prior concomitant medications received within 30 days before the first dose of study intervention through 30 days after the last dose of study intervention (or 90 days if used to treat an SAE) will be recorded.
Treatment randomization		X										Dose within 3 days of randomization.
Clinical Procedures/Assessments												
Complete physical examination	X							X				To be performed within 7 days before start of study intervention.
Directed physical examination		X	X	X	X	X	X		X			

									Posttreatment			Notes
Study Period	Screening	Treatment Cycle = 21 Days						EOT	Safety Follow-up	Efficacy Follow-up	Survival Follow-up	All procedures are to be performed before study intervention administration unless otherwise indicated. Refer to Section 8.11 for visit details.
Visit Timing/Cycle Number	-28 to -1	1	2	3	4	5	6 to 35	At DC	30 Days post last dose	Every 12 weeks	Every 12 weeks	
Cycle Day		1	1	1	1	1	1	–				
Scheduling Window (Days)		+3	±3	±3	±3	±3	±3		+14	±7	±14	
Height	X											
Vital signs and weight	X	X	X	X	X	X	X	X	X			Predose and as clinically indicated.
12-lead ECG	X											
ECOG Performance Status	X	X	X	X	X	X	X	X	X			Performed within 7 days prior to randomization and before each treatment administration.
Study intervention administration		X	X	X	X	X	X					
AE/SAE monitoring	X	X	X	X	X	X	X	X	X	X		Report AEs occurring within 30 days after the last dose of study intervention. Report SAEs occurring within 90 days after the last dose of study intervention, or 30 days after the last dose of study intervention if a new anticancer therapy is initiated, whichever is earlier.
Subsequent antineoplastic therapy status								X	X	X	X	All anticancer therapy will be recorded until time of death or termination of Survival Follow-up. If a clinic visit is not feasible, follow-up information may be obtained via documented contact.
Survival status											X	Refer to Sections 8.11.5.3 & 8.11.6. Updated survival status may be requested by the Sponsor at any time during the course of the study.

									Posttreatment			Notes
Study Period	Screening	Treatment Cycle = 21 Days						EOT	Safety Follow-up	Efficacy Follow-up	Survival Follow-up	All procedures are to be performed before study intervention administration unless otherwise indicated. Refer to Section 8.11 for visit details.
Visit Timing/Cycle Number	-28 to -1	1	2	3	4	5	6 to 35	At DC	30 Days post last dose	Every 12 weeks	Every 12 weeks	
Cycle Day		1	1	1	1	1	1	—				
Scheduling Window (Days)		+3	±3	±3	±3	±3	±3		+14	±7	±14	
Imaging												
Brain imaging	X											Required for all participants at screening. See Section 8.2.1.2 for other requirements. If MRI is contraindicated or cannot be performed, CT of the head with IV contrast is acceptable.
Bone imaging	X											Required at screening for participants with bone metastases. See Section 8.2.1.2 for other requirements.
Tumor imaging and response assessment (chest, abdomen, and pelvis)	X	X						X		X		Schedule should be followed regardless of treatment delays. Perform imaging at Screening, then Q6W (42 days ±7 days) from randomization through 36 weeks (±7 days), Q9W (±7 days) through 54 weeks, and Q12W (±7 days) thereafter until PD confirmed by BICR or initiation of a new anticancer regimen. If imaging was obtained within 4 weeks prior to treatment DC, scan at DC is not mandatory. Follow-up visits may be scheduled to coincide with the imaging schedule.

									Posttreatment			Notes
Study Period	Screening	Treatment Cycle = 21 Days						EOT	Safety Follow-up	Efficacy Follow-up	Survival Follow-up	All procedures are to be performed before study intervention administration unless otherwise indicated. Refer to Section 8.11 for visit details.
Visit Timing/Cycle Number	-28 to -1	1	2	3	4	5	6 to 35	At DC	30 Days post last dose	Every 12 weeks	Every 12 weeks	
Cycle Day		1	1	1	1	1	1	–				
Scheduling Window (Days)		+3	±3	±3	±3	±3	±3		+14	±7	±14	
Laboratory Assessments												
Pregnancy test for WOCBP	X	X	X	X	X	X	X	X	X			WOCBP require negative serum test within 72 hours or negative urine test within 24 hours prior to each dose of study intervention.
Hepatitis B and C and HIV serology	X											Required at baseline if mandated by local health authority.
CBC with differential	X		X	X	X	X	X	X	X			Performed locally within 10 days before first dose. After C1, collect within 3 days before dosing. Urinalysis should be performed every 4 cycles (C5, etc.).
Chemistry panel	X		X	X	X	X	X	X	X			
Urinalysis	X					X	X	X	X			Screening samples collected within 10 days prior to first dose of study intervention. Additional testing to be conducted as clinically indicated for participants taking anticoagulant therapy.
PT/INR and aPTT/PTT	X											Should be performed at Screening and Day 1 of every other cycle starting from C2. Participants may be dosed in subsequent cycles after C1 while thyroid function tests are pending. Free T3 and free T4 are acceptable.
Thyroid function (T3, T4, and TSH)	X		X		X		X	X	X			
Tumor Tissue Collection												
Newly obtained/archival tissue sample for PD-L1 analysis and other biomarkers	X											May use archival tissue sample obtained before screening as part of the participant’s SOC.

									Posttreatment			Notes
Study Period	Screening	Treatment Cycle = 21 Days						EOT	Safety Follow-up	Efficacy Follow-up	Survival Follow-up	All procedures are to be performed before study intervention administration unless otherwise indicated. Refer to Section 8.11 for visit details.
Visit Timing/Cycle Number	-28 to -1	1	2	3	4	5	6 to 35	At DC	30 Days post last dose	Every 12 weeks	Every 12 weeks	
Cycle Day		1	1	1	1	1	1	—				
Scheduling Window (Days)		+3	±3	±3	±3	±3	±3		+14	±7	±14	
Pharmacokinetics												
Blood for Serum MK-7684 and pembrolizumab		X	X		X		X		X			PK and ADA samples should be drawn within 24 hours prior to study intervention administration. Additional postdose (end-of-infusion) PK only samples will be drawn within 10 minutes after end of infusion at Cycles 1 and 8. Every effort should be taken to collect samples 30 days after end of study intervention.
Blood for ADA of MK-7684 and pembrolizumab ^a		X	X		X		X		X			
Biomarkers												
Blood for genetic analysis		X										Collect before study intervention.
Blood for serum biomarker analyses		X	X	X				X				Collect at predose on Day 1 of C1, C2, and C3, and at EOT.
Blood for RNA analysis		X	X	X				X				Collect at predose on Day 1 of C1, C2, C3, and at EOT.
Blood for ctDNA Analysis	X	X	X	X	X	X	X	X		X		Collect at Screening, predose on Day 1 of C1, C2, C3, C4, C5, C7, C9, C11, C13, C16, C19, and then on Day 1 of every 4 cycles. Collect also at EOT and Efficacy Follow-up. During follow-up, if a clinic visit is not feasible, blood for ctDNA collection will not be collected.

Abbreviations: ADA = antidrug antibodies; AE = adverse event; aPTT = activated partial thromboplastin time; CBC = complete blood count; CR = complete response; CT = computed tomography; CXDY = Cycle X Day Y; DC = discontinuation; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; FBR = future biomedical research; hCG = human chorionic gonadotropin; HIV = human immunodeficiency virus; ICF = informed consent form; INR = international normalized ratio; IV = intravenous; MRI = magnetic resonance imaging; PD = progressive disease; PD-L1 = programmed cell death ligand 1; PK = pharmacokinetic(s); PT = prothrombin time; PTT = partial thromboplastin time; QXW = every X weeks; RNA = ribonucleic acid; SAE = serious adverse event; SOC = standard of care T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; WOCBP = women of childbearing potential.

Note: Country-specific requirements are noted in Appendix 7.

- a. PK/ADA of MK-7684 and pembrolizumab: Predose trough PK and anti-MK-7684 and anti-pembrolizumab antibody samples will be collected at Cycles 1, 2, 4, 8, and every 4 cycles thereafter, and until discontinuation of study treatment (or until the participant starts new anticancer therapy). Note that 2 samples will need to be drawn at each PK and ADA collection time, 1 each for MK-7684 and pembrolizumab.

1.3.2 Second Course Treatment Phase (Arms 1 and 2 Only)

Table 2 Study Schedule of Activities - Second Course Treatment Phase

Study Period:	Treatment Cycle = 21 Days						End of Treatment	Posttreatment			Notes
Visit Timing/ Cycle Number	1	2	3	4	5	6 to 17	At DC	Safety Follow-up	Efficacy Follow-Up	Survival Follow-up	All procedures are to be performed before study intervention administration unless otherwise indicated. Refer to Section 8.11 for visit details.
								30 days post last dose	Every 12 weeks post-DC	Every 12 weeks	
Scheduling Window (Days):		± 3	± 3	± 3	± 3	± 3		+ 14	± 7	± 14	
Administrative Procedures											
Eligibility Criteria	X										
Concomitant Medication Review	X	X	X	X	X	X	X	X			Concomitant medications received within 30 days before the first dose of study intervention in the Second Course through 30 days after the last dose of study intervention (or 90 days if used to treat an SAE) will be recorded.
Clinical Procedures/Assessments											
Review Adverse Events	X	X	X	X	X	X	X	X	X		
Complete Physical Examination	X						X				
Directed Physical Examination		X	X	X	X	X		X			
Vital Signs and Weight	X	X	X	X	X	X	X	X			Predose and if clinically indicated.
ECOG Performance Status	X	X	X	X	X	X	X				Performed within 7 days of beginning of Cycle 1 and before each treatment administration.
MK-7864A Administration	X	X	X	X	X	X					
Poststudy Anticancer Therapy Status							X	X	X	X	

086RM4

Study Period:	Treatment Cycle = 21 Days						End of Treatment	Posttreatment			Notes
Visit Timing/ Cycle Number	1	2	3	4	5	6 to 17	At DC	Safety Follow-up	Efficacy Follow-Up	Survival Follow-up	All procedures are to be performed before study intervention administration unless otherwise indicated. Refer to Section 8.11 for visit details.
								30 days post last dose	Every 12 weeks post-DC	Every 12 weeks	
Scheduling Window (Days):		± 3	± 3	± 3	± 3	± 3		+ 14	± 7	± 14	
Imaging											
Tumor Imaging (Chest, Abdomen and Pelvis)	X		X		X	X	X		X		<p>Schedule should be followed regardless of treatment delays. Images are for investigator assessment of disease status only and should not be sent to the iCRO. If tumor image documenting PD was obtained >28 days before entry into Second Course, a new image must be obtained and reviewed by the site before treatment initiation.</p> <p>Perform imaging Q6W through 36 weeks, Q9W through EOT, and Q12W thereafter, until confirmed PD or initiation of a new anticancer regimen. The window for imaging is ±7 days. If imaging was obtained within 4 weeks before DC, scan at DC is not mandatory. Follow-up visits may be scheduled to coincide with the imaging schedule.</p>

aPTT = activated partial thromboplastin time; CXDY= Cycle X Day Y; CBC = complete blood count; CT = computed tomography; DC = Discontinuation Visit; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; MRI = magnetic resonance imaging; PT/INR = prothrombin time/international normalized ratio; FT4 = free thyroxine; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; WOCBP = women of childbearing potential.

Note: Country-specific requirements are noted in Appendix 7.

2 INTRODUCTION

MK-7684A is a coformulation of MK-7684 and pembrolizumab. MK-7684 is a humanized, antagonist mAb that binds to the immune checkpoint receptor, TIGIT, and blocks the interaction between TIGIT and its ligands. Pembrolizumab is a potent humanized IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2. The coformulation of MK-7684A is being developed as a cancer immunotherapeutic with the potential to be used to increase benefit to patients with metastatic NSCLC.

2.1 Study Rationale

The global incidence of lung cancer was 2.1 million cases in 2018, resulting in an estimated 1.8 million deaths [International Agency for Research on Cancer 2018]. NSCLC represents approximately 85% of all lung cancers [National Cancer Institute 2020]. Of patients with NSCLC, tumor histology is approximately 46% adenocarcinoma, 16% squamous, and the remainder “not otherwise specified” [Sulpher, J. A., et al 2013], though histology varies somewhat by geographic region. At the time of diagnosis, approximately 80% of patients in the United States with lung cancer have locally advanced or metastatic disease that is not amenable to surgical resection, and the 5-year relative survival for patients with metastatic lung cancer is only approximately 6% [National Cancer Institute 2020].

The therapeutic landscape in metastatic NSCLC was dramatically changed with approvals of immunotherapy agents in both treatment naïve and previously treated cancer, irrespective of histology. In previously treated patients with advanced NSCLC, immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway (pembrolizumab, nivolumab, and atezolizumab) have proven benefits for survival over the standard chemotherapy, docetaxel [Borghaei, H., et al 2015] [Brahmer, J., et al 2015] [Herbst, R. S., et al 2016] [Rittmeyer, A., et al 2017].

The results from the KEYNOTE-001 (a Phase 1 study evaluating efficacy and safety of pembrolizumab) and KEYNOTE-010 (a Phase 2/3 study of pembrolizumab versus docetaxel) showed that pembrolizumab provided substantial, clinically meaningful benefits in OS, PFS, and ORR in patients with NSCLC whose disease progressed after platinum-containing chemotherapy and whose tumor cells expressed PD-L1. Based on these 2 studies, pembrolizumab monotherapy is approved for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS $\geq 1\%$), with PD during or after platinum-containing chemotherapy. In addition, the NCCN Guidelines recommend immune checkpoint inhibitors as the preferred agent for subsequent therapy in patients with metastatic NSCLC based on improved survival rates, longer DOR, and fewer AEs compared with cytotoxic chemotherapy [National Comprehensive Cancer Network 2018].

Furthermore, the PROLUNG investigator-initiated, Phase 2 randomized study of pembrolizumab plus docetaxel versus docetaxel alone in IO-naïve advanced NSCLC patients who were previously treated with platinum-based chemotherapy revealed a statistically significant improvement in ORR and PFS in the pembrolizumab plus docetaxel arm

[Arrieta, O., et al 2020]. Pembrolizumab and docetaxel was well tolerated and improved ORR and PFS irrespective of PD-L1 or EGFR mutation status.

Although cancer immunotherapies have revolutionized treatment paradigms in first-line and second-line treatment of metastatic NSCLC, unfortunately, many patients do not benefit from or become resistant to IO monotherapy, or IO in combination with chemotherapy. For patients with disease recurrence or disease progression while on IO therapy, the prognosis is very poor, with a median OS of 9 months [Metro, G., et al 2019]. Tumor resistance to immunotherapy is an emerging issue impacting outcomes. Patients have either primary resistance to immune checkpoint inhibitors and do not respond to initial therapy or acquire resistance and relapse after response to treatment. Therefore, there is still a substantial unmet medical need for novel treatments that can potentiate the clinical benefit of IO therapies, extend the benefit to a broader population of patients, and further improve treatment response and survival in patients with metastatic NSCLC with prior exposure to IO therapies.

Furthermore, pembrolizumab use in second-line NSCLC is declining due to first-line utilization. Docetaxel is an accepted second-line SOC treatment for patients with NSCLC, demonstrating an ORR of approximately 5% to 10%, median PFS of approximately 3 months, and median OS of approximately 7.5 months. Outcomes remain poor, especially in those that have progressed after immunotherapy [Fossella, F. V., et al 2000] [Shepherd, F. A., et al 2000] [Hanna, N., et al 2004].

Enhancing the proven anti-PD-1 immune stimulatory mechanism through a novel mechanism of action is therefore an attractive scientific concept. One avenue for further investigation is the T-cell stimulatory/inhibitory network CD226-TIGIT/PVRIG/TACTILE TIGIT pathway. Antibody blockade of TIGIT, a T-cell inhibitory receptor within this network, has shown promising activity in preclinical cancer models, as well as in clinical studies. MK-7684 is a humanized IgG1 that blocks the inhibitory checkpoint receptor TIGIT expressed on T-cells and NK cells. Therefore, a strong rationale exists to develop anti-PD-1 and anti-TIGIT combination therapies. MK-7684 is being developed in combination with pembrolizumab in advanced solid tumors. Preliminary data for MK-7684-001, a Phase 1 study of MK-7684 as monotherapy or coformulated with pembrolizumab (known as MK-7684A) in advanced solid tumors demonstrates promising activity in PD-1 naïve and PD-1 refractory NSCLC (see Section 2.2.3.1).

In conclusion, there remains a great unmet need to develop newer, more efficacious, well tolerated therapies for the treatment of patients with metastatic NSCLC that have progressed on immunotherapy. The goal of this study is to enhance the approved anti-PD-1 immune stimulatory mechanism of pembrolizumab through combining it with a novel immune modulatory mechanism of action, blockade of TIGIT, along with the SOC chemotherapy for this population. This Phase 2 study is designed to assess the efficacy and safety of MK-7684A alone or MK-7684A plus docetaxel versus docetaxel alone. This study will examine whether MK-7684A alone or in combination with docetaxel will result in greater PFS and OS than SOC docetaxel in this population of patients. The MK-7684A alone arm provides the opportunity to explore a potential chemotherapy-free regimen as well, which is of particular interest to both patients and physicians. Outcomes of this study could inform future Phase 3 studies.

2.2 Background

Refer to the MK-7684A IB and the pembrolizumab IB for detailed background information on MK-7684A and pembrolizumab, respectively.

2.2.1 Pharmaceutical and Therapeutic Background

The importance of intact immune surveillance function in controlling outgrowth of neoplastic transformations has been known for decades [Disis, M. L. 2010]. Accumulating evidence shows a correlation between tumor-infiltrating lymphocytes in cancer tissue and favorable prognosis in various malignancies. In particular, the presence of CD8+ T-cells and the ratio of CD8+ effector T-cells/FoxP3+ regulatory T-cells (Tregs) correlates with improved prognosis and long-term survival in solid malignancies, such as ovarian cancer, colorectal cancer, and pancreatic cancer; hepatocellular carcinoma, malignant melanoma, and renal cell carcinoma. Tumor-infiltrating lymphocytes can be expanded ex vivo and reinfused, inducing durable objective tumor responses in cancers such as melanoma [Dudley, M. E., et al 2005] [Hunder, N. N., et al 2008].

2.2.1.1 MK-7684 Background

MK-7684 is a humanized, antagonist mAb that binds to the immune checkpoint receptor, TIGIT, and blocks the interaction between TIGIT and its ligands. This human IgG1 antibody is being developed as a cancer immunotherapeutic with the potential to be used as monotherapy or to be combined with pembrolizumab (a humanized anti-PD-1 receptor antibody) to increase benefit to patients with various tumor types.

TIGIT is an immunomodulatory receptor expressed primarily on activated CD4+ and CD8+ T-cells, NK cells, and NKT cells. Its structure reveals a single extracellular immunoglobulin domain, a transmembrane region, an immunoglobulin tail tyrosine-like phosphorylation motif, and an immunoreceptor tyrosine-based inhibitory motif.

TIGIT forms part of a costimulatory network that consists of a positive (CD226) and negative (TIGIT) immunomodulatory receptor on T-cells, and ligands (CD155 and CD112) expressed on tumor cells and antigen presenting cells [Levin, S. D., et al 2011]. Whereas CD226 is widely expressed on most immune cells, TIGIT is highly expressed on memory T-cells, Tregs, NK cells, and NKT cells [Dardalhon, V., et al 2005] [Stanietsky, N., et al 2013]. CD155/PVR (poliovirus receptor) and CD112/PVRL-2 (poliovirus receptor-related 2) are 2 nectin family members that are widely expressed both on cells of the hematopoietic system and on fibroblasts and endothelial cells. Functionally, these receptor ligands are involved in cell adhesion and motility. CD155 is reported to be overexpressed in several tumor types, and has been found to be induced by Ras activation and genotoxic stress [Carlsten, M., et al 2007] [Hirota, T., et al 2005] [Masson, D., et al 2001] [Soriani, A., et al 2009] [Stanietsky, N., et al 2009].

In addition, TIGIT is highly coexpressed with PD-1 on both CD4+ and CD8+ TILs including Tregs, in mouse and human tumors, and has been reported to be coexpressed with PD-1 and T-cell immunoglobulin and mucin domain containing-3 (Tim-3) on the TILs with the most

exhausted phenotype [Chauvin, J. M., et al 2015] [Johnston, R. J., et al 2014]. Furthermore, enhanced antitumor efficacy is observed in preclinical models when an anti-TIGIT antibody is used with an anti-PD-1 antibody. We hypothesize, therefore, that combining MK-7684 with pembrolizumab will offer substantially augmented antitumor efficacy.

2.2.1.2 Pembrolizumab Background

Pembrolizumab is a potent humanized IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2. Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD-1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications. For more details on specific indications refer to the IB.


2.2.2 Preclinical and Clinical Studies

2.2.2.1 MK-7684A Preclinical Studies

Evaluation of TIGIT modulation as an approach to enhance tumor immunity was prompted by preclinical observations showing that antagonizing TIGIT has potent immunostimulatory effects. Results of studies performed showed in vivo antitumor activity of rat anti-mouse TIGIT antibodies. In order to understand how antibody backbone differences may impact the antitumor efficacy of anti-TIGIT antibodies, parental rat anti-mouse TIGIT mAbs, or chimeric versions of these antibodies, were tested in multiple established (80-180mm³) syngeneic tumor models as single agents and in combination with an anti-mouse PD-1 mAb (muDX400). All anti-TIGIT mAbs tested resulted in a trend toward enhanced antitumor activity when combined with an anti-mouse PD-1 mAb (mDX400). The chimeric anti-TIGIT IgG2a mAbs (strong FcγR binding) showed the most robust single-agent activity as compared with anti-TIGIT IgG1 (D265A mutant; minimal FcγR binding) mAbs and the most combination benefit when combined with anti-mouse PD-1.

A representative dose titration study demonstrating significant single-agent efficacy of the anti-mouse TIGIT 18G10-mIgG2a antibody in the murine MC38 colon carcinoma tumor model is shown in [Figure 3](#). Anti-mouse TIGIT (18G10-mIgG2a) displayed single-agent activity comparable to anti-mouse PD-1 (mDX400). The MC38 tumor model has been classified as very responsive to anti-PD-1 treatment, and MC38 model selection was based on baseline TIGIT protein surface expression on CD8+ and CD4+ TILs, baseline mRNA expression of CD155, and induction of TIGIT and CD155 expression in tumors after anti-PD-1 treatment.


Figure 3 Results of a Dose Titration Study of Anti-TIGIT 18G10-IgG2a in the MC38 Colon Carcinoma Mouse Model



C57BL/6 mice bearing MC38 mouse syngeneic tumors (mean tumor volume at start of treatment 98 mm³) were administered anti-mouse TIGIT antibodies at doses of 2 mg/kg, 10 mg/kg, or 20 mg/kg, anti-mouse PD 1 (mDX400) at a dose of 5 mg/kg, or isotype controls every 4 days for 5 cycles (n=10/group). Tumor volume curves are presented for the average of 10 animals within each group. The anti-mouse TIGIT 18G10-IgG2a antibody resulted in 82%, 94%, and 96% tumor growth inhibition at the 2 mg/kg, 10 mg/kg, and 20 mg/kg doses, respectively. Anti-mouse PD-1 (mDX400) resulted in 17% tumor regression at the 5 mg/kg dose. Ig = immunoglobulin; mpk = mg/kg; PD 1 = programmed death 1; TIGIT = T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif.

A representative study evaluating anti-TIGIT treatment as a single agent and in combination with anti-PD-1(muDX400) therapy in the murine subcutaneous CT26 tumor-bearing model is shown in Figure 4. The CT26 colon carcinoma model has been classified as partially responsive to anti-PD-1 treatment with only partial tumor growth inhibition observed. CT26 model selection was based on baseline TIGIT protein surface expression on CD8+ and CD4+ TILs, baseline mRNA expression of CD155, and induction of TIGIT and CD155 expression in tumors after anti-PD-1 treatment. Combination treatment of 18G10-G2a with anti-PD-1 (mDX400) showed significantly enhanced efficacy and survival as compared with anti-TIGIT and anti-PD-1 monotherapy treatments. Animals with complete responses showed curative protection from tumor rechallenge, consistent with the development of immune memory (data not shown).

Figure 4 Antitumor Efficacy of Anti-TIGIT 18G10-IgG2a as a Single Agent and in Combination With Anti-PD-1(muDX400) Therapy in the Murine Subcutaneous CT26 Colon Carcinoma Tumor-bearing Model



CT26 tumor-bearing BALB/cAnN mice (mean tumor volume at start of treatment ~100 mm³) were administered anti-TIGIT antibody (18G10-G2a) at a dose of 18 mg/kg and an anti-murine anti-PD-1 antibody (mDX400) at a dose of 10 mg/kg by intraperitoneal injection, every 4 days for 5 cycles. Tumor volume curves are presented for individual animals within each group (n=10/group). CR = complete response; Ig = immunoglobulin; PD 1 = programmed death 1; TIGIT = T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif.

These studies (and others) have demonstrated that anti-mouse TIGIT mAb treatment can augment antitumor T-cell responses and induce tumor rejection in several murine tumor models when used alone and in combination with an anti-mouse PD-1 mAb. In these studies, the combination of anti-mouse TIGIT and anti-mouse PD-1 led to an increased ratio of T_{eff}s to T_{regs} in the tumor, but these effects were not observed in the draining lymph node.

The results of studies using chimeric anti-mouse TIGIT mAbs on the IgG2a backbone revealed that administration of single-agent anti-mouse TIGIT mAbs are efficacious in treating multiple established subcutaneous murine tumors and that combining anti-mouse TIGIT 18G10-G2a with anti-mouse PD-1 leads to enhanced combination benefit over either single agent alone.

Findings in toxicology studies of MK-7684 monotherapy and pembrolizumab monotherapy in nonhuman primates were attributed to the proinflammatory pharmacology of each agent, but were not overlapping. Moreover, using an in vitro cytokine release assay, the

combination of MK-7684 and pembrolizumab did not enhance cytokine induction in human peripheral blood monocytes. Potential increase in immune-mediated adverse effects resulting from the combination of MK-7684 and pembrolizumab, however, cannot be ruled out. See MK-7684 and pembrolizumab IBs for more information.

2.2.2.2 Pembrolizumab Preclinical and Clinical Studies

Refer to the IB for preclinical and clinical study data for pembrolizumab.

2.2.3 Ongoing Clinical Studies

2.2.3.1 MK-7684 Ongoing Clinical Studies

Study MK-7684-001

MK-7684-001 is a safety, efficacy, and PK study examining MK-7684 as monotherapy and in combination with pembrolizumab or with pembrolizumab plus chemotherapy in adults with metastatic solid tumors for which there are no available therapies expected to convey clinical benefit. The study consists of a Part A dose escalation phase and a Part B expansion phase.

Part A of this study is a dose escalation and confirmation phase to evaluate safety and estimate the RP2D for MK-7684 monotherapy or in combination with pembrolizumab, or pembrolizumab with chemotherapy.

As of 03-MAR-2020, Part A was completed. A total of 85 participants were treated with escalating doses of MK-7684 from 2.1 mg to 700 mg either as monotherapy (n=34), in combination with a fixed dose of 200 mg pembrolizumab (n=41), or in combination with pembrolizumab and chemotherapy (n=10). No DLTs were observed in the MK-7684 monotherapy or MK-7684 plus pembrolizumab arms. Antitumor activity was observed in Part A, particularly in participants treated with MK-7684 in combination with pembrolizumab. In the monotherapy arm, the combined best overall response by RECIST 1.1 was 2.9% without confirmation, with 1 of the 34 participants experiencing a PR. In the combination therapy arm, the combined best overall response without confirmation was 17.1%, with 7 of the 41 participants experiencing a PR.

Part B of this study intends to assess the antitumor efficacy of MK-7684 at the RP2D of 200 mg when used as monotherapy and in combination with pembrolizumab in distinct tumor indications, including PD-1 refractory NSCLC and PD-1 naïve NSCLC.

As of 03-MAR-2020, MK-7684 was given as monotherapy and in combination with pembrolizumab 200 mg with or without chemotherapy to 366 participants. It was well tolerated and had a manageable safety profile. In addition, in Part B, MK-7684 has showed promising antitumor activity across multiple tumor types, particularly for MK-7684 plus pembrolizumab.

As of March 2020, preliminary safety and efficacy results were available for 41 participants with anti-PD-1/PD-L1-naïve NSCLC treated with MK-7684 + pembrolizumab [Niu, J., et al 2020]. Of the 41 participants enrolled, 73% had received ≥ 1 prior lines of therapy. Median age was 62 years; 68% were male and 83% had an ECOG Performance Status of 1. Median follow-up was 11 months (range, 7-18). TRAEs occurred in 34 participants (83%); pruritus (34%), hypoalbuminemia (29%), and pyrexia (20%) were the most frequent ($\geq 20\%$). In all participants (ITT population) investigator-assessed ORR by RECIST 1.1 was 29% (95% CI: 16, 46). In participants with available PD-L1 testing (n=25), the ORR was 46% (95% CI: 19, 75) in participants with tumors expressing PD-L1 TPS $\geq 1\%$ (6/13 participants experienced a response), and ORR was 25% (95% CI: 5, 57) in participants with tumors expressing PD-L1 TPS $< 1\%$ (3/12 participants experienced a response). There was also a trend toward improved median PFS in participants with PD-L1 TPS $\geq 1\%$ (8.4 months, 95% CI: 3.9, 10.2) compared with participants with tumors expressing PD-L1 $< 1\%$ (4.1 months, 95% CI: 1.9, NR) or the ITT population 5.4 months (95% CI: 2.1, 8.2). In this limited dataset, ORR and PFS are improved compared with historical pembrolizumab monotherapy efficacy in 2L NSCLC in KEYNOTE-010 (n=690): ORR by BICR was 18% and median PFS was 4.0 months (95% CI: 3.1, 4.1). Overall, these data are promising and warrant further study of MK-7684 and pembrolizumab therapy in NSCLC naïve to PD-1 therapy.

Part B also tested MK-7684 alone or in combination with pembrolizumab in NSCLC participants that had progressed on previous anti-PD-1 or PD-L1 therapy. In this cohort, median follow-up was 11 months (range, 5 to 16) for 79 participants with anti-PD-1/PD-L1-refractory NSCLC (n = 41, MK-7684; n = 38 MK-7684 plus pembrolizumab). Median age was 65 years, 60% were male, and 78% received ≥ 2 lines of prior therapy. AEs were reported in $\geq 97\%$ and TRAEs in $\geq 65\%$ of participants in both arms. The most common TRAEs ($\geq 10\%$ in either arm) were pruritus, fatigue, rash, arthralgia, and decreased appetite. Ten participants reported Grade 3-4 TRAEs; the most common were lipase increased and hypertension. One participant in the MK-7684 plus pembrolizumab arm died due to treatment-related pneumonitis. ORR was 7% (95% CI: 2, 20) with MK-7684 monotherapy and 5% (95% CI: < 1 , 18) with MK-7684 plus pembrolizumab. Median DOR was 9 months (range, 9 to 9) with MK-7684 monotherapy and 13 months (range, 4+ to 13) with MK-7684 plus pembrolizumab. The data show that MK-7684 was well tolerated as a monotherapy and in combination with pembrolizumab and that modest antitumor activity was observed in participants with advanced NSCLC refractory to anti-PD-1/PD-L1 therapy in both treatment arms, though a trend toward longer treatment duration was observed in the combination therapy arm.

Additional details regarding other ongoing studies of MK-7684 and specific benefits and risks for participants in the MK-7684 studies may be found in the IB.

2.2.3.2 Pembrolizumab Ongoing Clinical Studies

Numerous clinical studies involving pembrolizumab are currently ongoing in a number of advanced solid tumor indications, as well as in hematological malignancies.

In the NSCLC development program, pembrolizumab monotherapy for PD-L1 positive NSCLC was approved in the first-line setting based on KEYNOTE-024 and KEYNOTE-042

and approved in the second-line setting based on KEYNOTE-001 and KEYNOTE-010. KEYNOTE-189 and KEYNOTE-407 led to the approval of pembrolizumab in combination with chemotherapy for first-line treatment of metastatic NSCLC irrespective of PD-L1 status, while KEYNOTE-021 established the benefits of the combination. For further details, refer to the IB.

2.3 Benefit/Risk Assessment

It cannot be guaranteed that participants in clinical studies will directly benefit from treatment during participation, as clinical studies are designed to provide information about the safety and effectiveness of an investigational medicine.

Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have been approved as first-line therapy for NSCLC. There is an unmet medical need for safe and efficacious for second-line therapy and beyond (2L+) in patients whose disease has progressed with first-line treatment. The existing data suggest that blockade of TIGIT with MK-7684 offers a new immunological mechanism, which has been shown to enhance the activity of pembrolizumab in preclinical and early clinical observations. The combination of both MK-7684 and pembrolizumab as coformulated MK-7684A is believed to achieve increased therapeutic efficacy with minimal added toxicity over pembrolizumab monotherapy. We hypothesize that MK-7684A will enhance the efficacy of pembrolizumab therapy without significant added toxicity. Therefore, risk/benefit is expected to be favorable.

Inhibiting TIGIT in combination with PD-1 blockade is a promising therapeutic strategy, and the benefit/risk assessment for patients in this study is favorable, making MK-7684A alone or in combination with docetaxel a promising 2L+ therapeutic option in patients with metastatic NSCLC and no *EGFR* or *ALK* or *ROS1* genomic tumor aberrations, regardless of PD-L1 expression.

Additional details regarding specific benefits and risks for participants in this study may be found in the accompanying IBs and informed consent documents.

3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS

Male/female participants with metastatic NSCLC with progressive disease after treatment with a platinum doublet chemotherapy and immunotherapy who are 18 years of age or older may be enrolled in this study.

Objectives	Endpoints
Primary	
<ul style="list-style-type: none"> Objective: To compare MK-7684A + docetaxel to normal saline placebo + docetaxel with respect to PFS per RECIST 1.1 by BICR. Hypothesis (H1): MK-7684A + docetaxel is superior to normal saline placebo + docetaxel with respect to PFS per RECIST 1.1 by BICR. Objective: To compare MK-7684A to normal saline placebo + docetaxel with respect to PFS per RECIST 1.1 as assessed by BICR. Hypothesis (H2): MK-7684A is superior to normal saline placebo + docetaxel with respect to PFS per RECIST 1.1 by BICR. 	<ul style="list-style-type: none"> PFS: The time from randomization to the first documented disease progression or death due to any cause, whichever occurs first.
Secondary	
<ul style="list-style-type: none"> To evaluate ORR in participants treated with MK-7684A + docetaxel, MK-7684A, or normal saline placebo + docetaxel per RECIST 1.1 by BICR. 	<ul style="list-style-type: none"> Objective response: defined as a confirmed CR or PR.
<ul style="list-style-type: none"> To evaluate OS in participants treated with MK-7684A + docetaxel, MK-7684A, or normal saline placebo + docetaxel. 	<ul style="list-style-type: none"> OS: defined as the time from randomization to the date of death due to any cause.
<ul style="list-style-type: none"> To evaluate DOR per RECIST 1.1 as assessed by BICR in participants treated with MK-7684A + docetaxel, MK-7684A, or normal saline placebo + docetaxel. 	<ul style="list-style-type: none"> DOR: for participants who demonstrate confirmed CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
<ul style="list-style-type: none"> To evaluate the safety and tolerability in participants treated with MK-7684A + docetaxel, MK-7684A, or normal saline placebo + docetaxel. 	<ul style="list-style-type: none"> AEs. Discontinuations of study intervention due to an AE.

Objectives	Endpoints
Tertiary/Exploratory	
<ul style="list-style-type: none">To identify molecular (genomic, metabolic, and/or proteomic) biomarkers that may be indicative of clinical response/resistance, safety, pharmacodynamic activity, monitoring, and/or the mechanism of action of MK-7684 and pembrolizumab and other treatments.	<ul style="list-style-type: none">Molecular (genomic, metabolic and/or proteomic) determinants of response or resistance to treatments, using blood and/or tumor tissue.

The study will be considered a success if the success criterion for any of the primary hypotheses is met.

4 STUDY DESIGN

4.1 Overall Design

This is a Phase 2 randomized, placebo- and active-controlled, parallel-group, multisite, double-blind (Arm 1 and Arm 3 only), 3 arm study comparing MK-7684A + docetaxel or MK-7684A to normal saline placebo + docetaxel. Participants with metastatic NSCLC and PD after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 mAb (either sequentially or in combination with chemotherapy) will be enrolled in the study. This study will be conducted in participants with measurable disease in whom *EGFR*-, *ALK*-, or *ROS1*-targeted therapy is not indicated.

Participants will provide tumor tissue obtained any time from initial diagnosis of NSCLC and before receiving immunotherapy (anti-PD-1/PD-L1) for determination of PD-L1 expression and study stratification. Participants will be stratified by:

- Prior anti-PD-1/PD-L1 mAb (immediate prior therapy versus not immediate prior therapy)
- PD-L1 TPS (<50% versus $\geq 50\%$)
- ECOG Performance Status (0 versus 1)

Initial Treatment

Overall, approximately 240 participants will be randomized 1:1:1 to:

- MK-7684A + docetaxel (Arm 1)
- MK-7684A (Arm 2)

- Normal saline placebo + docetaxel (Arm 3)

No treatment crossover is planned for the study. The study design is shown in [Figure 1](#) (Initial Treatment Phase) and The Second Course study design is depicted in [Figure 2](#) (Second Course).

Participants will be evaluated with radiographic imaging to assess response to study intervention every 6 weeks from randomization through 36 weeks, every 9 weeks through 54 weeks, and subsequently every 12 weeks until confirmed PD or initiation of a new anticancer regimen. All imaging obtained during the initial treatment phase of the study will be submitted to the iCRO for BICR, which will assess the images using RECIST 1.1 for determination of PFS, OR, and DOR. Tumor imaging showing site-assessed PD should be submitted immediately for verification by BICR before study intervention discontinuation. Once disease progression is verified centrally, subsequent imaging (if acquired) should not be submitted to the iCRO.

Participants may be permitted to continue study intervention beyond PD confirmed by BICR per RECIST 1.1 if the treating investigator considers that the participant may experience clinical benefit with continued treatment and the participant is clinically stable and tolerating study intervention; however, this decision must be approved by the Sponsor. If the investigator recommends continuation of study intervention beyond disease progression, the participant or legally acceptable representative will be asked to provide a new documented informed consent.

Survival follow-up will continue after PD, discontinuation of study intervention, and the start of new anticancer treatment. In addition, on Sponsor request, participants may be contacted for survival status at any time during the study.

AE monitoring will be ongoing throughout the study. AEs will be graded in severity according to the guidelines outlined in the NCI CTCAE, version 5.0.

Treatment with MK-7684A/normal saline placebo will continue for up to 35 treatment cycles, or until a discontinuation criterion is met (see Section 7.1). Treatment may be discontinued for participants with a confirmed CR (see Section 6.6.2 for requirements).

Treatment with docetaxel may continue until a discontinuation criterion is met (see Section 7.1), or as per approved local label.

Second Course Treatment Phase

The Second Course retreatment option is only available for Arm 1 and Arm 2. Treatment assignment will be unblinded only for those participants who meet all criteria for the Second Course Phase. Participants in Arm 3 (normal saline placebo + docetaxel) are not eligible for the Second Course Phase.

Participants who stop MK-7684A after receiving 35 treatment cycles or participants who stop MK-7684A after attaining a confirmed CR may be eligible for the Second Course. See Section 6.6.3 for details.

Specific procedures to be performed during the study, as well as their prescribed times and associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure are provided in Section 8.

4.2 Scientific Rationale for Study Design

This Phase 2, randomized, placebo- and active-controlled, double-blind study with respect to Arm 1 and Arm 3, and open-label with respect to Arm 2, is being conducted to compare the efficacy and safety of MK-7684A plus docetaxel or MK-7684A to docetaxel monotherapy in metastatic NSCLC. The results will inform future Phase 3 studies.

4.2.1 Rationale for Endpoints

4.2.1.1 Efficacy Endpoints

This study will use PFS based on RECIST 1.1 criteria as assessed by BICR as the primary endpoint. Progression-free survival is an acceptable measure of clinical benefit for a late stage study that demonstrates superiority of a new antineoplastic therapy, especially if the magnitude of the effect is large and the therapy has an acceptable risk/benefit profile. The use of BICR and RECIST 1.1 to assess PFS is considered acceptable by regulatory authorities. Images will be submitted to an iCRO and read by an independent central review blinded to treatment assignment to minimize bias in the response assessments. In addition, the final determination of radiologic progression will be based on the central assessment of progression, rather than a local site investigator/radiology assessment. Expedited verification of radiologic progression as determined by central review will be communicated to the site.

The secondary efficacy endpoint OS has been recognized as the gold standard for the demonstration of superiority of a new antineoplastic therapy in randomized clinical studies.

The secondary efficacy endpoints of OR and DOR based on RECIST 1.1 and assessed by BICR is accepted by regulatory authorities and the oncology community.

RECIST 1.1 will be used by the BICR when assessing images for efficacy measures. Although original RECIST 1.1 publication recommends a maximum of 5 target lesions in total and 2 per organ, this protocol has implemented an adjustment to RECIST 1.1 to allow a maximum of 10 target lesions in total and 5 per organ, if a larger number of target lesions is needed to adequately represent the tumor burden. Refer to Section 8.2.1.5 for additional detail.

4.2.1.2 Safety Endpoints

Safety parameters commonly used for evaluating investigational systemic anticancer treatments are included as safety endpoints including, but not limited to, the incidence of,

causality, and outcome of AEs/SAEs; and changes in vital signs and laboratory values. AEs will be assessed as defined by CTCAE, Version [5.0].

4.2.1.3 Pharmacokinetic Endpoints

Blood samples will be obtained to characterize PK parameters and immunogenicity of MK-7684 and pembrolizumab when coadministered.

4.2.1.4 Planned Exploratory Biomarker Research

Cancer immunotherapies represent an important and novel class of antitumor agents. However, the mechanism of action of these exciting new therapies is not completely understood and much remains to be learned regarding how best to leverage these new drugs in treating patients. Thus, to aid future patients, it is important to investigate the determinants of response or resistance to cancer immunotherapy and other treatments administered, as well as determinants of AEs in the course of our clinical studies. These efforts may identify novel predictive/PD biomarkers and generate information that may better guide single-agent and combination therapy with immuno-oncology drugs. To identify novel biomarkers, biospecimens (ie, blood components, tumor material) will be collected to support analyses of cellular components (eg, protein, DNA, RNA, metabolites) and other circulating molecules. Investigations may include but are not limited to:

Germline (blood) genetic analyses (eg, SNP analyses, whole exome sequencing, whole genome sequencing)

This research may evaluate whether genetic variation within a clinical study population correlates with response to the treatment(s) under evaluation. If genetic variation is found to predict efficacy or AEs, the data might inform optimal use of therapies in the patient population. Furthermore, it is important to evaluate germline DNA variation across the genome in order to interpret tumor-specific DNA mutations. Finally, MSI may be evaluated as this is an important biomarker for some cancers (ie, colorectal cancer).

Genetic (DNA) analyses from tumor

The application of new technologies, such as next generation sequencing, has provided scientists the opportunity to identify tumor-specific DNA changes (ie, mutations, methylation status, microsatellite instability). Key molecular changes of interest to immuno-oncology drug development include the mutational burden of tumors and the clonality of T-cells in the tumor microenvironment. Increased mutational burden (sometimes referred to as a ‘hyper-mutated’ state) may generate neo-antigen presentation in the tumor microenvironment. To conduct this type of research, it is important to identify tumor-specific mutations that occur across all genes in the tumor genome. Thus, genome-wide approaches may be used for this effort. Note that in order to understand tumor-specific mutations, it is necessary to compare the tumor genome with the germline genome. Microsatellite instability may also be evaluated as this is an important biomarker for some cancers (ie, colorectal cancer). Circulating tumor DNA and/or RNA may also be evaluated from blood samples.

Tumor and blood RNA analyses

Both genome-wide and targeted mRNA expression profiling and sequencing in tumor tissue and in blood may be performed to define gene signatures that correlate to clinical response to treatment with pembrolizumab or other immunotherapies. Pembrolizumab induces a response in tumors that likely reflects an inflamed/immune phenotype. Specific immune-related gene sets (ie, those capturing interferon-gamma transcriptional pathways) may be evaluated and new signatures may be identified. Individual genes related to the immune system may also be evaluated (eg, IL-10). MicroRNA profiling may also be pursued as well as exosomal profiling.

Proteomics and IHC using blood or tumor

Tumor and blood samples from this study may undergo proteomic analyses (eg, PD-L1 IHC). PD-L1 protein level in tumor sections, assessed by IHC, has been shown to correlate with response to pembrolizumab in patients with NSCLC, and an IVD device has been developed for use with pembrolizumab in NSCLC. Preliminary data indicates that this association may also be true in additional cancer types (ie, triple negative breast cancer, head and neck, and gastric). Additional tumor or blood-derived proteins may also correlate with response to pembrolizumab. Therefore, tumor tissue may be subjected to proteomic analyses using a variety of platforms that could include but are not limited to immunoassays and liquid chromatography/mass spectrometry. This approach could identify novel protein biomarkers that could aid in patient selection for pembrolizumab (MK-3475) therapy.

Other blood-derived biomarkers

In addition to expression on the tumor tissue, PD-L1 and other tumor derived proteins can be shed from tumor and released into the blood. Assays such as ELISA measure such proteins in serum. Correlation of expression with response to pembrolizumab therapy may identify new approaches for predictive biomarkers in blood, representing a major advance from today's reliance on assessing tumor biomarkers. This research would serve to develop such assays for future clinical use.

Other molecular changes of interest include the subtype of T-cells in the tumor microenvironment. The T-cell repertoire from tumor tissue and blood components may be evaluated.

4.2.1.5 Future Biomedical Research

The Sponsor will conduct FBR on specimens for which consent was provided during this study. This research may include genetic analyses (DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, depending on which specimens are consented for FBR.

Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main study) and will only be conducted on specimens from appropriately consented participants. The objective of collecting/retaining specimens for

FBR is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs/vaccines, and/or to ensure that participants receive the correct dose of the correct drug/vaccine at the correct time. The details of FBR research are presented in Appendix 6.

4.2.2 Rationale for the Use of Comparator/Placebo

Docetaxel is approved as second-line therapy for locally advanced or metastatic NSCLC after platinum therapy failure and is the most frequently prescribed second-line agent.

The use of normal saline placebo in combination with docetaxel will ensure that the investigators and participants (in Arm 1 and Arm 3) remain blinded during the study. The use of normal saline placebo also ensures the objectivity of investigator-assessed progression for Arm 1 and Arm 3, as well as any decisions regarding treatment interruption/discontinuation.

In this study, the efficacy of MK-7684A with or without docetaxel will be compared with demonstrate superiority over docetaxel monotherapy. In addition, the MK-7684A alone arm will also serve to determine the contribution of components for MK-7684A + docetaxel combination.

4.3 Justification for Dose

4.3.1 MK-7684A

Based on the totality of available data, including preliminary clinical PK, pharmacodynamics, safety, and efficacy from the dose escalation and confirmation portion of Study MK-7684-001, the selected dose of MK-7684 is 200 mg, to be administered as MK-7684A (a coformulation with 200 mg pembrolizumab) as a 30-minute IV infusion Q3W.

PK data from study MK-7684-001 in 323 participants across tumor types, including dose groups of 200/210 mg Q3W and 700 mg Q3W indicate that observed PK parameters were generally similar across tumor types. Observed PK profiles of MK-7684 suggest that target-mediated clearance of MK-7684 is saturated at the 200/210 mg and 700 mg doses. The PK of MK-7684 is generally consistent with that of other humanized mAbs, which typically have low CL and a limited Vc [Keizer,R.J., et al 2010] [Dostalek,M., et al 2012] [Dirks, N. L. and Meibohm, B 2010]. As with other mAbs, body weight was found to be related to MK-7684 CL and Vc parameters, but the relationship was weak for both parameters. As such, this supports that fixed dosing would provide better control of PK variability than body weight-based dosing [Hendrikx, J. J. M. A., et al 2017] [Bai,S., et al 2012].

Available clinical safety data indicated that MK-7684 is tolerable at doses up to and including 700 mg, both when used as monotherapy and in combination with pembrolizumab. No DLTs were observed at any of the MK-7684 doses tested either as monotherapy or in combination with pembrolizumab during the dose escalation and confirmation portion of Study MK-7684-001, and the MTD was not reached.

Clinical activity was observed at the 200/210-mg and the 700-mg dose levels of MK-7684 both during the dose escalation and confirmation portion of Study MK-7684-001 in participants with advanced solid tumors of all types and during the dose expansion portion, particularly in PD-1/PD-L1 inhibitor treatment-naïve participants with NSCLC, ovarian cancer, breast cancer, and cervical cancer treated with MK-7684 in combination with pembrolizumab.

The 200 mg and 700 mg doses were compared in a randomized dose-finding cohort of participants with anti-PD-1/PD-L1 treatment naïve cervical cancer in MK-7684-001 Part B. Exploratory analysis of exposure versus best change in tumor size (based on preliminary data from 63 participants) shows a flat relationship, suggesting that 200 mg is at the plateau of the exposure-efficacy relationship. The mean difference in target lesion percent change from baseline between the 200 mg and 700 mg groups for the first scan was -2.1% (95% CI: -21.2, 16.9) with 2-sided *p*-value of 0.824, and for best overall scan was -8.1% (95% CI: -31.1, 15) with 2-sided *p*-value of 0.488. Therefore, tumor size reduction showed no significant difference between the 2 dose groups.

Overall, the totality of data, including lack of a clinically meaningful effect of body weight on PK, consistency of PK across indications and a flat dose-exposure-tumor size response relationship support that a fixed dose of 200 mg Q3W is an optimal dose for MK-7684 in combination with 200 mg pembrolizumab.

For more information, see the MK-7684A IB.

4.3.2 Pembrolizumab

The planned dose of pembrolizumab for this study is 200 mg Q3W. Based on the totality of data generated in the pembrolizumab development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type. This dose is justified by:

- Clinical data from 8 randomized studies demonstrating flat dose- and exposure-efficacy relationships from 2 mg/kg Q3W to 10 mg/kg Q2W.
- Clinical data showing meaningful improvement in benefit-risk including OS at 200 mg Q3W across multiple indications, and
- Pharmacology data showing full target saturation in both systemic circulation (inferred from PK data) and tumor (inferred from PBPK analysis) at 200 mg Q3W.

For more information please refer to the pembrolizumab IB.

4.3.3 Maximum Dose/Exposure for This Study

The maximum dose/exposure of MK-7684A allowed in this study is 200 mg MK-7684/200 mg pembrolizumab for up to 2 years (35 treatment cycles) of initial treatment (Section 6.6.2) and an additional 1 year (17 cycles) for Second Course (Section 6.6.3).

The maximum dose of docetaxel is 75 mg/m² IV. Docetaxel may be continued until a discontinuation criterion is met (Section 7.1) or as per approved local label.

4.4 Beginning and End of Study Definition

The overall study begins when the first participant (or their legally acceptable representative) provides documented informed consent.

The overall study ends when the last participant completes the last study-related contact, withdraws consent, or is lost to follow-up (ie, the participant is unable to be contacted by the investigator).

For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last laboratory result or at the time of final contact with the last participant, whichever comes last.

If the study includes countries in the European Economic Area (EEA), the local start of the study in the EEA is defined as First Site Ready (FSR) in any Member State.

4.4.1 Clinical Criteria for Early Study Termination

Recruitment in the study or at (a) particular study site(s) may be stopped due to insufficient compliance with the protocol, GCP and/or other applicable regulatory requirements, procedure-related problems or the number of discontinuations for administrative reasons is too high.

Early study termination will be the result of the criteria specified below:

1. Incidence or severity of emerging effects/clinical endpoints is such that the risk/benefit ratio for the study population as a whole is unacceptable.
2. Plans to modify or discontinue the development of the study medication.

Ample notification will be provided in the event of Sponsor decision to no longer supply MK-7684A.

5 STUDY POPULATION

As stated in the Code of Conduct for Clinical Trials (Appendix 1.1), our studies include people of varying age, race, ethnicity, and sex. The collection and use of these demographic data are to follow all local laws and guidelines in keeping with the needs for participant confidentiality while supporting the study of the disease, its related factors, and the IMP under investigation.

Participants with metastatic NSCLC and PD after platinum doublet chemotherapy and an anti-PD-1/PD-L1 mAb (either concomitantly or sequentially) will be enrolled into the study.

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

5.1 Inclusion Criteria

Participants are eligible for the study only if all of the following criteria are met:

Type of Participant and Disease Characteristics

1. Has a histologically or cytologically confirmed diagnosis of metastatic NSCLC (Stage IV: M1a, M1b, M1c, AJCC Staging Manual, version 8).

Note: Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.

2. Has confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy (documentation of the absence of tumor-activating EGFR mutations [eg, DEL19 or L858R], AND absence of ALK and ROS1 gene rearrangements).

Note: If participant's tumor is known to have a predominantly squamous histology, molecular testing for *EGFR* mutation and *ALK* and *ROS1* translocations will not be required, as this is not part of current diagnostic guidelines.

3. Has PD on treatment with one prior anti-PD-1/PD-L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. Anti-PD-1/PD-L1 treatment progression is defined by meeting ALL of the following criteria:

- Treatment with at least 2 doses of an anti-PD-1/PD-L1 mAb.
- PD after an anti-PD-1/PD-L1 mAb as defined by RECIST 1.1, based on the following:
 - Imaging before anti-PD-1/PD-L1 treatment or image showing nadir during anti-PD-1/PD-L1 treatment; AND
 - Imaging to determine that radiographic progression has occurred per RECIST 1.1 within 12 weeks (84 days) from the last dose of an anti-PD-1/PD-L1 mAb.

Note: Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment.

4. Has PD as determined by the investigator after platinum doublet chemotherapy for metastatic disease.

Note: A platinum-containing doublet is defined as a platinum-based cytotoxic systemic agent administered in the same cycle as another cytotoxic systemic chemotherapeutic agent.

Note: Completion of treatment with a platinum-containing doublet as neo-adjuvant or adjuvant therapy or as part of definitive chemo-radiation treatment for early stage disease (Stage I-III) within 1 year of signing the ICF will satisfy the prior platinum doublet chemotherapy treatment requirement.

Note: Eligible participants will have PD after an anti-PD-1/PD-L1 therapy AND platinum doublet chemotherapy (sequentially or concomitantly).

5. Has measurable disease based on RECIST 1.1, as determined by the local site assessment.

Note: Measurable disease is defined as having at least 1 measurable lesion by CT or MRI per RECIST 1.1. Lesions that appear measurable, but are situated in a previously irradiated area can be considered measurable (eligible for selection as target lesions) if they have shown documented growth since the completion of radiation.

6. Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample (defined as: from initial diagnosis of NSCLC and before receiving immunotherapy [anti-PD-1/PD-L1], from the primary lesion or a metastatic lesion) or newly obtained (defined as: after completion of immunotherapy [anti-PD-1/PD-L1] and before receiving a randomization number) core or excisional biopsy of a tumor lesion not previously irradiated.

Note: The tissue sample must be received and evaluated by the central vendor before randomization for stratification in the study. FFPE tissue blocks are preferred to slides. Details pertaining to tumor tissue submission can be found in the Procedures Manual.

Demographics

7. Is male or female, ≥ 18 years of age at the time of providing documented informed consent.
8. Has a life expectancy of at least 3 months.
9. Has an ECOG Performance Status of 0 to 1 assessed within 7 days prior to randomization.

Male Participants

10. **Male participants randomized to docetaxel** are eligible to participate if they agree to the following during the intervention period and for at least 180 days after the last dose of docetaxel:
 - Refrain from donating sperm.

PLUS either:

- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

OR

- Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause [Appendix 5]) as detailed below:
 - Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant.
 - Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.
 - Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed.

Female Participants

11. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

- Is not a WOCBP

OR

- Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), as described in Appendix 5 during the intervention period and for at least 120 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention.
- A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours for urine or within 72 hours for serum before the first dose of study intervention.
- A WOCBP randomized to docetaxel is eligible to participate if she is using a contraceptive method that is highly effective with low user dependency or is abstinent from heterosexual intercourse as her preferred and usual lifestyle and agrees not to donate

or freeze/store eggs during the intervention period and for at least 180 days after the last dose of docetaxel.

- If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
- Additional requirements for pregnancy testing during and after study intervention are located in Section 8.3.5.
- The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
- Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirement above, the local label requirements are to be followed.

Informed Consent

12. The participant (or legally acceptable representative if applicable) provides documented informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.

Additional Categories

13. Has adequate organ function as defined in [Table 3](#). Specimens must be collected within 10 days before the start of study intervention.

Table 3 Adequate Organ Function Laboratory Values

System	Laboratory Value
Hematological	
Absolute neutrophil count	$\geq 1500/\mu\text{L}$
Platelets	$\geq 100,000/\mu\text{L}$
Hemoglobin	$\geq 9.0 \text{ g/dL}$ or $\geq 5.6 \text{ mmol/L}^a$
Renal	
Creatinine <u>OR</u> Measured or calculated ^b CrCl (GFR can also be used in place of creatinine or CrCl)	$\leq 1.5 \times \text{ULN}$ <u>OR</u> $\geq 30 \text{ mL/min}$ for participant with creatinine levels $> 1.5 \times \text{institutional ULN}$
Hepatic	
Total bilirubin	$\leq 1.5 \times \text{ULN}$ <u>OR</u> direct bilirubin $\leq \text{ULN}$ for participants with total bilirubin levels $> 1.5 \times \text{ULN}$
AST (SGOT) and ALT (SGPT)	$\leq 2.5 \times \text{ULN}$ ($\leq 5 \times \text{ULN}$ for participants with liver metastases)
Coagulation	
INR or PT aPTT/PTT	$\leq 1.5 \times \text{ULN}$ unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
<p>Abbreviations: ALT (SGPT) = alanine aminotransferase (serum glutamic-pyruvic transaminase); aPTT = activated partial thromboplastin time; AST (SGOT) = aspartate aminotransferase (serum glutamic oxaloacetic transaminase); CrCl = creatinine clearance; GFR = glomerular filtration rate; INR = international normalized ratio; PT = prothrombin time; PTT = partial thromboplastin time; ULN = upper limit of normal.</p> <p>Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value requirements should be adapted according to local regulations and guidelines for the administration of specific chemotherapies.</p> <p>^a Criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within last 2 weeks.</p> <p>^b CrCl should be calculated per institutional standard.</p>	

5.2 Exclusion Criteria

The participant must be excluded from the study if the participant:

Medical Conditions

1. Has known active or untreated CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks by repeat imaging (note: repeat imaging should be performed during study screening), clinically stable, and without requirement of steroid treatment for at least 7 days before the first dose of study intervention.
2. Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy.

Note: The time requirement for no evidence of disease for at least 3 years does not apply to the NSCLC for which a participant is enrolled in the study. The time requirement also does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.

Prior/Concomitant Therapy

3. Has received docetaxel as monotherapy or in combination with other therapies.
4. Has received previous treatment with another agent targeting the TIGIT receptor pathway.
5. Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.

Note: Participants must have recovered from all AEs due to previous therapies to \leq Grade 1 or baseline (except alopecia). Participants with Grade ≤ 2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤ 2 requiring treatment or hormone replacement may be eligible.

6. Has received radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease.
7. Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.

Prior/Concurrent Clinical Study Experience

8. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.

Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks since the last dose of the previous investigational agent.

Diagnostic Assessments

9. Has severe hypersensitivity (\geq Grade 3) to docetaxel or MK-7684A and/or any of its excipients (eg, polysorbate 80).
10. Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
11. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention.
12. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
13. Has a known history of interstitial lung disease. Lymphangitic spread of the NSCLC is not exclusionary.
14. Has an active infection requiring systemic therapy.
15. Has a known history of HIV infection. No HIV testing is required unless mandated by local health authority.
16. Has a known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.

Note: No testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.

17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.

18. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

Other Exclusions

19. If the participant had major surgery, the participant must have recovered adequately from the procedure and/or any complications from the surgery before starting study intervention.

20. Has had an allogenic tissue/solid organ transplant.

Country-specific requirements are noted in Appendix 7.

5.3 Lifestyle Considerations

5.3.1 Meals and Dietary Restrictions

Participants should maintain a normal diet unless modifications are required to manage an AE such as diarrhea, nausea, or vomiting.

5.3.2 Caffeine, Alcohol, and Tobacco Restrictions

No restrictions are necessary.

5.3.3 Activity Restrictions

No restrictions are necessary.

5.4 Screen Failures

Screen failures are defined as participants who consent to participate in the clinical study, but are not subsequently randomized in the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the CONSORT publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting requirements as outlined in the data entry guidelines.

Participants who fail screening may be rescreened for eligibility.

5.5 Participant Replacement Strategy

A participant who discontinues from study intervention OR withdraws consent from the study will not be replaced.

6 STUDY INTERVENTION

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.

Clinical supplies (MK-7684A) will be packaged to support enrollment. Normal saline placebo will be sourced locally by the site. Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.

6.1 Study Intervention(s) Administered

The study interventions to be used in this study are outlined in [Table 4](#).

Country-specific requirements are noted in Appendix 7.

When concurrently administered, MK-7684A/normal saline placebo should be given before chemotherapy; chemotherapy should be given as per the local label.

All study interventions will be administered on an outpatient basis.

All products indicated in [Table 4](#) will be provided centrally by the Sponsor or locally by the study site, subsidiary or designee, depending on local country operational or regulatory requirements.

For any commercially available product that is provided by the study site, subsidiary, or designee, every attempt will be made to source these supplies from a single lot/batch number. The study site is responsible for recording the lot number, manufacturer, and expiry date for any locally purchased product as per local guidelines unless otherwise instructed by the Sponsor.

Refer to Section 8.1.8 for details regarding administration of the study intervention.

Table 4 Study Interventions

Arm Name	Arm Type	Intervention Name	Intervention Type	Dose Formulation	Unit Dose Strength(s)	Dosage Level(s)	Route of Administration	Regimen/ Treatment Period	Use	IMP or NIMP/ AxMP	Sourcing
Arm 1	Experimental	MK-7684A	Biological/ Vaccine	Solution for Infusion	MK-7684 200 mg + pembrolizumab 200 mg/ 20 mL vial	200mg/ 200mg	IV Infusion	Q3W up to 35 cycles	Test Product	IMP	Central
Arm 1	Experimental	Docetaxel	Drug	Solution for Infusion	20 mg/mL	75 mg/m ²	IV Infusion	Q3W until a discontinuation criterion is met or as per approved local label.	Test Product	IMP	Provided centrally by the Sponsor or locally by the study site, subsidiary or designee
Arm 2	Experimental	MK-7684A	Biological/ Vaccine	Solution for Infusion	MK-7684 200 mg + pembrolizumab 200 mg/ 20 mL vial	200mg/ 200mg	IV Infusion	Q3W up to 35 cycles	Test Product	IMP	Central

Arm Name	Arm Type	Intervention Name	Intervention Type	Dose Formulation	Unit Dose Strength(s)	Dosage Level(s)	Route of Administration	Regimen/ Treatment Period	Use	IMP or NIMP/ AxMP	Sourcing
Arm 3	Active Comparator	Docetaxel	Drug	Solution for Infusion	20 mg/mL	75 mg/m ²	IV Infusion	Q3W until a discontinuation criterion is met or as per approved local label.	Test Product	IMP	Provided centrally by the Sponsor or locally by the study site, subsidiary or designee
Arm 3	Placebo Comparator	Normal saline placebo	Biological/ Vaccine	Solution for Infusion	0 mg	0 mg	IV Infusion	Q3W up to 35 cycles	Placebo	IMP	Local
<p>MK-7684A = Coformulated as 200 mg MK-7684 and 200 mg pembrolizumab.</p> <p>EEA=European Economic Area; IMP=investigational medicinal product; NIMP/AxMP=noninvestigational/auxiliary medicinal product.</p> <p>The classification of IMP and NIMP/AxMP in this table is based on guidance issued by the European Commission and applies to countries in the EEA. Country differences with respect to the definition/classification of IMP and NIMP/AxMP may exist. In these circumstances, local legislation is followed.</p>											

6.2 Preparation/Handling/Storage/Accountability

6.2.1 Dose Preparation

Details on preparation and administration of MK-7684A/normal saline placebo are provided in the Pharmacy Manual.

Docetaxel will be prepared and administered as per the approved local product label. Docetaxel 75 mg/m² will be administered as an IV infusion over 1 hour every Q3W.

6.2.2 Handling, Storage, and Accountability

The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received, and any discrepancies are reported and resolved before use of the study intervention.

Only participants enrolled in the study may receive study intervention, and only authorized site staff may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.

The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).

For all study sites, the local country Sponsor personnel or designee will provide appropriate documentation that must be completed for drug accountability and return, or local discard and destruction if appropriate. Where local discard and destruction is appropriate, the investigator is responsible for ensuring that a local discard/destruction procedure is documented.

The study site is responsible for recording the lot number, manufacturer, and expiry date for any locally purchased product (if applicable) as per local guidelines unless otherwise instructed by the Sponsor.

The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution, and usage of study interventions in accordance with the protocol and any applicable laws and regulations.

6.3 Measures to Minimize Bias: Randomization and Blinding

6.3.1 Intervention Assignment

Intervention randomization will occur centrally using an IRT system. There are 3 study intervention arms. Participants will be assigned randomly in a 1:1:1 ratio to MK-7684A + docetaxel (Arm 1), MK-7684A (Arm 2), or normal saline placebo + docetaxel (Arm 3), respectively.

6.3.2 Stratification

Intervention randomization will be stratified according to the following factors:

1. ECOG PS (0 vs 1)
2. Prior anti-PD-1/PD-L1 mAb (immediate prior therapy vs not immediate prior therapy)
3. PD-L1 TPS (<50% vs ≥50%)

6.3.3 Blinding

For MK-7684A + docetaxel (Arm 1) and normal saline placebo + docetaxel (Arm 3), a double-blinding technique with in-house blinding will be used. MK-7684A/normal saline placebo will be prepared and dispensed in a blinded fashion by an unblinded pharmacist or qualified study site personnel so that the blind is maintained. The participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the study intervention administration or clinical evaluation of the participants are unaware of the intervention assignments.

Arm 2 (MK-7684A), which does not contain docetaxel, will be open-label; therefore, the Sponsor, investigator, and participant will know the study intervention administered.

Access to the randomization schedule and unblinded results for presentation of summaries and analyses to the eDMC will be restricted to an unblinded statistician and, as needed an unblinded scientific programmer performing the analysis, who will have no other responsibilities associated with the study.

See Section 8.1.10 for a description of the method of unblinding a participant during the study should such action be warranted.

6.4 Study Intervention Compliance

If there are interruptions in the study intervention schedule, the details of and reason for any interruption of study intervention will be documented in the participant's medical record.

Refer to Section 6.6.1 for dose modification and toxicity management for irAEs associated with MK-7684A and for other allowed dose interruptions of MK-7684A.

When participants are dosed at the site, they will receive study intervention directly from the investigator or designee, under medical supervision. The date and time of each dose administered in the clinic will be recorded in the source documents and recorded in the CRF. The dose of study intervention and study participant ID will be confirmed at the time of dosing by a member of the study site staff other than the person administering the study intervention.

6.5 Concomitant Therapy

Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the treatment period. If there is a clinical indication for any medication or vaccination specifically prohibited, discontinuation from study therapy or vaccination may be required. The investigator should discuss any questions regarding this with the Sponsor's Clinical Director. The final decision on any supportive therapy or vaccination rests with the investigator and/or the participant's primary physician. However, the decision to continue the participant on study intervention requires the mutual agreement of the investigator, the Sponsor, and the participant.

Participants are prohibited from receiving the following therapies during the screening and treatment periods of this study:

- Antineoplastic systemic chemotherapy or biological therapy.
- Immunotherapy not specified in this protocol.
- Chemotherapy not specified in this protocol.
- Investigational agents other than MK-7684A.
- Radiation therapy for disease control.

Note: Palliative radiotherapy is permitted for nontarget lesions if considered medically necessary by the treating physician and on discussion with the Sponsor.

- Live or live-attenuated vaccines within 30 days before the first dose of study intervention and while participating in the study. Note: Killed vaccines are allowed.
- Systemic glucocorticoids are permitted only for the following purposes:
 - To modulate symptoms of an AE that is suspected to have an immunologic etiology.
 - As needed for the prevention of emesis.
 - Premedication for IV contrast allergies.
 - Short-term oral or IV use in doses >10 mg/day prednisone equivalent for COPD exacerbations.

- For chronic systemic replacement not to exceed 10 mg/day prednisone equivalent.
- In addition, the following glucocorticoid use is allowed:
 - For topical use or ocular use.
 - Intraarticular joint use.
 - For inhalation in the management of asthma or chronic obstructive pulmonary disease.

If the investigator determines that a participant requires any of the aforementioned treatments for any reason, study intervention (all study interventions in combination arms) must be discontinued.

All treatments that the investigator considers necessary for a participant's welfare may be administered at the discretion of the investigator in keeping with the community standards of medical care. All concomitant medication will be recorded on the eCRF including all prescription, OTC products, herbal supplements, and IV medications, and fluids. If changes occur during the study period, documentation of drug dosage, frequency, route, and date should also be included on the eCRF.

All concomitant medications received within 30 days prior to the first dose of study intervention and up to 30 days after the last dose of study intervention should be recorded. All concomitant medications administered during SAEs or ECIs are to be recorded. SAEs and ECIs are defined in Section 8.4.

6.5.1 Rescue Medications and Supportive Care

Participants should receive appropriate supportive care measures as deemed necessary by the treating investigator. Suggested supportive care measures for the management of AEs with potential immunologic etiology are outlined along with the dose modification guidelines in Section 6.6.1.

Note: If after the evaluation of the event, it is determined not to be related to MK-7684A, the investigator does not need to follow the treatment guidance. Refer to [Table 5](#) in Section 6.6.1 for guidelines regarding dose modification and supportive care.

Participants in the docetaxel arm should receive premedication with corticosteroids for 3 days starting 1 day before docetaxel administration to reduce the risk of fluid retention and the severity of hypersensitivity reactions. Refer to the approved product label for docetaxel dose interruptions and dose reductions.

6.6 Dose Modification (Escalation/Titration/Other)

6.6.1 Immune-Related Events and Dose Modification (Withhold, Treat, Discontinue)

Dose Modification and Toxicity Management for Immune-related AEs Associated with Pembrolizumab Monotherapy, Coformulations or IO Combinations

AEs associated with pembrolizumab monotherapy, coformulation, or IO combination exposure may represent an immune-related response. These irAEs may occur shortly after the first dose or several months after the last dose of pembrolizumab monotherapy, coformulation, or IO combination treatment and may affect more than one body system simultaneously. Therefore, early recognition and initiation of treatment is critical to reduce complications. Based on existing clinical study data, most irAEs were reversible and could be managed with interruptions of pembrolizumab monotherapy, coformulation, or IO combination administration of corticosteroids and/or other supportive care. For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be included as part of the evaluation.

Attribution of Toxicity:

When study interventions are administered in combination, attribution of an adverse event to a single component is likely to be difficult. Therefore, while the investigator may attribute a toxicity event to pembrolizumab monotherapy, coformulations, or IO combinations, pembrolizumab monotherapy, coformulations, or IO combinations must be held according to the criteria in the Dose Modification and Toxicity Management Guidelines for Immune-Related Adverse Events.

Holding Study Interventions:

When study interventions are administered in combination and if the AE is considered immune-related, pembrolizumab monotherapy, coformulations, or IO combinations should be held according to recommended Dose Modification criteria.

If the toxicity does not resolve or the criteria for resuming treatment are not met, the participant must be discontinued from pembrolizumab monotherapy, coformulations, or IO combinations.

Restarting Study Interventions:

Participants may restart pembrolizumab monotherapy, coformulations, or IO combinations as described below:

If the toxicities do resolve and conditions are aligned with what is defined in the Dose Modification and Toxicity Management Guidelines for irAEs, pembrolizumab monotherapy, coformulations, or IO combinations may be restarted at the discretion of the investigator.

Dose Modification and Toxicity Management Guidelines for irAEs associated with pembrolizumab monotherapy, coformulations, or IO combinations are provided in [Table 5](#).

Table 5 Dose Modification and Toxicity Management Guidelines for Immune-related Adverse Events Associated with Pembrolizumab Monotherapy, Coformulations or IO Combinations

General instructions: 1. Severe and life-threatening irAEs should be treated with IV corticosteroids followed by oral steroids. Other immunosuppressive treatment should begin if the irAEs are not controlled by corticosteroids. 2. Pembrolizumab monotherapy, coformulations or IO combinations must be permanently discontinued if the irAE does not resolve or the corticosteroid dose is not ≤ 10 mg/day within 12 weeks of the last treatment. 3. The corticosteroid taper should begin when the irAE is \leq Grade 1 and continue at least 4 weeks. 4. If pembrolizumab monotherapy, coformulations or IO combinations have been withheld, treatment may resume after the irAE decreased to \leq Grade 1 after corticosteroid taper.				
irAEs	Toxicity Grade (CTCAE v5.0)	Action With Pembrolizumab Monotherapy, Coformulations or IO Combinations	Corticosteroid and/or Other Therapies	Monitoring and Follow-up
Pneumonitis	Grade 2	Withhold	<ul style="list-style-type: none"> Administer corticosteroids (initial dose of 1 to 2 mg/kg prednisone or equivalent) followed by taper Add prophylactic antibiotics for opportunistic infections 	<ul style="list-style-type: none"> Monitor participants for signs and symptoms of pneumonitis Evaluate participants with suspected pneumonitis with radiographic imaging and initiate corticosteroid treatment
	Recurrent Grade 2, Grade 3 or 4	Permanently discontinue		
Diarrhea/Colitis	Grade 2 or 3	Withhold	<ul style="list-style-type: none"> Administer corticosteroids (initial dose of 1 to 2 mg/kg prednisone or equivalent) followed by taper 	<ul style="list-style-type: none"> Monitor participants for signs and symptoms of enterocolitis (ie, diarrhea, abdominal pain, blood or mucus in stool with or without fever) and of bowel perforation (ie, peritoneal signs and ileus) Participants with \geqGrade 2 diarrhea suspecting colitis should consider GI consultation and performing endoscopy to rule out colitis Participants with diarrhea/colitis should be advised to drink liberal quantities of clear fluids. If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via IV infusion
	Recurrent Grade 3 or Grade 4	Permanently discontinue		

irAEs	Toxicity Grade (CTCAE v5.0)	Action With Pembrolizumab Monotherapy, Coformulations or IO Combinations	Corticosteroid and/or Other Therapies	Monitoring and Follow-up
AST or ALT Elevation or Increased Bilirubin	Grade 2 ^a	Withhold	<ul style="list-style-type: none"> Administer corticosteroids (initial dose of 0.5 to 1 mg/kg prednisone or equivalent) followed by taper 	<ul style="list-style-type: none"> Monitor with liver function tests (consider weekly or more frequently until liver enzyme value returned to baseline or is stable)
	Grade 3 ^b or 4 ^c	Permanently discontinue	<ul style="list-style-type: none"> Administer corticosteroids (initial dose of 1 to 2 mg/kg prednisone or equivalent) followed by taper 	
T1DM or Hyperglycemia	New onset T1DM or Grade 3 or 4 hyperglycemia associated with evidence of β -cell failure	Withhold ^d	<ul style="list-style-type: none"> Initiate insulin replacement therapy for participants with T1DM Administer antihyperglycemic in participants with hyperglycemia 	<ul style="list-style-type: none"> Monitor participants for hyperglycemia or other signs and symptoms of diabetes
Hypophysitis	Grade 2	Withhold	<ul style="list-style-type: none"> Administer corticosteroids and initiate hormonal replacements as clinically indicated 	<ul style="list-style-type: none"> Monitor for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency)
	Grade 3 or 4	Withhold or permanently discontinue ^d		
Hyperthyroidism	Grade 2	Continue	<ul style="list-style-type: none"> Treat with nonselective beta-blockers (eg, propranolol) or thionamides as appropriate 	<ul style="list-style-type: none"> Monitor for signs and symptoms of thyroid disorders
	Grade 3 or 4	Withhold or permanently discontinue ^d		
Hypothyroidism	Grade 2, 3 or 4	Continue	<ul style="list-style-type: none"> Initiate thyroid replacement hormones (eg, levothyroxine or liothyronine) per standard of care 	<ul style="list-style-type: none"> Monitor for signs and symptoms of thyroid disorders

irAEs	Toxicity Grade (CTCAE v5.0)	Action With Pembrolizumab Monotherapy, Coformulations or IO Combinations	Corticosteroid and/or Other Therapies	Monitoring and Follow-up
Nephritis: grading according to increased creatinine or acute kidney injury	Grade 2	Withhold	<ul style="list-style-type: none"> Administer corticosteroids (prednisone 1 to 2 mg/kg or equivalent) followed by taper 	<ul style="list-style-type: none"> Monitor changes of renal function
	Grade 3 or 4	Permanently discontinue		
Neurological Toxicities	Grade 2	Withhold	<ul style="list-style-type: none"> Based on severity of AE administer corticosteroids 	<ul style="list-style-type: none"> Ensure adequate evaluation to confirm etiology and/or exclude other causes
	Grade 3 or 4	Permanently discontinue		
Myocarditis	Grade 1	Withhold	<ul style="list-style-type: none"> Based on severity of AE administer corticosteroids 	<ul style="list-style-type: none"> Ensure adequate evaluation to confirm etiology and/or exclude other causes
	Grade 2, 3 or 4	Permanently discontinue		
Exfoliative Dermatologic Conditions	Suspected SJS, TEN, or DRESS	Withhold	<ul style="list-style-type: none"> Based on severity of AE administer corticosteroids 	<ul style="list-style-type: none"> Ensure adequate evaluation to confirm etiology or exclude other causes
	Confirmed SJS, TEN, or DRESS	Permanently discontinue		
All Other irAEs	Persistent Grade 2	Withhold	<ul style="list-style-type: none"> Based on severity of AE administer corticosteroids 	<ul style="list-style-type: none"> Ensure adequate evaluation to confirm etiology or exclude other causes
	Grade 3	Withhold or discontinue based on the event ^c		
	Recurrent Grade 3 or Grade 4	Permanently discontinue		

irAEs	Toxicity Grade (CTCAE v5.0)	Action With Pembrolizumab Monotherapy, Coformulations or IO Combinations	Corticosteroid and/or Other Therapies	Monitoring and Follow-up
<p>AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; DRESS=Drug Rash with Eosinophilia and Systemic Symptom; GI=gastrointestinal; IO=immuno-oncology; ir=immune related; IV=intravenous; SJS=Stevens-Johnson Syndrome; T1DM=type 1 diabetes mellitus; TEN=Toxic Epidermal Necrolysis; ULN=upper limit of normal.</p> <p>Note: Non-irAE will be managed as appropriate, following clinical practice recommendations.</p> <p>^a AST/ALT: >3.0 to 5.0 x ULN if baseline normal; >3.0 to 5.0 x baseline, if baseline abnormal; bilirubin:>1.5 to 3.0 x ULN if baseline normal; >1.5 to 3.0 x baseline if baseline abnormal</p> <p>^b AST/ALT: >5.0 to 20.0 x ULN, if baseline normal; >5.0 to 20.0 x baseline, if baseline abnormal; bilirubin:>3.0 to 10.0 x ULN if baseline normal; >3.0 to 10.0 x baseline if baseline abnormal</p> <p>^c AST/ALT: >20.0 x ULN, if baseline normal; >20.0 x baseline, if baseline abnormal; bilirubin: >10.0 x ULN if baseline normal; >10.0 x baseline if baseline abnormal</p> <p>^d The decision to withhold or permanently discontinue pembrolizumab monotherapy, coformulations or IO combinations is at the discretion of the investigator or treating physician. If control achieved or ≤ Grade 2, pembrolizumab monotherapy, coformulations or IO combinations may be resumed.</p> <p>^e Events that require discontinuation include, but are not limited to: encephalitis and other clinically important irAEs (eg, vasculitis and sclerosing cholangitis).</p>				

Dose Modification and Toxicity Management of Infusion Reactions Related to MK-7684A

MK-7684A may cause severe or life-threatening infusion-reactions including severe hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after drug infusion and generally resolve completely within 24 hours of completion of infusion. Dose modification and toxicity management guidelines on MK-7684A associated infusion reaction are provided in [Table 6](#).

Table 6 MK-7684A Infusion Reaction Dose Modification and Treatment Guidelines

NCI CTCAE Grade	Treatment	Premedication at Subsequent Dosing
Grade 1 Mild reaction; infusion interruption not indicated; intervention not indicated	Increase monitoring of vital signs as medically indicated until the participant is deemed medically stable in the opinion of the investigator	None
Grade 2 Requires therapy or infusion interruption but responds promptly to symptomatic treatment (eg, antihistamines, NSAIDs, narcotics, IV fluids); prophylactic medications indicated for ≤ 24 hrs	<p>Stop Infusion</p> <p>Additional appropriate medical therapy may include but is not limited to:</p> <ul style="list-style-type: none"> IV fluids Antihistamines NSAIDs Acetaminophen Narcotics <p>Increase monitoring of vital signs as medically indicated until the participant is deemed medically stable in the opinion of the investigator.</p> <p>If symptoms resolve within 1 hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate (eg, from 100 mL/hr to 50 mL/hr). Otherwise dosing will be held until symptoms resolve and the participant should be premedicated for the next scheduled dose.</p> <p>Participants who develop Grade 2 toxicity despite adequate premedication should be permanently discontinued from further study drug intervention.</p>	<p>Participant may be premedicated 1.5 h (± 30 minutes) prior to infusion of study intervention with:</p> <ul style="list-style-type: none"> Diphenhydramine 50 mg PO (or equivalent dose of antihistamine). Acetaminophen 500-1000 mg PO (or equivalent dose of analgesic).

NCI CTCAE Grade	Treatment	Premedication at Subsequent Dosing
Grades 3 or 4 Grade 3: Prolonged (ie, not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae (eg, renal impairment, pulmonary infiltrates) Grade 4: Life-threatening; pressor or ventilatory support indicated	Stop Infusion. Additional appropriate medical therapy may include but is not limited to: Epinephrine** IV fluids Antihistamines NSAIDs Acetaminophen Narcotics Oxygen Pressors Corticosteroids Increase monitoring of vital signs as medically indicated until the participant is deemed medically stable in the opinion of the investigator. Hospitalization may be indicated. **In cases of anaphylaxis, epinephrine should be used immediately. Participant is permanently discontinued from further study drug intervention.	No subsequent dosing
Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period of drug administration. For further information, please refer to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE) at http://ctep.cancer.gov		

Other Allowed Dose Interruption for MK-7684A

MK-7684A may be interrupted for situations other than treatment-related AEs such as medical or surgical events and/or unforeseen circumstances not related to study intervention. However, study intervention is to be restarted within 3 weeks of the originally scheduled dose and within 6 weeks of the previously administered dose, unless otherwise discussed with the Sponsor. The reason for study intervention interruption is to be documented in the participant's study record.

Docetaxel

Refer to the approved product label for docetaxel.

6.6.2 Initial Treatment or First Course

The initial treatment or first course of MK-7684A Q3W consists of 35 treatments (approximately 2 years). Note: The number of treatments is calculated starting with the first dose.

For participants who have attained a confirmed CR and have received at least 8 doses of MK-7684A, including at least 2 doses of MK-7684A beyond the initial CR confirmation date, treatment may be stopped.

These participants may be eligible for Second Course described in Section 6.6.3.

6.6.3 Second Course

All participants who have SD, PR, or CR may be eligible for up to an additional 17 cycles of MK-7684A if there is BICR verification of radiographic disease progression by RECIST 1.1 after initial treatment or first course has been completed or stopped for confirmed CR, as specified in Section 6.6.2. This retreatment is the Second Course of this study.

Participants may enter the Second Course if all of the following criteria are met:

1. The participant received MK-7684A, determined on unblinding if applicable
2. No new anticancer treatment was administered after the last dose of study intervention
3. The participant meets all of the inclusion criteria and none of the exclusion criteria
4. The study is ongoing

An objective response or disease progression that occurs during the Second Course will not be counted as an event for the primary analysis of either endpoint in this study.

6.7 Intervention After the End of the Study

There is no study-specified intervention following the end of the study.

6.8 Clinical Supplies Disclosure

The emergency unblinding call center will use the intervention/randomization schedule for the study to unblind participants and to unmask study intervention identity for MK-7684A or normal saline placebo (Arm 1 and Arm 3) of this study. The emergency unblinding call center should only be used in cases of emergency (see Section 8.1.10). In the event that the emergency unblinding call center is not available for a given site in this study, the central electronic intervention randomization system (IRT) should be used to unblind participants and to unmask study intervention identity. The Sponsor will not provide random code/disclosure envelopes or lists with the clinical supplies.

6.9 Standard Policies

At the close of the study after unblinding, a letter is to be sent by the investigator to those participants who received placebos to provide the following advice: “You have participated in a study conducted by the Sponsor. This letter is to advise you that you were among those who received a look-alike solution for infusion created by the Sponsor to resemble the drug MK-7684A as much as possible. You did not receive the active drug MK-7684A as manufactured by MSD.”

7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT WITHDRAWAL

7.1 Discontinuation of Study Intervention

Discontinuation of study intervention does not represent withdrawal from the study.

As certain data on clinical events beyond study intervention discontinuation may be important to the study, they must be collected through the participant’s last scheduled follow-up, even if the participant has discontinued study intervention. Therefore, all participants who discontinue study intervention prior to completion of the protocol-specified treatment period will still continue to be monitored in this study and participate in the study visits and procedures as specified in Section 1.3 and Section 8.11.4 unless the participant has withdrawn from the study (see Section 7.2).

Participants may discontinue study intervention at any time for any reason or be discontinued from the study intervention at the discretion of the investigator should any untoward effect occur. In addition, a participant may be discontinued from study intervention by the investigator or the Sponsor if study intervention is inappropriate, the study plan is violated, or for administrative and/or other safety reasons.

A participant must be discontinued from study intervention but continue to be monitored in the study for any of the following reasons:

- The participant or participant’s legally acceptable representative requests to discontinue study intervention.
- Any prolonged interruption of study intervention beyond the permitted periods, for irAE management or other allowed dose interruptions, as noted in Section 6.6.1, require Sponsor consultation prior to restarting treatment. If treatment will not be restarted, the participant will continue to be monitored in the study and the reason for discontinuation of study intervention will be recorded in the medical record.
- The participant has a medical condition or personal circumstance which, in the opinion of the investigator and/or Sponsor, placed the participant at unnecessary risk from continued administration of study intervention.
- The participant has a confirmed positive serum pregnancy test.

- Taking any prohibited medications noted in Section 6.5.
- Radiographic disease progression outlined in Section 8.2.1.5 (after obtaining informed consent addendum and Sponsor communication, the investigator may elect to continue treatment beyond iCRO-verified disease progression).
- Any progression or recurrence of any malignancy, or any occurrence of another malignancy that requires active treatment.
- Any study intervention-related toxicity specified as a reason for permanent discontinuation as defined in the guidelines for dose modification due to AEs in Section 6.6.1.

For participants who are discontinued from study intervention but continue to be monitored in the study, all visits and procedures, as outlined in the SoA, should be completed.

7.2 Participant Withdrawal From the Study

If a participant fails to return for scheduled visits and/or if the study site is unable to contact the participant after multiple attempts (ie, is lost to follow-up), the procedures to be performed are outlined in Section 7.3.

If a participant decides not to continue receiving study intervention, the participant is to be encouraged to continue visits in the study for follow-up, imaging, and vital status assessment.

Participants who withdraw consent during the study.

If the participant or participant's legally acceptable representative withdraws consent from the study, the participant must be withdrawn from the study.

Section 8.1.9 delineates the specific procedures performed at the time of withdrawal and withdrawal from future biomedical research. Any AEs that are present at the time of withdrawal should be followed in accordance with the safety requirements outlined in Section 8.4.

7.3 Lost to Follow-up

If a participant fails to return to the clinic for a required study visit and/or if the site is unable to contact the participant, the following procedures are to be performed:

- The site must attempt to contact the participant and reschedule the missed visit. If the participant is contacted, the participant should be counseled on the importance of maintaining the protocol-specified visit schedule.
- The investigator or designee must make every effort to regain contact with the participant at each missed visit (eg, telephone calls and/or a certified letter to the participant's last

known mailing address or locally equivalent methods). These contact attempts should be documented in the participant's medical record.

- Note: A participant is not considered lost to follow-up until the last scheduled visit for the individual participant. The missing data for the participant will be managed via the prespecified statistical data handling and analysis guidelines.

8 STUDY ASSESSMENTS AND PROCEDURES

- Study procedures and their timing are summarized in the SoA.
- Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.
- The investigator is responsible for ensuring that procedures are conducted by appropriately qualified (by education, training, and experience) staff. Delegation of study site personnel responsibilities will be documented in the Investigator Trial File Binder (or equivalent).
- All study-related medical decisions must be made by an investigator who is a qualified physician.
- All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.
- Procedures conducted as part of the participant's routine clinical management (eg, blood count) and obtained before signing of ICF may be utilized for screening or baseline purposes provided the procedure met the protocol-specified criteria and were performed within the time frame defined in the SoA.
- Additional evaluations/testing may be deemed necessary by the investigator and or the Sponsor for reasons related to participant safety. In some cases, such evaluation/testing may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations may require that additional informed consent be obtained from the participant. In these cases, such evaluations/testing will be performed in accordance with those regulations.

The maximum amount of blood collected from each participant over the duration of the study will be provided in the Procedures Manual.

Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples.

8.1 Administrative and General Procedures

8.1.1 Informed Consent

The investigator or medically qualified designee (consistent with local requirements) must obtain documented consent from each potential participant or each participant's legally acceptable representative prior to participating in a clinical study or future biomedical research. If there are changes to the participant's status during the study (eg, health or age of majority requirements), the investigator or medically qualified designee must ensure the appropriate consent is in place.

8.1.1.1 General Informed Consent

Informed consent given by the participant or their legally acceptable representative must be documented on a consent form. The form must include the study protocol number, study protocol title, dated signature, and agreement of the participant (or his/her legally acceptable representative) and of the person conducting the consent discussion.

A copy of the documented informed consent form should be given to the participant (or their legally acceptable representative) before participation in the study.

The initial ICF, any subsequent revised ICF, and any written information provided to the participant must receive the IRB/IEC's approval/favorable opinion in advance of use. The participant or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the participant's willingness to continue participation in the study. The communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the participant's or the participant's legally acceptable representative's dated signature.

If the investigator recommends continuation of study intervention beyond disease progression, the participant or their legally acceptable representative will be asked to provide documented informed consent.

Specifics about the study and the study population are to be included in the study informed consent form.

Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and Sponsor requirements.

8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research

The investigator or medically qualified designee will explain the future biomedical research consent to the participant or the participant's legally acceptable representative, answer all of his/her questions, and obtain documented informed consent before performing any procedure related to future biomedical research. A copy of the informed consent will be given to the participant before performing any procedure related to future biomedical research.

8.1.2 Inclusion/Exclusion Criteria

All inclusion and exclusion criteria will be reviewed by the investigator, who is a qualified physician, to ensure that the participant qualifies for the study.

8.1.3 Participant Identification Card

All participants will be given a participant identification card identifying them as participants in a research study. The card will contain study site contact information (including direct telephone numbers) to be used in the event of an emergency. The investigator or qualified designee will provide the participant with a participant identification card immediately after the participant provides documented informed consent. At the time of intervention randomization, site personnel will add the treatment/randomization number to the participant identification card.

The participant identification card also contains contact information for the emergency unblinding call center so that a healthcare provider can obtain information about study intervention in emergency situations where the investigator is not available.

8.1.4 Medical History

A medical history will be obtained by the investigator or qualified designee. The medical history will collect all active conditions and any condition diagnosed within the prior 10 years that the investigator considers to be clinically important. Details regarding the disease for which the participant has enrolled in this study will be recorded separately and not listed as medical history.

8.1.5 Prior and Concomitant Medications Review

8.1.5.1 Prior Medications

The investigator or qualified designee will review prior medication use, including any protocol-specified washout requirement, and record prior medication taken by the participant within 30 days before starting the study. Treatment for the disease for which the participant has enrolled in this study will be recorded separately and not listed as a prior medication.

8.1.5.2 Concomitant Medications

The investigator or qualified designee will record medication, if any, taken by the participant during the study through the Safety Follow-up visit (30 days after the last dose of study intervention or 90 days if used to treat an SAE). Any new anticancer therapy started after the participant's discontinuation from initial treatment will be recorded separately. Additional information collected on this treatment will include, but is not limited to, best response and date of progression.

In addition, medications taken within 30 days of the first dose of Second Course treatment through the Second Course Safety Follow-up Visit (30 days after the last dose of study intervention or 90 days if used to treat an SAE) should be recorded.

8.1.6 Assignment of Screening Number

All consented participants will be given a unique screening number that will be used to identify the participant for all procedures that occur prior to randomization. Each participant will be assigned only 1 screening number. Screening numbers must not be re-used for different participants.

Any participant who is screened multiple times will retain the original screening number assigned at the initial screening visit. Specific details on the Screening/rescreening visit requirements are provided in Section 8.11.1.

8.1.7 Assignment of Treatment/Randomization Number

All eligible participants will be randomly allocated and will receive a treatment/randomization number. The treatment/randomization number identifies the participant for all procedures occurring after treatment randomization. Once a treatment/randomization number is assigned to a participant, it can never be reassigned to another participant.

A single participant cannot be assigned more than 1 treatment/randomization number.

8.1.8 Study Intervention Administration

Study interventions will be administered by the investigator and/or study staff according to the specifications within the Pharmacy Manual.

Study intervention should begin within 3 days of randomization.

8.1.8.1 Timing of Dose Administration

All study treatment will be dosed on Day 1 of each 21-day cycle. After Cycle 1 Day 1, study medication may be administered up to 3 days before or after the scheduled Day 1 of each subsequent cycle for administrative reasons.

The Pharmacy Manual contains specific instructions for the preparation and administration of the infusion solutions.

Arm 2 will receive MK-7684A on Day 1 of each cycle.

In Arm 1 and Arm 3 MK-7684A/normal saline placebo will be administered first on Day 1 of each cycle, followed by docetaxel. Participants should receive premedication per the approved product label for docetaxel.

Docetaxel will be prepared and administered as per the approved local product label. Docetaxel 75 mg/m² will be administered as an IV infusion over 1 hour every Q3W. All participants randomized to docetaxel should be premedicated with steroids for 3 days starting 1 day before docetaxel administration to reduce the risk of fluid retention and the severity of hypersensitivity reactions (or according to the approved product label).

8.1.9 Discontinuation and Withdrawal

Section 7.2 provides a complete description of withdrawal of consent from the study. Participants who withdraw consent from the study should be encouraged to complete all applicable activities scheduled for the final study visit at the time of withdrawal.

8.1.9.1 Withdrawal From Future Biomedical Research

Participants may withdraw their consent for future biomedical research. Participants may withdraw consent at any time by contacting the investigator for the main study. If medical records for the main study are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@MSD.com). Subsequently, the participant's consent for future biomedical research will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the investigator to inform the participant of completion of withdrawal. Any analyses in progress at the time of request for withdrawal or already performed prior to the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received.

In the event that the medical records for the main study are no longer available (eg, if the investigator is no longer required by regulatory authorities to retain the main study records) or the specimens have been completely anonymized, there will no longer be a link between the participant's personal information and their specimens. In this situation, the request for specimen withdrawal cannot be processed.

8.1.10 Participant Blinding/Unblinding

STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY EFFORT SHOULD BE MADE NOT TO UNBLIND.

For emergency situations where the investigator or medically qualified designee (consistent with local requirements) needs to identify the intervention used by a participant and/or the dosage administered, he/she will contact the emergency unblinding call center by telephone and make a request for emergency unblinding. As requested by the investigator or medically qualified designee, the emergency unblinding call center will provide the information to him/her promptly and report unblinding to the Sponsor. Before contacting the emergency unblinding call center to request unblinding of a participant's intervention assignment, the investigator who is a qualified physician should make reasonable attempts to enter the intensity/toxicity grade of the AEs observed, the relation to study intervention, the reason thereof, etc, in the medical record. If it is not possible to record this assessment in the medical record before the unblinding, the unblinding should not be delayed.

If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and person performing the unblinding) must be documented promptly, and the Sponsor Clinical Director notified as soon as possible.

Once an emergency unblinding or a nonemergency unblinding that is part of the study design has taken place, the investigator, site personnel, and Sponsor personnel may be unblinded so that the appropriate follow-up medical care can be provided to the participant.

Participants whose treatment assignment has been unblinded by the investigator or medically qualified designee and/or nonstudy treating physician should continue to be monitored in the study.

Additionally, the investigator or medically qualified designee must go into the IRT system and perform the unblind in the IRT system to update drug disposition. If the emergency unblinding call center is not available for a given site in this study, the IRT system should be used for emergency unblinding if this is required for participant safety.

At the end of the study, random code/disclosure envelopes or lists and unblinding logs are to be returned to the Sponsor or designee.

8.1.11 Calibration of Equipment

The investigator or qualified designee has the responsibility to ensure that any device or instrument used for a clinical evaluation/test during a clinical study that provides information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. Documentation of equipment calibration must be retained as source documentation at the study site.

8.1.12 Tumor Tissue for Biomarker Status

During the Screening period, a tissue sample for each participant is required and is to be:

FFPE tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.

Details pertaining to tumor tissue submission can be found in the Procedures Manual.

The central laboratory will use the tissue sample to ascertain PD-L1 status using the PD-L1 IHC 22C3 pharmDx (Investigational Use Only) diagnostic kit. The diagnostic test is identical to the US FDA-approved PD-L1 IHC 22C3 pharmDx kit except it is labeled IUO.

8.2 Efficacy Assessments

8.2.1 Tumor Imaging and Assessment of Disease

In addition to survival, efficacy will be assessed based on scans to evaluate changes in tumor burden over time, until the participant is discontinued from the study or enters the survival follow-up. The process for scan collection and transmission to the iCRO can be found in the Site Imaging Manual.

Chest, abdomen, and pelvis scans are required for all participants. CT scans are preferred over other tumor imaging methods. For the abdomen and pelvis, contrast-enhanced MRI may be used when CT with iodinated contrast is contraindicated, or when mandated by local practice. The same type of scan should be used in a participant throughout the study to optimize the reproducibility of the assessment of existing and new tumor burden and improve the accuracy of the response assessment. Note: for the purposes of assessing tumor scans, the term “investigator” refers to the local investigator at the site and/or the radiological reviewer at the site or at an offsite facility.

If brain scans are performed, MRI is preferred; however, CT scans are acceptable if MRI is medically contraindicated.

Bone scans may be performed to evaluate bone metastases. Any supplemental scans performed to support a positive or negative bone scan, such as plain X-rays acquired for correlation, should also be submitted to the iCRO.

Additional imaging (including via other modalities, such as PET-CT, X-ray) that are obtained at an unscheduled time point to determine disease progression, and scans obtained for other reasons that capture radiologic progression based on investigator assessment, should be submitted to the iCRO. Other types of scans (eg, ultrasound) should not be submitted to the iCRO and will not be included in response assessment.

Participant eligibility will be determined using local assessment (investigator assessment) based on RECIST 1.1. When the investigator identifies radiographic progression per RECIST 1.1, the iCRO will perform expedited verification of radiologic disease progression and communicate the results to the study site and Sponsor via email. In clinically stable participants, imaging should continue until disease progression has been verified by BICR (if initial site-assessed disease progression was not verified by BICR, each subsequent scan must be submitted to iCRO with verification of disease progression request until disease progression has been verified by BICR). Once disease progression is verified centrally, subsequent imaging (if acquired) should not be submitted to the iCRO.

8.2.1.1 Initial Tumor Imaging

Initial tumor imaging at Screening must be performed within 28 days before the date of randomization. Tumor imaging performed as part of routine clinical management is acceptable for use as Screening tumor imaging if it is of diagnostic quality and performed within 28 days before randomization. The screening images must be submitted to the iCRO for retrospective review.

Brain imaging is required for all participants at Screening. Bone imaging is required at Screening for participants with a history of bone metastases and/or for those participants with clinical indication, such as bone pain or elevated alkaline phosphatase.

8.2.1.2 Tumor Imaging During the Study

The first on-study imaging assessment should be performed at 6 weeks (42 days \pm 7 days) from the date of randomization. Subsequent tumor imaging should be performed every 6 weeks (42 days \pm 7 days), or more frequently if clinically indicated. After 36 weeks (252 days \pm 7 days), imaging should be performed every 9 weeks (63 days \pm 7 days) through Week 54 (378 days \pm 7 days), and every 12 weeks (84 days \pm 7 days) thereafter. Imaging timing should follow calendar days and should not be adjusted for delays in cycle starts. Imaging should continue to be performed until disease progression is identified by the investigator and verified by BICR, the start of new anticancer treatment, withdrawal of consent, or death, whichever occurs first. All supplemental imaging must be submitted to the iCRO.

Objective response should be confirmed by a repeat imaging assessment. Tumor imaging to confirm PR or CR should be performed at least 4 weeks after the first indication of a response is observed. Participants will then return to regular scheduled imaging, starting with the next scheduled imaging time point. Participants who receive additional imaging for confirmation do not need to undergo the next scheduled tumor imaging if it is less than 4 weeks later; tumor imaging may resume at the subsequent scheduled imaging time point. Note: Response does not typically need to be verified in real time by the BICR.

On-study brain or bone imaging should be performed if clinically indicated or to confirm CR (if other lesions indicate CR and brain or bone lesions existed at baseline).

Treatment beyond BICR-verified PD per RECIST 1.1 may be permitted at the discretion of the investigator after consulting with the Sponsor and after the participant provides a new documented informed consent (Figure 5). Participants who continue treatment beyond BICR-verified PD must continue tumor imaging assessments as described in the SoA (Section 1.3.1). Investigator assessments are to be documented on the eCRF, but scans are not to be submitted to the iCRO. Further progression and discontinuation of study intervention are to be determined by the investigator.

For participants who have unconfirmed disease progression (investigator assessment of disease progression, but BICR assessment of disease progression per RECIST 1.1 = “No”), treatment can continue at the investigator’s discretion for clinically stable participants (see Section 8.2.1.5). Imaging should continue to be performed as per imaging schedule and must be submitted to the iCRO along with a VOP request until central confirmation of progression is received.

8.2.1.3 End-of-Treatment and Follow-up Tumor Imaging

For participants who discontinue study intervention, tumor imaging should be performed at the time of treatment discontinuation (\pm 4 week window). If previous imaging was obtained within 4 weeks prior to the date of discontinuation, then imaging at treatment discontinuation is not mandatory. For participants who discontinue study intervention due to documented disease progression, this is the final required tumor imaging.

For participants who complete all 35 cycles of initial treatment or discontinue study intervention without documented disease progression, every effort should be made to continue monitoring disease status by tumor imaging using the same imaging schedule used while on treatment calculated from the date of randomization (see Section 8.2.1.2) until the start of a new anticancer treatment, disease progression, pregnancy, death, withdrawal of consent, or the end of the study, whichever occurs first.

8.2.1.4 Second Course (Retreatment) Tumor Imaging

Before a participant may enter the Second Course Phase, BICR verification of radiographic disease progression must have occurred. Tumor imaging must be performed within 28 days prior to restarting treatment with MK-7684A. The disease progression imaging may also be used as the Second Course baseline imaging if it is within 28 days before restarting treatment and otherwise meets the baseline standards outlined in the Site Imaging Manual.

Response assessments and progressive disease in the Second Course are determined by site assessment only. No imaging from the Second Course Phase should be provided to the central vendor, except for the Second Course Phase baseline scan if this scan is also the final imaging for the Initial Treatment Phase.

The first on-study imaging assessment should be performed at 6 weeks (42 days \pm 7 days) after the restart of treatment. Subsequent tumor imaging should be performed every 6 weeks (42 days \pm 7 days) through Week 36 (252 days \pm 7 days), every 9 weeks (63 days \pm 7 days) through the end of treatment, and every 12 weeks (84 days \pm 7 days) thereafter, or more frequently if clinically indicated. Imaging should continue to be performed until disease progression, the start of a new anticancer treatment, withdrawal of consent, death, or notification by the Sponsor, whichever occurs first. The schedule should be followed regardless of treatment delays.

For participants who discontinue Second Course study intervention, tumor imaging should be performed at the time of intervention discontinuation (\pm 4 week window). If previous imaging was obtained within 4 weeks prior to the date of discontinuation, then imaging at intervention discontinuation is not mandatory. For participants who discontinue study intervention due to documented disease progression, this is the final required tumor imaging.

For participants who complete all 17 cycles of Second Course treatment or discontinue Second Course treatment without documented disease progression, every effort should be made to continue monitoring their disease status by radiologic imaging every 12 weeks (84 days \pm 7 days) until the start of a new anticancer treatment, disease progression, death, or the end of the study, whichever occurs first.

8.2.1.5 RECIST 1.1 Assessment of Disease

RECIST 1.1 will be used by BICR as the primary measure for assessment of tumor response, date of disease progression, and as a basis for all protocol guidelines related to disease status (eg, discontinuation of study intervention). Although RECIST 1.1 references a maximum of

5 target lesions in total and 2 per organ, this protocol allows a maximum of 10 target lesions in total and 5 per organ, if clinically relevant to enable a broader sampling of tumor burden.

Upon investigator-assessed disease progression, the indicative scan(s) are to be submitted immediately to iCRO for BICR verification of progression. After submission of scan(s), the iCRO will email the assessment to the site and Sponsor.

If disease progression is not verified, the process continues as follows:

- If participant is clinically stable, continue study intervention per protocol
 - Resume imaging per protocol schedule (≥ 4 weeks to next scan)
 - Send scans to iCRO
 - Continue local assessment
 - Do not change investigator assessment of progression
 - If subsequent scan(s) indicate progression, submit scan(s) to iCRO to request verification
- If the participant is not clinically stable, best medical practice is to be applied

Before stopping study intervention or imaging or starting new anticancer therapy in a participant who is clinically stable, communication with the Sponsor is required.

If disease progression is verified, the process continues as follows:

- Investigator judgment will determine action
- If the participant is clinically stable and study intervention is to continue, communication with the Sponsor is required and a reconsent addendum must be signed

Note: the reconsent addendum may be signed any time after investigator-assessed progression is identified, but must be signed before starting study intervention after verification of disease progression is provided by the iCRO


- Obtain scans locally per original protocol schedule
- Do not send scans to iCRO

Figure 5 illustrates the decision process involving verification of disease progression for participants.

For the purpose of this decision process, lack of clinical stability is defined as:

- Unacceptable toxicity
- Clinical signs or symptoms indicating clinically significant disease progression
- Decline in performance status
- Rapid disease progression or threat to vital organs or critical anatomical sites (eg, CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention

Figure 5 Decision-Making Process When Progression Observed by Investigator
 Decision Making Process When Progression Observed by Investigator



iCRO = imaging CRO; RECIST = Response Evaluation Criteria in Solid Tumors.

8.3 Safety Assessments

Details regarding specific safety procedures/assessments to be performed in this study are provided. The total amount of blood/tissue to be drawn/collected over the course of the study (from prestudy to poststudy visits), including approximate blood/tissue volumes drawn/collected by visit and by sample type per participant, can be found in Section 8.

Planned time points for all safety assessments are provided in the SoA.

8.3.1 Physical Examinations

8.3.1.1 Full Physical Examination

The investigator or qualified designee will perform a complete physical examination during the Screening period. Height will also be measured and recorded at Screening. Clinically significant abnormal findings should be recorded as medical history. The time points for full physical exams are described in Section 1.3. After the first dose of study intervention, new clinically significant abnormal findings should be recorded as AEs.

Investigators should pay special attention to clinical signs related to previous serious illnesses.

8.3.1.2 Directed Physical Examination

For cycles that do not require a full physical examination as defined in Section 1.3, the investigator or qualified designee will perform a directed physical examination as clinically indicated before study intervention administration. New clinically significant abnormal findings should be recorded as AEs.

Investigators should pay special attention to clinical signs related to previous serious illnesses.

8.3.2 Vital Signs

- Temperature (oral, tympanic, rectal, axillary, skin, or temporal artery), pulse rate, respiratory rate, and blood pressure will be assessed.
- Blood pressure and pulse measurements will be assessed with a completely automated device. Manual techniques will be used only if an automated device is not available.
- Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.
- Vital signs (to be taken before blood collection for laboratory tests) will consist of 1 pulse and 1 blood pressure measurement (after the participant has been sitting for 5 minutes, 1 blood pressure reading will be recorded). OR
- Vital signs will be measured in a semisupine position after 5 minutes rest and will include temperature, systolic and diastolic blood pressure, pulse and respiratory rate.
- Weight will also be measured and recorded.

8.3.3 Electrocardiograms

A standard 12-lead ECG will be obtained and reviewed by an investigator or medically qualified designee (consistent with local requirements) as outlined in the SoA using an ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT intervals.

8.3.4 Clinical Safety Laboratory Assessments

Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for the timing and frequency.

- The investigator or medically qualified designee (consistent with local requirements) must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
- All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in accordance with the laboratory manual and the SoA.
- If laboratory values from nonprotocol-specified laboratory assessments performed at the institution's local laboratory require a change in study participant management or are considered clinically significant by the investigator (eg, SAE or AE or dose modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
- For any laboratory tests with values considered clinically significantly abnormal during participation in the study or within 30 days after the last dose of study intervention, every attempt should be made to perform repeat assessments until the values return to normal or baseline or if a new baseline is established as determined by the investigator.

Details regarding specific laboratory procedures/assessments to be performed in this study are provided below. The total amount of blood/tissue to be drawn/collected over the course of the study (from prestudy to poststudy visits), including approximate blood/tissue volumes drawn/collected by visit and by sample type per participant can be found in the Study Procedures Manual. Refer to the SoA (Section 1.3) for the timing of laboratory assessments.

8.3.4.1 Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis)

Laboratory tests for hematology, chemistry, and urinalysis are specified in Appendix 2 and schedule is provided in the SoA (Section 1.3).

8.3.5 Pregnancy Testing

Pregnancy testing requirements for study inclusion are described in Section 5.1.

Pregnancy testing (urine or serum as required by local regulations) should be conducted prior to every cycle (Q3W), or more frequently if required by local regulations.

Pregnancy testing (urine or serum as required by local regulations) should be conducted 120 days after the last dose of MK-7684A and 180 days after the last dose of docetaxel, whichever occurs latest.

Additional serum or urine pregnancy tests may be performed, as determined necessary by the investigator or required by local regulation, to establish the absence of pregnancy at any time during the participant's participation in the study.

8.3.6 Eastern Cooperative Oncology Group Performance Status

The investigator or qualified designee will assess ECOG status at Screening, before the administration of each dose of study intervention and during the follow-up period as specified in the SoA (Section 1.3).

8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety Events

The definitions of an AE or SAE, as well as the method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting AE, SAE, and other reportable safety event reports can be found in Appendix 3.

Progression of the cancer under study is not considered an AE as described in Section 8.4.6 and Appendix 3.

Adverse events, SAEs, and other reportable safety events will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).

The investigator and any designees are responsible for detecting, documenting, and reporting events that meet the definition of an AE or SAE as well as other reportable safety events. Investigators need to document if an SAE was associated with a medication error, misuse, or abuse. Investigators remain responsible for following up AEs, SAEs, and other reportable safety events for outcome according to Section 8.4.3.

The investigator, who is a qualified physician, will assess events that meet the definition of an AE or SAE as well as other reportable safety events with respect to seriousness, intensity/toxicity and causality.

Adverse events will not be collected for participants during the prescreening period (for determination of archival tissue status) as long as that participant has not undergone any protocol-specified procedure or intervention. If the participant requires a blood draw, fresh tumor biopsy, etc, the participant is first required to provide consent to the main study, and AEs will be captured according to guidelines for standard AE reporting.

8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information

All AEs, SAEs, and other reportable safety events that occur after the participant provides documented informed consent but before intervention allocation/randomization must be reported by the investigator if the participant is receiving placebo run-in or other run-in treatment, if the event cause the participant to be excluded from the study, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, or a procedure.

- All AEs from the time of intervention randomization through 30 days following cessation of study intervention must be reported by the investigator.
- All AEs meeting serious criteria, from the time of intervention randomization through 90 days following cessation of study intervention or 30 days following cessation of study intervention if the participant initiates new anticancer therapy, whichever is earlier, must be reported by the investigator.
- All pregnancies and exposure during breastfeeding, from the time of intervention randomization through 120 days following cessation of MK-7684A or 180 days following cessation of docetaxel, or 30 days following cessation of study intervention if the participant initiates new anticancer therapy must be reported by the investigator.
- Additionally, any SAE brought to the attention of an investigator at any time outside of the time period specified above must be reported immediately to the Sponsor if the event is considered related to study intervention.

Investigators are not obligated to actively seek AEs or SAEs or other reportable safety events in former study participants. However, if the investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and he/she considers the event to be reasonably related to the study intervention or study participation, the investigator must promptly notify the Sponsor.

All initial and follow-up AEs, SAEs, and other reportable safety events will be recorded and reported to the Sponsor or designee within the time frames as indicated in [Table 7](#).

Exception: A positive pregnancy test at the time of initial screening is not a reportable event unless the participant has received study intervention.

Table 7 Reporting Time Periods and Time Frames for Adverse Events and Other Reportable Safety Events

Type of Event	<u>Reporting Time Period:</u> Consent to Randomization/ Allocation	<u>Reporting Time Period:</u> Randomization/ Allocation through Protocol-specified Follow-up Period	<u>Reporting Time Period:</u> After the Protocol- specified Follow-up Period	Time Frame to Report Event and Follow-up Information to Sponsor:
NSAE	Report if: - due to protocol- specified intervention - causes exclusion - participant is receiving placebo run- in or other run-in treatment	Report all	Not required	Per data entry guidelines
SAE including Cancer and Overdose	Report if: - due to protocol- specified intervention - causes exclusion - participant is receiving placebo run- in or other run-in treatment	Report all	Report if: - drug/vaccine related. (Follow ongoing to outcome)	Within 24 hours of learning of event
Pregnancy/ Lactation Exposure	Report if: - participant has been exposed to any protocol-specified intervention (eg, procedure, washout or run-in treatment including placebo run- in) Exception: A positive pregnancy test at the time of initial screening is not a reportable event unless the participant has received study intervention.	Report all	Previously reported – Follow to completion/ termination; report outcome	Within 24 hours of learning of event
ECI (require regulatory reporting)	Report if: - due to intervention - causes exclusion	Report - potential DILI - require regulatory reporting	Not required	Within 24 hours of learning of event
ECI (do not require regulatory reporting)	Report if: - due to intervention - causes exclusion	Report - non-DILI ECIs and those not requiring regulatory reporting	Not required	Within 5 calendar days of learning of event

DILI=drug-induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse event

8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events

Care will be taken not to introduce bias when detecting AEs and/or SAEs and other reportable safety events. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrence.

8.4.3 Follow-up of AE, SAE, and Other Reportable Safety Event Information

After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events, including pregnancy and exposure during breastfeeding, ECIs, cancer, and overdose will be followed until resolution, stabilization, until the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). In addition, the investigator will make every attempt to follow all nonserious AEs that occur in randomized participants for outcome. Further information on follow-up procedures is given in Appendix 3.

8.4.4 Regulatory Reporting Requirements for SAE

Prompt notification (within 24 hours) by the investigator to the Sponsor of SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.

The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country-specific regulatory requirements and global laws and regulations relating to safety reporting to regulatory authorities, IRB/IECs, and investigators.

Investigator safety reports must be prepared for SUSARs according to local regulatory requirements and Sponsor policy and forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing an SAE or other specific safety information (eg, summary or listing of SAE) from the Sponsor will file it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.

8.4.5 Pregnancy and Exposure During Breastfeeding

Although pregnancy and infant exposure during breastfeeding are not considered AEs, any pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to the investigator or their designee) that occurs during the study are reportable to the Sponsor.

All reported pregnancies must be followed to the completion/termination of the pregnancy.

Any pregnancy complication will be reported as an AE or SAE.

The medical reason (example: maternal health or fetal disease) for an elective termination of a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born with severe abnormalities/congenital anomalies that leads to an elective termination of a pregnancy will be reported as an SAE for the fetus.

Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported.

8.4.6 Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or SAEs

Efficacy endpoints as outlined in this section will not be reported to the Sponsor as described in Section 8.4.1.

Specifically, the suspected/actual events covered in this exception include any event that is disease progression of the cancer under study.

The Sponsor will ensure that unblinded aggregated efficacy endpoint events and safety data are monitored to safeguard the participants in the study.

8.4.7 Events of Clinical Interest

Selected serious and nonserious AEs are also known as ECIs and must be reported to the Sponsor.

Events of clinical interest for this study include:

- An overdose of Sponsor's product, as defined in Section 8.5.
- An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of normal and an elevated total bilirubin lab value that is greater than or equal to 2X the upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less than 2X the upper limit of normal, as determined by way of protocol-specified laboratory testing or unscheduled laboratory testing.*

*Note: These criteria are based upon available regulatory guidance documents. The purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underlying etiology. The study site guidance for assessment and follow up of these criteria can be found in the Investigator Study File Binder (or equivalent).

8.5 Treatment of Overdose

For this study, an overdose of MK-7684A will be defined as any dose exceeding 3 times or 300% the prescribed dose. No specific information is available on the treatment of overdose of MK-7684A.

There is no known antidote for docetaxel overdose. In the event of overdose, the specific intervention should be withheld, and the participant should be observed closely for signs of toxicity. Appropriate supportive treatment should be provided if clinically indicated.

Refer to the local package insert for the definition and treatment of overdose with docetaxel.

8.6 Pharmacokinetics

8.6.1 Blood Collection for Plasma MK-7684 and Pembrolizumab

Sample collection, storage, and shipment instructions for plasma samples will be provided in the operations/laboratory manual.

8.6.1.1 Blood Collection for PK

Sample collection, storage, and shipment instructions for serum samples will be provided in the procedure manual. Pharmacokinetic samples should be drawn according to the PK collection schedule for all participants. Every effort should be taken to collect samples at 30 days after end of study intervention.

8.6.1.2 Blood Collection for Antidrug Antibodies

Sample collection, storage, and shipment instructions for serum samples will be provided in the procedure manual. Antidrug antibody samples should be drawn according to the ADA collection schedule for all participants (Section 1.3). Every effort should be taken to collect samples at 30 days after end of study intervention for ADA. Simultaneous PK sampling is required for interpretation of ADA analysis.

8.7 Pharmacodynamics

Pharmacodynamic parameters will not be evaluated in this study.

8.8 Biomarkers

To identify novel biomarkers, the following biospecimens to support exploratory analyses of cellular components (eg, protein, RNA, DNA, metabolites) and other circulating molecules will be collected from all participants in this study as specified in the SoA:

- Blood (DNA) for genetic analysis
- Blood for serum biomarker analyses
- Blood for RNA analyses
- Blood for ctDNA Analysis
- Newly obtained/archival tissue specimen

Sample collection, storage and shipment instructions for the exploratory biomarker specimens will be provided in the laboratory manual.

8.8.1 Planned Genetic Analysis Sample Collection

The planned genetic analysis sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This sample will not be collected at the site if there is either a local law or regulation prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for these purposes. If the sample is collected, leftover extracted DNA will be stored for future biomedical research if the participant provides documented informed consent for future biomedical research.

Sample collection, storage, and shipment instructions for planned genetic analysis samples will be in the Operations/Laboratory Manual.

8.9 Future Biomedical Research Sample Collection

If the participant provides documented informed consent for future biomedical research, the following specimens will be obtained as part of future biomedical research:

- Leftover DNA for future research
- Leftover RNA
- Leftover serum from biomarker analyses
- Leftover plasma or derivative for ctDNA
- Leftover tumor

8.10 Health Economics Medical Resource Utilization and Health Economics

All-cause hospitalizations and emergency department visits must be reported in the eCRF, from the time of treatment allocation/randomization through 90 days after cessation of study intervention, or 30 days after cessation of study intervention, if the participant initiates new anticancer therapy, whichever is earlier.

8.11 Visit Requirements

Visit requirements are outlined in Section 1.3. Specific procedure-related details are provided in Section 8.

8.11.1 Screening

Written consent must be obtained before performing any protocol-specific procedure. Results of a test performed before the participant signing consent as part of routine clinical management are acceptable in lieu of a screening test if performed within the specified time frame. Screening procedures are to be completed within 28 days before the first dose of study intervention except for the following:

- Laboratory tests are to be performed within 10 days before the first dose of study intervention. An exception is hepatitis testing which may be performed up to 28 days before the first dose of study intervention.
- Evaluation of ECOG is to be performed within 7 days before the first dose of study intervention.
- For WOCBP, a serum pregnancy test will be performed within 72 hours or a urine pregnancy test within 24 hours prior to the first dose of study intervention. If urine pregnancy results cannot be confirmed as negative, a serum pregnancy test will be required (performed by the local study site laboratory). Additional pregnancy testing can be conducted if required by local regulations or clinically indicated.
- Archival tumor sample collection is not required to be obtained within 28 days before the first dose of study intervention. Newly obtained tumor tissue may be obtained according to the Procedures Manual.

Participants may be rescreened after initially failing to meet the inclusion/exclusion criteria. Results from assessments during the initial Screening period are acceptable in lieu of a repeat Screening test if performed within the specified time frame and the corresponding inclusion/exclusion criteria is met. Participants who are rescreened will retain their original Screening number.

8.11.2 Initial Treatment Period

Visit requirements are outlined in the SoA (Section 1.3). Specific procedure-related details are provided in Section 8.1.

8.11.3 Second Course Treatment Phase

See Section 6.6.3 for details concerning the Second Course.

8.11.4 Discontinued Participants Continuing to be Monitored in the Study

Participants who discontinue study treatment due to disease recurrence or start of a new anticancer therapy will have Safety Follow-up and then proceed directly to Survival Follow-up as described in Section 8.11.5.

The Discontinuation Visit should occur at the time study intervention is discontinued for any reason. If the Discontinuation Visit occurs 30 days from the last dose of study intervention, at

the time of the mandatory Safety Follow-up Visit, the Discontinuation Visit procedures and any additional Safety Follow-up procedures should be performed.

8.11.5 Posttreatment Visit

8.11.5.1 Safety Follow-up Visit

The mandatory Safety Follow-up Visit should be conducted approximately 30 days after the last dose of study intervention or before the initiation of a new anticancer treatment, whichever comes first.

Participants who are eligible for Second Course Treatment with MK-7684A may have up to 2 safety follow-up visits, 1 after the Initial Treatment Period and 1 after the Second Course Treatment.

8.11.5.2 Efficacy Follow-up Visits

Participants who complete the protocol-required cycles of study intervention or who discontinue study intervention for a reason other than disease progression will begin the Efficacy Follow-up Phase and should be assessed every 12 weeks to monitor disease status. Imaging should be continued to be collected in the Efficacy Follow-up Phase (see Section 8.2.1.3). Every effort should be made to collect information regarding disease status until the start of new anticancer therapy, disease progression, death, or end of study. Information regarding poststudy anticancer treatment will be collected if new treatment is initiated. Participants who completed all efficacy assessments and/or will not have further efficacy assessments must enter the Survival Follow-up Phase.

Participants who are eligible to receive Second Course Treatment with MK-7684A according to the criteria in Section 6 will move from the Efficacy Follow-up Phase to the Second Course Treatment Phase when they experience disease progression. Details are provided in the SoA (Section 1.3.2) for Second Course Treatment with MK-7684A.

8.11.5.3 Survival Follow-up Contacts

Participant Survival Follow-up status will be assessed approximately every 12 weeks to assess for survival status until death, withdrawal of consent, or the end of the study, whichever occurs first.

The first Survival Follow-up assessment should be scheduled as described below:

- For participants who discontinue treatment intervention and who will not enter the Efficacy Follow-up Phase, the first Survival Follow-up contact will be scheduled 12 weeks after the Discontinuation Visit and/or Safety Follow-up Visit (whichever is last).

- For participants who completed assessments in the Efficacy Follow-up Phase, the first Survival Follow-up contact will be scheduled 12 weeks after the last efficacy assessment follow-up visit has been performed.

8.11.6 Survival Status

To ensure current and complete survival data is available at the time of database locks, updated survival status may be requested during the course of the study by the Sponsor. For example, updated survival status may be requested prior to but not limited to an eDMC review, interim and/or final analysis. Upon Sponsor notification, all participants who do not/will not have a scheduled study visit or study contact during the Sponsor defined time period will be contacted for their survival status (excluding participants that have a previously recorded death event in the collection tool).


9 STATISTICAL ANALYSIS PLAN

This section outlines the statistical analysis strategy and procedures for the study. If, after the study has begun, but prior to any unblinding/final database lock, changes are made to primary and/or key secondary hypotheses, or the statistical methods related to those hypotheses, then the protocol will be amended (consistent with ICH Guideline E-9). Changes to exploratory or other nonconfirmatory analyses made after the protocol has been finalized, but prior to final database lock, will be documented in a supplemental SAP (sSAP) and referenced in the CSR for the study. Post hoc exploratory analyses will be clearly identified in the CSR.

9.1 Statistical Analysis Plan Summary

Key elements of the statistical analysis plan are summarized below; the comprehensive plan is provided in Sections 9.2 to 9.12.

Study Design Overview	A Phase 2, multicenter, randomized, placebo- and active-controlled, parallel-group, double-blind (Arm 1 and Arm 3 only), 3 arm study comparing MK-7684A + docetaxel or MK-7684A to docetaxel alone in participants with metastatic NSCLC with PD after platinum doublet chemotherapy and anti-PD-1/PD-L1 immunotherapy.
Treatment Assignment	Approximately 240 participants will be randomized in a 1:1:1 ratio to: <ul style="list-style-type: none">• Arm 1 (MK-7684A + docetaxel)• Arm 2 (MK-7684A)• Arm 3 normal saline placebo + docetaxel) The stratification factors are: Prior anti-PD-1/PD-L1 mAb (immediate prior therapy versus not the immediate prior therapy); PD-L1 TPS (<50% versus ≥50%); and ECOG Performance Status (0 versus 1)
Analysis Populations	Efficacy: ITT Safety: APaT
Primary Endpoint	PFS per RECIST 1.1 by BICR

Secondary Endpoints	<ul style="list-style-type: none"> • OR per RECIST 1.1 by BICR • OS • DOR per RECIST 1.1 by BICR • Safety and tolerability
Statistical Methods for Key Efficacy Analyses	The primary hypothesis will be evaluated by comparing Arm 1 to Arm 3, and Arm 2 to Arm 3 with respect to PFS using a stratified log-rank test. The HR will be estimated using a stratified Cox regression model. Event rates over time will be estimated within each treatment group using the Kaplan-Meier method.
Statistical Methods for Key Safety Analyses	The analysis of safety results will follow a tiered approach. The tiers differ with respect to the analyses that will be performed. There are no events of interest that warrant elevation to Tier 1 events in this study. Tier 2 parameters will be assessed via point estimates with 95% CIs provided for between-group comparisons; only point estimates by treatment group are provided for Tier 3 safety parameters. The 95% CIs for between treatment differences in the percentage of participants with events will be provided using the Miettinen and Nurminen method [Miettinen, O. and Nurminen, M. 1985].
Interim Analyses	There are no planned interim analyses for this study.
Multiplicity	There are 2 primary hypotheses. Each hypothesis is tested at 0.05 (one-sided) alpha level. If significant, the hypothesis will further be tested at a more stringent alpha level 0.025 (one-sided).
Sample Size and Power	<p>The planned sample size is ~80 for each of Arm 1, Arm 2, and Arm 3 with a total of ~240 participants in the study. CCI</p> 

9.2 Responsibility for Analyses/In-house Blinding

The statistical analyses of the data obtained from this study will be the responsibility of the Clinical Biostatistics Department of the Sponsor.

The study will be conducted as a partially blinded study (Arm 1 and Arm 3 are double blinded, Arm 2 is open-label), ie, participants, investigator, and Sponsor personnel will be aware of participants treatment assignment to Arm 2 vs Arm 1 or Arm 3 after each participant is enrolled and treatment is assigned.

The Sponsor will generate the randomized allocation schedule(s) for study intervention assignment for this protocol, and the randomization will be implemented in IRT.

An eDMC will conduct regular safety monitoring at intervals specified in the eDMC charter. Treatment-level safety analyses will be provided by the unblinded statistician to the eDMC. The eDMC will review the results of safety analyses and make recommendations for protocol modifications to the study EOC. If the eDMC recommends modifications to the design of the

protocol, the EOC (and potentially other limited Sponsor personnel) may be unblinded to results at the treatment level to act on these recommendations. The extent to which individuals are unblinded with respect to results of analyses for eDMC monitoring will be documented by the unblinded statistician external to the Sponsor. Additional logistical details will be provided in the eDMC charter.

Prior to final study unblinding, the unblinded statistician will not be involved in any discussions regarding modifications to the protocol or statistical methods, identification of protocol deviations, or data validation efforts.

9.3 Hypotheses/Estimation

Objectives and hypotheses of the study are stated in Section 3.

9.4 Analysis Endpoints

9.4.1 Efficacy Endpoints

Primary

- **Progression-free Survival (PFS)**

PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.

Secondary

- **Objective Response (OR)**

A confirmed CR or PR per RECIST 1.1 based on BICR.

- **Overall Survival (OS)**

OS is defined as the time from randomization to death due to any cause.

- **Duration of Response (DOR)**

For participants who demonstrate confirmed CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

9.4.2 Safety Endpoints

Key safety endpoints are AEs and study treatment discontinuations due to AEs. In addition, safety parameters commonly used for evaluating investigational systemic anticancer treatments, including, but not limited to all AEs, SAEs, fatal AEs, and laboratory changes,

will be evaluated by clinical review. AEs will be assessed as defined by CTCAE, Version 5.0. A description of safety measures is provided in Section 8.3.

9.5 Analysis Populations

9.5.1 Efficacy Analysis Populations

The analyses of efficacy endpoints are based on the ITT population. All randomized participants will be included in this population. Participants will be analyzed in the treatment arms to which they are randomized.

9.5.2 Safety Analysis Populations

The APaT population will be used for the analysis of safety data in this study. The APaT population consists of all randomized participants who receive at least 1 dose of study treatment. Participants will be analyzed in the treatment arm corresponding to the study treatment they actually received. For most participants, this will be the treatment group to which they are randomized. Participants who received incorrect study treatment for the entire treatment period will be included in the treatment arm corresponding to the study treatment actually received.

At least one laboratory measurement obtained subsequent to at least one dose of study treatment is required for inclusion in the analysis of each specific parameter. To assess change from baseline, a baseline measurement is also required.

9.6 Statistical Methods

9.6.1 Statistical Methods for Efficacy Analyses

This section describes the statistical methods that address the primary and secondary objectives. Methods related to exploratory objectives will be described in the supplemental SAP. The stratification factors used for randomization (see Section 6.3.2) will be applied to all stratified analyses, in particular, the stratified log-rank test, stratified Cox model, and stratified Miettinen and Nurminen method [Miettinen, O. and Nurminen, M. 1985]. In the event that there are small strata, for the purpose of analysis, strata will be combined to ensure sufficient number of participants, responses, and events in each stratum. Details regarding the pooling strategy will be prespecified in the sSAP prior to the database lock, and decisions regarding the pooling will be based on a blinded review of response and event counts by stratum.

The efficacy analyses for PFS, ORR, and DOR will include documented progression events and responses that occur prior to Second Course Treatment.

9.6.1.1 Progression-free Survival (PFS)

The nonparametric Kaplan-Meier method will be used to estimate the PFS curve in each treatment group. The treatment difference in PFS will be assessed by the stratified log-rank test. A stratified Cox proportional hazard model with Efron's method of tie handling will be

used to assess the magnitude of the treatment difference (ie, HR) between the treatment arms. The HR and its 95% CI from the stratified Cox model with a single treatment covariate will be reported. The stratification factors used for randomization (see Section 6.3.2) will be applied to both the stratified log-rank test and the stratified Cox model.

Since disease progression is assessed periodically, PD can occur any time in the time interval between the last assessment where PD was not documented and the assessment when PD is documented. The true date of disease progression will be approximated by the earlier of the date of the first assessment at which PD is objectively documented per RECIST 1.1 by BICR and the date of death. Death is always considered a PD event.

For the primary analysis, any participant who experiences an event (PD or death) immediately after 2 or more missed disease assessments will be censored at the last disease assessment prior to the missed visits. In addition, any participant who initiates new anticancer therapy prior to documented progression will be censored at the last disease assessment prior to the initiation of new anticancer therapy. Participants who do not start new anticancer therapy and who do not experience an event will be censored at the last disease assessment. If a participant meets multiple criteria for censoring, the censoring criterion that occurs earliest will be applied. Sensitivity analyses will be performed for comparison of PFS based on investigator's assessment.

In order to evaluate the robustness of the PFS endpoint per RECIST 1.1 by BICR, 2 sensitivity analyses with different sets of censoring rules will be performed. The first sensitivity analysis follows the intention-to-treat principle. That is, PDs/deaths are counted as events regardless of missed study visits or initiation of new anticancer therapy. The second sensitivity analysis considers initiation of new anticancer treatment or discontinuation of treatment due to reasons other than complete response, whichever occurs later, to be a PD event for participants without documented PD or death. If a participant meets multiple criteria for censoring, the censoring criterion that occurs earliest will be applied. The censoring rules for the primary and sensitivity analyses are summarized in [Table 8](#).

Table 8 Censoring Rules for Primary and Sensitivity Analyses of PFS

Situation	Primary Analysis	Sensitivity Analysis 1	Sensitivity Analysis 2
PD or death documented after ≤ 1 missed disease assessment, and before new anticancer therapy, if any	Progressed at date of documented PD or death	Progressed at date of documented PD or death	Progressed at date of documented PD or death
Death or progression immediately after ≥ 2 consecutive missed disease assessments, or after new anticancer therapy	Censored at last disease assessment prior to the earlier date of ≥ 2 consecutive missed disease assessment and new anticancer therapy, if any	Progressed at date of documented PD or death	Progressed at date of documented PD or death
No PD and no death; and new anticancer treatment is not initiated	Censored at last disease assessment	Censored at last disease assessment	Progressed at treatment discontinuation due to reasons other than complete response; otherwise censored at last disease assessment if still on study treatment or completed study treatment.
No PD and no death; new anticancer treatment is initiated	Censored at last disease assessment before new anticancer treatment	Censored at last disease assessment	Progressed at date of new anticancer treatment

9.6.1.2 Objective Response Rate (ORR)

The stratified Miettinen and Nurminen method will be used for comparison of the ORR between 2 treatment groups (Arm 1 vs Arm 3; Arm 2 vs Arm 3). The difference in ORR and its 95% confidence interval from the stratified Miettinen and Nurminen method with strata weighting by sample size will be reported. The stratification factors used for randomization (see Section 6.3.2) will be applied to the analysis. The point estimate of ORR will be provided by treatment group, together with 95% CI using exact binomial method proposed by Clopper and Pearson [Clopper, C. J. and Pearson, E. S. 1934].

9.6.1.3 Overall Survival (OS)

The nonparametric Kaplan-Meier method will be used to estimate the survival curves. The treatment difference in survival will be assessed by the stratified log-rank test. A stratified Cox proportional hazard model with Efron's method of tie handling will be used to assess the magnitude of the treatment difference (ie, the HR). The HR and its 95% confidence interval from the stratified Cox model with a single treatment covariate will be reported. The stratification factors used for randomization (see Section 6.3.2) will be applied to both the stratified log-rank test and the stratified Cox model. Participants without documented death at the time of analysis will be censored at the date the participant was last known to be alive.

9.6.1.4 Duration of Response (DOR)

If sample size permits, DOR will be summarized descriptively using Kaplan-Meier medians and quartiles. Only the subset of participants who show a confirmed complete response or partial response will be included in this analysis. Censoring rules for DOR are summarized in [Table 9](#).

For each DOR analysis, a corresponding summary of the reasons responding participants are censored will also be provided. Responding participants who are alive, have not progressed, have not initiated new anticancer treatment, have not been determined to be lost to follow-up, and have had a disease assessment within ~5 months of the data cutoff date are considered ongoing responders at the time of analysis. If a participant meets multiple criteria for censoring, the censoring criterion that occurs earliest will be applied.

Table 9 Censoring Rules for DOR

Situation	Date of Progression or Censoring	Outcome
No progression nor death, no new anticancer therapy initiated	Last adequate disease assessment	Censor (nonevent)
No progression nor death, new anticancer therapy initiated	Last adequate disease assessment before new anticancer therapy initiated	Censor (nonevent)
Death or progression immediately after ≥ 2 consecutive missed disease assessments or after new anticancer therapy, if any	Earlier date of last adequate disease assessment prior to ≥ 2 missed adequate disease assessments and new anticancer therapy, if any	Censor (nonevent)
Death or progression after ≤ 1 missed disease assessments and before new anticancer therapy, if any	PD or death	End of response (Event)
A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response.		

9.6.1.5 Analysis Strategy for Key Efficacy Variables

A summary of the primary analysis strategy for the key efficacy endpoints is provided in [Table 10](#). The strategy to address multiplicity issues with regard to multiple endpoints is described in Section 9.8.

Table 10 Analysis Strategy for Key Efficacy Variables

Endpoint/Variable	Statistical Method	Analysis Population	Missing Data Approach
Primary Analyses			
PFS per RECIST 1.1 by BICR	Testing: stratified log-rank test Estimation: Stratified Cox model with Efron's tie handling method	ITT	Censored according to rules in Table 8
Secondary Analyses			
ORR per RECIST 1.1 by BICR	Testing and estimation: stratified M&N method	ITT	Participants with missing data are considered nonresponders
OS	Testing: stratified log-rank test Estimation: Stratified Cox model with Efron's tie handling method	ITT	Censored at participant's last known alive date
DOR per RECIST 1.1 as assessed by BICR	Summary statistics using Kaplan-Meier method	Responders in ITT population	Censored according to rules in Table 9
Abbreviations: BICR=blinded independent central review; DOR=duration of response; DCR=disease control rate; ITT=intent-to-treat; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; RECIST 1.1=Response Evaluation Criteria in Solid Tumors.			

9.6.2 Statistical Methods for Safety Analyses

Safety and tolerability will be assessed by clinical review of all relevant parameters including AEs, laboratory tests, vital signs.

The analysis of safety results will follow a tiered approach ([Table 11](#)). The tiers differ with respect to the analyses that will be performed. Adverse events (specific terms as well as system organ class terms) are either prespecified as “Tier 1” endpoints or will be classified as belonging to “Tier 2” or “Tier 3” based on the number of events observed.

Tier 1 Events

Safety parameters or adverse events of special interest that are identified a priori constitute “Tier 1” safety endpoints that will be subject to inferential testing for statistical significance. There are no Tier 1 events for this protocol. Based on a review of historic docetaxel data and data from ongoing MK-7684A clinical studies, there are no AEs that warrant inferential testing between treatment groups.

Tier 2 Events

Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences in the proportion of participants with events using the Miettinen and Nurminen method, an unconditional, asymptotic method [Miettinen, O. and Nurminen, M. 1985].

Membership in Tier 2 requires that at least 10% of participants in any treatment group show the event; all other AEs and predefined limits of change will belong to Tier 3. The threshold of at least 10% of participants was chosen for Tier 2 events because the population enrolled in this study is in critical condition and usually experiences various AEs of similar types regardless of treatment; events reported less frequently than 10% of participants would obscure the assessment of the overall safety profile and add little to the interpretation of potentially meaningful treatment differences. In addition, Grade 3 to 5 AEs ($\geq 5\%$ of participants in 1 of the treatment groups) and SAEs ($\geq 5\%$ of participants in 1 of the treatment groups) will be considered Tier 2 endpoints. Because many 95% CIs may be provided without adjustment for multiplicity, the CIs should be regarded as a helpful descriptive measure to be used in safety review, not as a formal method for assessing the statistical significance of the between-group differences.

Tier 3 Events

Safety endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point estimates by treatment group are provided for Tier 3 safety parameters.

Continuous Safety Measures

For continuous measures such as changes from baseline in laboratory parameters, summary statistics for baseline, on treatment, and change from baseline values will be provided by treatment group in table format.

Table 11 Analysis Strategy for Safety Parameters

Safety Tier	Safety Endpoint	95% CI for Treatment Comparison	Descriptive Statistics
Tier 2	Specific Grade 3-5 AE (incidence \geq X% of participants in one of the treatment groups)	X	X
	Specific SAE (incidence \geq X% of participants in one of the treatment groups)	X	X
	Specific AEs (incidence \geq X% of participants in one of the treatment groups)	X	X
Tier 3	Any AE		X
	Any Grade 3-5 AE		X
	Any Serious AE		X
	Any Drug-Related AE		X
	Any Drug-Related SAE		X
	Any Grade 3-5 and Drug-Related AE		X
	Discontinuation due to AE		X
	Death		X
	Specific AEs, SOC's (incidence $>0\%$ of participants in all of the treatment groups)		X
	Change from Baseline Results (laboratory test result: toxicity shift)		X
Abbreviations: AE = adverse event; CI = confidence interval; SAE = serious adverse event; SOC = system organ class.			

9.6.3 Demographic and Baseline Characteristics

The comparability of the treatment groups for each relevant demographic and baseline characteristic will be assessed by the use of tables and/or graphs. No statistical hypothesis tests will be performed on these characteristics. The number and percentage of participants screened and randomized and the primary reasons for screening failure and discontinuation will be displayed. Demographic variables, baseline characteristics, primary and secondary diagnoses, and prior and concomitant therapies will be summarized by treatment either by descriptive statistics or categorical tables.

9.7 Interim Analyses

There is no interim analysis planned in this study. The eDMC will conduct regular safety monitoring. The timing of the safety monitoring will be specified in the eDMC charter. eDMC monitoring for safety will be conducted at a minimum every 6 months until such time that the eDMC determines that monitoring at a different frequency is appropriate.

9.8 Multiplicity

There are 2 primary hypotheses in the study: H1 is for MK-7684A + docetaxel vs. control docetaxel in PFS; H2 is for MK-7684A vs. control in PFS. Since MK-7684A + docetaxel and MK-7684A may be considered as 2 different therapies (one is combination with chemotherapy and the other is a chemotherapy-sparing therapy) being evaluated in a multiarm study with shared control, family-wise error rate (FWER) adjustment is not necessary [Freidlin, B., et al 2008] [Howard, D. R., et al 2018] [Collignon, O., et al 2020]. In this study, each hypothesis is tested at 0.05 (one-sided) alpha level. If a given hypothesis is significant at the alpha level 0.05 (one-sided), that hypothesis will further be tested at a more stringent alpha level 0.025 (one-sided).

9.9 Sample Size and Power Calculations

The study will randomize approximately 240 participants in a 1:1:1 ratio into Arm 1 (MK-7684A + docetaxel), Arm 2 (MK-7684A), and Arm 3 (docetaxel). PFS is the primary endpoint for the study, with ORR, OS, and DOR as the secondary endpoints. If the PFS result is positive in either arm at the final analysis, follow-up of the study may be extended to collect more OS data for the entire study population.

For the PFS endpoint, based on a target number of CCI

approximately CCI

The above sample size and power calculations for PFS assume the following:

- PFS follows an CCI for the control group [Herbst, R. S., et al 2016].
- Enrollment period of CCI.
- CCI.
- A follow-up period of approximately 6 months for PFS, after the last participant enrolls.

The sample size and power calculations were performed using EAST[®] 6.4 software.

CCI

9.10 Subgroup Analyses

To determine whether the treatment effect is consistent across various subgroups, the between-group treatment effect for PFS (with a nominal 95% CI) will be estimated and plotted by treatment group within each category of the following subgroup variables:

- Geographic region (East Asia, Non-East Asia)
- ECOG Performance Status (0, 1)
- PD-L1 TPS (<50%, ≥50%)
- Prior anti-PD-1/PD-L1 mAb (immediate prior therapy vs not immediate prior therapy)
- Histology (squamous, nonsquamous)
- Age category (<65 years, ≥65 years)
- Sex (female, male)
- Race (white, nonwhite)
- Smoking status (never, former/current smoker)
- Brain metastasis at baseline (presence, absence)
- Liver metastasis at baseline (presence, absence)

The consistency of the treatment effect will be assessed using descriptive statistics for each category of the subgroup variables listed above. If the number of participants in a category of a subgroup variable is less than 10% of the ITT population, the subgroup analysis will not be performed for this category of the subgroup variable, and this subgroup variable will not be displayed in the forest plot. The subgroup analyses for PFS and OS will be conducted using an unstratified Cox model, and the subgroup analysis for ORR will be conducted using the unstratified Miettinen and Nurminen method.

9.11 Compliance (Medication Adherence)

Drug accountability data for study intervention will be collected during the study. Any deviation from protocol directed administration will be reported.

9.12 Extent of Exposure

The extent of exposure will be summarized as duration of treatment in cycles.

10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations

10.1.1 Code of Conduct for Clinical Trials

Merck Sharp & Dohme LLC, Rahway, NJ, USA (MSD)

Code of Conduct for Interventional Clinical Trials

I. Introduction

A. Purpose

MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted in compliance with local and/or national regulations (including all applicable data protection laws and regulations), and International Council for Harmonisation Good Clinical Practice (ICH-GCP), and also in accordance with the ethical principles that have their origin in the Declaration of Helsinki.

B. Scope

Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by MSD irrespective of the party (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or which are retrospective. Further, this Code does not apply to investigator-initiated trials, which are not under the full control of MSD.

II. Scientific Issues

A. Trial Conduct

1. Trial Design

Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety, efficacy and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine patient preferences, etc.

The design (i.e., participant population, duration, statistical power) must be adequate to address the specific purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where applicable, third parties. Participants must meet protocol entry criteria to be enrolled in the trial.

2. Site Selection

MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, sites are evaluated by MSD personnel (or individuals acting on behalf of MSD) to assess the ability to successfully conduct the trial.

3. Site Monitoring/Scientific Integrity

Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus

source documentation according to standard operating procedures. Per MSD policies and procedures, if potential fraud, scientific/research misconduct, privacy incidents/breaches or Clinical Trial-related Significant Quality Issues are reported, such matters are investigated. When necessary, appropriate corrective and/or preventative actions are defined and regulatory authorities and/or ethics review committees are notified.

B. Publication and Authorship

Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of marketed products in which treatment is assigned, according to the pre-specified plans for data analysis. To the extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis-generating rather than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues such as multiplicity.

MSD's policy on authorship is consistent with the recommendations published by the International Committee of Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in publications.

III. Participant Protection

A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics Committee [IEC])

All protocols and protocol amendments will be submitted by MSD for regulatory authority acceptance/authorization prior to implementation of the trial or amendment, in compliance with local and/or national regulations.

The protocol, protocol amendment(s), informed consent form, investigator's brochure, and other relevant trial documents must be reviewed and approved by an IRB/IEC before being implemented at each site, in compliance with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with local and/or national regulations.

B. Safety

The guiding principle in decision-making in clinical trials is that participant welfare is of primary importance. Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial designs will take into account the local standard of care.

All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or receipt of, medical care that may otherwise be available to them.

C. Confidentiality

MSD is committed to safeguarding participant confidentiality, to the greatest extent possible, as well as all applicable data protection rights. Unless required by law, only the investigator, Sponsor (or individuals acting on behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records that might identify the participant by name.

D. Genomic Research

Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an ethics committee.

IV. Financial Considerations

A. Payments to Investigators

Clinical trials are time- and labor-intensive. It is MSD's policy to compensate investigators (or the sponsoring institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be made to compensate for the time spent in extra recruiting efforts.

MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent on chart review and medical evaluation to identify potentially eligible participants.

B. Clinical Research Funding

Informed consent forms will disclose that the trial is sponsored by MSD, and that the investigator or sponsoring institution is being paid or provided a grant for performing the trial. However, the local ethics committee may wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.

C. Funding for Travel and Other Requests

Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be consistent with local guidelines and practices.

V. Investigator Commitment

Investigators will be expected to review MSD's Code of Conduct as an appendix to the trial protocol, and in signing the protocol, agree to support these ethical and scientific standards.

10.1.2 Financial Disclosure

Financial Disclosure requirements are outlined in the US Food and Drug Administration Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the Sponsor's responsibility to determine, based on these regulations, whether a request for Financial Disclosure information is required. It is the investigator's/subinvestigator's responsibility to comply with any such request.

The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to allow for the submission of complete and accurate certification and disclosure statements. The investigator/subinvestigator(s) further agree to provide this information on a Certification/Disclosure Form, commonly known as a financial disclosure form, provided by the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this information to the Sponsor in the United States for these purposes. This may involve the transmission of information to countries that do not have laws protecting personal data.

10.1.3 Data Protection

The Sponsor will conduct this study in compliance with all applicable data protection regulations.

Participants will be assigned a unique identifier by the Sponsor. Any participant records or datasets that are transferred to the Sponsor will contain the identifier only; participant names or any information that would make the participant identifiable will not be transferred.

The participant must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant.

The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

10.1.3.1 Confidentiality of Data

By signing this protocol, the investigator affirms to the Sponsor that information furnished to the investigator by the Sponsor will be maintained in confidence, and such information will be divulged to the IRB, IEC, or similar or expert committee; affiliated institution and employees, only under an appropriate understanding of confidentiality with such board or committee, affiliated institution and employees. Data generated by this study will be considered confidential by the investigator, except to the extent that it is included in a publication as provided in the Publications section of this protocol.

10.1.3.2 Confidentiality of Participant Records

By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to verify worksheet/CRF data. By signing the consent form, the participant agrees to this process. If study documents will be photocopied during the process of verifying worksheet/CRF information, the participant will be identified by unique code only; full names/initials will be masked prior to transmission to the Sponsor.

By signing this protocol, the investigator agrees to treat all participant data used and disclosed in connection with this study in accordance with all applicable privacy laws, rules and regulations.

10.1.3.3 Confidentiality of IRB/IEC Information

The Sponsor is required to record the name and address of each IRB/IEC that reviews and approves this study. The Sponsor is also required to document that each IRB/IEC meets regulatory and ICH GCP requirements by requesting and maintaining records of the names and qualifications of the IRB/IEC members and to make these records available for regulatory agency review upon request by those agencies.

10.1.4 Committees Structure

10.1.4.1 Steering Committee

This study will be conducted in consultation with a Steering Committee. The Steering Committee is comprised of:

- Sponsor personnel,
- Investigators participating in the study, and
- Consulting therapeutic-area experts and clinical trialists.

The Steering Committee will provide guidance on the operational aspects of the study, evaluate recommendations from the DMC, and make recommendations to the EOC.

Specific details regarding responsibilities and governance of the Steering Committee will be described in a separate charter.

10.1.4.2 Executive Oversight Committee

The EOC is comprised of members of Sponsor Senior Management. The EOC will receive and decide on any recommendations made by the DMC or Steering Committee regarding the study.

10.1.4.3 External Data Monitoring Committee

To supplement the routine study monitoring outlined in this protocol, an external DMC will monitor the interim data from this study. The voting members of the committee are external to the Sponsor. The members of the DMC must not be involved with the study in any other way (eg, they cannot be study investigators) and must have no competing interests that could affect their roles with respect to the study.

The DMC will make recommendations to the EOC regarding steps to ensure both participant safety and the continued ethical integrity of the study. Also, the DMC will review interim study results, consider the overall risk and benefit to study participants (Section 9.7) and recommend to the EOC whether the study should continue in accordance with the protocol.

Specific details regarding composition, responsibilities, and governance, including the roles and responsibilities of the various members and the Sponsor protocol team; meeting facilitation; the study governance structure; and requirements for and proper documentation of DMC reports, minutes, and recommendations will be described in the DMC charter that is reviewed and approved by all the DMC members.

10.1.5 Publication Policy

The results of this study may be published or presented at scientific meetings. The Sponsor will comply with the requirements for publication of study results. In accordance with

standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.

If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.

10.1.6 Compliance with Study Registration and Results Posting Requirements

Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the Sponsor of the study is solely responsible for determining whether the study and its results are subject to the requirements for submission to <http://www.clinicaltrials.gov>, www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will review this protocol and submit the information necessary to fulfill these requirements. MSD entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. Information posted will allow participants to identify potentially appropriate studies for their disease conditions and pursue participation by calling a central contact number for further information on appropriate study locations and study site contact information.

By signing this protocol, the investigator acknowledges that the statutory obligations under FDAAA, the EMA clinical trials directive, or other locally mandated registries are that of the Sponsor and agrees not to submit any information about this study or its results to those registries.

10.1.7 Compliance with Law, Audit, and Debarment

By signing this protocol, the investigator agrees to conduct the study in an efficient and diligent manner and in conformance with this protocol; generally accepted standards of GCP (eg, International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use GCP: Consolidated Guideline and other generally accepted standards of GCP); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinical study.

The Code of Conduct, a collection of goals and considerations that govern the ethical and scientific conduct of clinical investigations sponsored by MSD, is provided in this appendix under the Code of Conduct for Clinical Trials.

The investigator agrees not to seek reimbursement from participants, their insurance providers, or from government programs for procedures included as part of the study reimbursed to the investigator by the Sponsor.

The investigator will promptly inform the Sponsor of any regulatory authority inspection conducted for this study.

The investigator agrees to provide the Sponsor with relevant information from inspection observations/findings to allow the Sponsor to assist in responding to any citations resulting from regulatory authority inspection and will provide the Sponsor with a copy of the proposed response for consultation before submission to the regulatory authority.

Persons debarred from conducting or working on clinical studies by any court or regulatory authority will not be allowed to conduct or work on this Sponsor's studies. The investigator will immediately disclose in writing to the Sponsor if any person who is involved in conducting the study is debarred or if any proceeding for debarment is pending or, to the best of the investigator's knowledge, threatened.

10.1.8 Data Quality Assurance

All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator or qualified designee is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

Detailed information regarding Data Management procedures for this protocol will be provided separately.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.

Study documentation will be promptly and fully disclosed to the Sponsor by the investigator upon request and also shall be made available at the study site upon request for inspection, copying, review, and audit at reasonable times by representatives of the Sponsor or any regulatory authorities. The investigator agrees to promptly take any reasonable steps that are requested by the Sponsor or any regulatory authorities as a result of an audit or inspection to cure deficiencies in the study documentation and worksheets/CRFs.

The Sponsor or designee is responsible for the data management of this study including quality checking of the data.

Study monitors will perform ongoing source data review and verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including participants' documented informed consent, pertaining to the conduct of this study must be retained by the investigator for 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the

Sponsor. No records may be transferred to another location or party without written notification to the Sponsor.

10.1.9 Source Documents

Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. The investigator/institution should maintain adequate and accurate source documents and study records that include all pertinent observations on each of the site's participants. Source documents and data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary (eg, via an audit trail). Source documents are filed at the investigator's site.

Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator/institution may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

10.1.10 Study and Site Closure

The Sponsor or its designee may stop the study or study site participation in the study for medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, regulations, and GCP.

In the event the Sponsor prematurely terminates a particular study site, the Sponsor or designee will promptly notify that study site's IRB/IEC as specified by applicable regulatory requirement(s).

10.2 Appendix 2: Clinical Laboratory Tests

- The tests detailed in Table 12 will be performed by the local laboratory.
- Protocol-specific requirements for inclusion or exclusion of participants are detailed in Section 5 of the protocol.
- Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.

Table 12 Protocol-required Safety Laboratory Assessments

Laboratory Assessments	Parameters			
Hematology	Platelet Count	RBC Indices: MCV ^a MCH ^a %Reticulocytes ^a	WBC count with Differential ^b Neutrophils Lymphocytes Monocytes Eosinophils Basophils	
	RBC Count			
	Hemoglobin			
	Hematocrit			
Chemistry	Blood Urea Nitrogen (BUN) ^c	Potassium	Aspartate Aminotransferase (AST)/ Serum Glutamic Oxaloacetic Transaminase (SGOT)	Total bilirubin (and direct bilirubin, if total bilirubin is elevated above the upper limit of normal)
	Albumin	Bicarbonate ^a	Chloride ^a	Phosphorous ^a
	Creatinine ^d	Sodium	Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase (SGPT)	Total Protein
	Glucose	Calcium	Alkaline phosphatase	
	TSH ^e	Free thyroxine (FT4) ^e	Lactate dehydrogenase (LDH)	Amylase
	Lipase	Triiodothyronine (Total T3) ^e		
Routine Urinalysis	<ul style="list-style-type: none"> Specific gravity pH, glucose, protein, blood, ketones, (bilirubin, urobilinogen, nitrite, leukocyte esterase) by dipstick Microscopic examination (if blood or protein is abnormal) 			
Other Screening Tests	<ul style="list-style-type: none"> PT/INR and aPTT/PTT^f Serology (HIV antibody, HBsAg, and hepatitis C virus antibody) NOTE: certain ex-US sites require testing for HIV and hepatitis B and C during screening. Consult with regional health authorities and institutional standards to confirm if such testing is applicable. Follicle-stimulating hormone (as needed in women of nonchildbearing potential only). Highly sensitive serum or urine hCG pregnancy test (as needed for WOCBP). 			

Laboratory Assessments	Parameters
<p>Abbreviations: FT4 = free thyroxine; HBsAg = hepatitis B surface antigen; hCG = human chorionic gonadotropin; HIV = human immunodeficiency virus; INR = international normalized ratio; MCH = mean corpuscular hemoglobin; MCV, mean corpuscular volume; PT = prothrombin time; PTT = partial thromboplastin time; RBC = red blood cells; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; WBC = white blood cell; WOCBP = women of childbearing potential.</p> <p>a. Performed only if considered local standard of care.</p> <p>b. Absolute or % acceptable per institutional standard.</p> <p>c. Urea is acceptable if BUN is not available as per institutional standard.</p> <p>d. Glomerular filtration rate (GFR) (measured or calculated) or creatinine clearance can be used in place of creatinine.</p> <p>e. Participants may be dosed in subsequent cycles after C1D1 while thyroid function tests are pending. Free T3 and free T4 are acceptable.</p> <p>f. Performed as part of the screening assessment and as clinically indicated for participants taking anticoagulants.</p>	

The investigator (or medically qualified designee) must document their review of each laboratory safety report.

10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

10.3.1 Definitions of Medication Error, Misuse, and Abuse

Medication error

This is an unintended failure in the drug treatment process that leads to or has the potential to lead to harm to the patient.

Misuse

This refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the terms of the product information.

Abuse

This corresponds to the persistent or sporadic, intentional excessive use of a medicinal product for a perceived psychological or physiological reward or desired nontherapeutic effect.

10.3.2 Definition of AE

AE definition

- An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
- NOTE: For purposes of AE definition, study intervention (also referred to as Sponsor's product) includes any pharmaceutical product, biological product, vaccine, diagnostic agent, medical device, combination product, or protocol-specified procedure whether investigational or marketed (including placebo, active comparator product, or run-in intervention), manufactured by, licensed by, provided by, or distributed by the Sponsor for human use in this study.

Events meeting the AE definition

- Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator.

- Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition.
- New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.
- Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication.
- For all reports of overdose (whether accidental or intentional) with an associated AE, the AE term should reflect the clinical symptoms or abnormal test result. An overdose without any associated clinical symptoms or abnormal laboratory results is reported using the terminology “accidental or intentional overdose without adverse effect.”
- Any new cancer (that is not a condition of the study). Progression of the cancer under study is not a reportable event. Refer to Section 8.4.6 for additional details.

Events NOT meeting the AE definition

- Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.
- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.
- Surgery planned prior to informed consent to treat a pre-existing condition that has not worsened.
- Refer to Section 8.4.6 for protocol-specific exceptions.

10.3.3 Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met.

An SAE is defined as any untoward medical occurrence that, at any dose:

a. Results in death

b. Is life-threatening

- The term “life-threatening” in the definition of “serious” refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

c. Requires inpatient hospitalization or prolongation of existing hospitalization

- Hospitalization is defined as an inpatient admission, regardless of length of stay, even if the hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not worsened is not an SAE.) A pre-existing condition is a clinical condition that is diagnosed prior to the use of an MSD product and is documented in the participant’s medical history.

d. Results in persistent or significant disability/incapacity

- The term disability means a substantial disruption of a person’s ability to conduct normal life functions.
- This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.

e. Is a congenital anomaly/birth defect

- In offspring of participant taking the product regardless of time to diagnosis.

f. Other important medical events

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the other outcomes listed in the above definition. These events should usually be considered serious.
- Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

10.3.4 Additional Events Reported in the Same Manner as SAE

Additional events that require reporting in the same manner as SAE

In addition to the above criteria, AEs meeting either of the below criteria, although not serious per ICH definition, are reportable to the Sponsor in the same time frame as SAEs to meet certain local requirements. Therefore, these events are considered serious by the Sponsor for collection purposes.

- Is a new cancer (that is not a condition of the study)
- Is associated with an overdose

10.3.5 Recording AE and SAE

AE and SAE recording

- When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to the event.
- The investigator will record all relevant AE/SAE information on the AE CRFs/worksheets at each examination.
- It is not acceptable for the investigator to send photocopies of the participant's medical records to the Sponsor in lieu of completion of the AE CRF page.
- There may be instances when copies of medical records for certain cases are requested by the Sponsor. In this case, all participant identifiers, with the exception of the participant number, will be blinded on the copies of the medical records before submission to the Sponsor.
- The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.

Assessment of intensity/toxicity

- An event is defined as "serious" when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, not when it is rated as severe.
- The investigator will make an assessment of intensity for each AE and SAE (and other reportable safety event) according to the NCI CTCAE, version 5. Any AE that changes CTCAE grade over the course of a given episode will have each change of grade recorded on the AE CRFs/worksheets.
 - Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

- Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.
- Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.
- Grade 4: Life threatening consequences; urgent intervention indicated.
- Grade 5: Death related to AE.

Assessment of causality

- Did the Sponsor's product cause the AE?
- The determination of the likelihood that the Sponsor's product caused the AE will be provided by an investigator who is a qualified physician. The investigator's signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a medically qualified assessment of causality was done. This initialed document must be retained for the required regulatory time frame. The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test product and the AE based upon the available information.
- **The following components are to be used to assess the relationship between the Sponsor's product and the AE; the greater the correlation with the components and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the AE:**
 - **Exposure:** Is there evidence that the participant was actually exposed to the Sponsor's product such as: reliable history, acceptable compliance assessment (pill count, diary, etc), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
 - **Time Course:** Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? Is the time of onset of the AE compatible with a drug-induced effect (applies to studies with investigational medicinal product)?
 - **Likely Cause:** Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmental factors.
 - **Dechallenge:** Was the Sponsor's product discontinued or dose/exposure/frequency reduced?

If yes, did the AE resolve or improve?

If yes, this is a positive dechallenge.

If no, this is a negative dechallenge.

(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improved despite continuation of the Sponsor's product; (3) the study is a single-dose drug study; or (4) Sponsor's product(s) is/are only used 1 time.)

- **Rechallenge:** Was the participant re-exposed to the Sponsor's product in this study?

If yes, did the AE recur or worsen?

If yes, this is a positive rechallenge.

If no, this is a negative rechallenge.

(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the study is a single-dose drug study; or (3) Sponsor's product(s) is/are used only 1 time.)

NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND MAY HAVE BEEN CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE-EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR CLINICAL DIRECTOR AS PER DOSE MODIFICATION GUIDELINES IN THE PROTOCOL, AND IF REQUIRED, THE INIRB/IEC.

- **Consistency with study intervention profile:** Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or drug class pharmacology or toxicology?
- The assessment of relationship will be reported on the case report forms/worksheets by an investigator who is a qualified physician according to his/her best clinical judgment, including consideration of the above elements.
- Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).

- Yes, there is a reasonable possibility of Sponsor's product relationship:

There is evidence of exposure to the Sponsor's product. The temporal sequence of the AE onset relative to the administration of the Sponsor's product is reasonable. The AE is more likely explained by the Sponsor's product than by another cause.

- No, there is not a reasonable possibility of Sponsor's product relationship:

Participant did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor's product is not reasonable OR the AE is more likely explained by another cause than the Sponsor's

product. (Also entered for a participant with overdose without an associated AE.)

- For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality.
- There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the Sponsor. However, it is very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the Sponsor.
- The investigator may change his/her opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.
- The causality assessment is 1 of the criteria used when determining regulatory reporting requirements.
- For studies in which multiple agents are administered as part of a combination regimen, the investigator may attribute each AE causality to the combination regimen or to a single agent of the combination. In general, causality attribution should be assigned to the combination regimen (ie, to all agents in the regimen). However, causality attribution may be assigned to a single agent if in the investigator's opinion, there is sufficient data to support full attribution of the AE to the single agent.

Follow-up of AE and SAE

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.
- New or updated information will be recorded in the CRF.
- The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the information.

10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor

AE, SAE, and other reportable safety event reporting to Sponsor via electronic data collection tool

- The primary mechanism for reporting to the Sponsor will be the EDC tool.
 - Electronic reporting procedures can be found in the EDC data entry guidelines (or equivalent).

- If the electronic system is unavailable for more than 24 hours, then the site will use the paper AE Reporting form.

Reference Section 8.4.1 for reporting time requirements.

- The site will enter the SAE data into the electronic system as soon as it becomes available.
- After the study is completed at a given site, the EDC tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the EDC tool has been taken off-line, then the site can report this information on a paper SAE form or by telephone (see next section).
- Contacts for SAE reporting can be found in the Investigator Study File Binder (or equivalent).

SAE reporting to the Sponsor via paper CRF

- If the EDC tool is not operational, facsimile transmission or secure e-mail of the SAE paper CRF is the preferred method to transmit this information to the Sponsor.
- In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.
- Initial notification via telephone does not replace the need for the investigator to complete and sign the SAE CRF pages within the designated reporting time frames.
- Contacts and instructions for SAE reporting and paper reporting procedures can be found in the Investigator Study File Binder (or equivalent).

10.4 Appendix 4: Medical Device and Drug-device Combination Products: Product Quality Complaints/Malfunctions: Definitions, Recording, and Follow-up

Not applicable.

10.5 Appendix 5: Contraceptive Guidance

10.5.1 Definitions

Women of Childbearing Potential (WOCBP)

A woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below):

If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.

Women in the following categories are not considered WOCBP:

- Premenarchal
- Premenopausal female with 1 of the following:
 - Documented hysterectomy
 - Documented bilateral salpingectomy
 - Documented bilateral oophorectomy

For individuals with permanent infertility due to an alternate medical cause other than the above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

Note: Documentation can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview.

- Postmenopausal female
 - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or HRT. However, in the absence of 12 months of amenorrhea, confirmation with two FSH measurements in the postmenopausal range is required.

- Females on HRT and whose menopausal status is in doubt will be required to use one of the nonhormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

10.5.2 Contraception Requirements

Contraceptives allowed during the study include^a:
Highly Effective Contraceptive Methods That Have Low User Dependency <i>Failure rate of <1% per year when used consistently and correctly.</i>
<ul style="list-style-type: none"> • Progestogen-only subdermal contraceptive implant^{b,c} • IUS^c • Non-hormonal IUD • Bilateral tubal occlusion
<ul style="list-style-type: none"> • Azoospermic partner (vasectomized or secondary to medical cause) This is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. A spermatogenesis cycle is approximately 90 days. Note: Documentation of azoospermia can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview.
Sexual Abstinence
<ul style="list-style-type: none"> • Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
^a Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants of clinical studies. ^b If locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to those which inhibit ovulation. ^c IUS is a progestin releasing IUD.
Note: The following are not acceptable methods of contraception: <ul style="list-style-type: none"> - Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM. - Male condom with cap, diaphragm, or sponge with spermicide. - Male and female condom should not be used together (due to risk of failure with friction).

10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical Research

1. Definitions

- a. Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.¹
- b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as related to drug/vaccine response.²
- c. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of variations in DNA sequence on drug/vaccine response.²
- d. DNA: Deoxyribonucleic acid.
- e. RNA: Ribonucleic acid.

2. Scope of Future Biomedical Research

The specimens consented and/or collected in this study as outlined in Section 8.9 will be used in various experiments to understand:

The biology of how drugs/vaccines work

Biomarkers responsible for how a drug/vaccine enters and is removed by the body

Other pathways with which drugs/vaccines may interact

The biology of disease

The specimen(s) may be used for future assay development and/or drug/vaccine development.

It is now well recognized that information obtained from studying and testing clinical specimens offers unique opportunities to enhance our understanding of how individuals respond to drugs/vaccines, enhance our understanding of human disease and ultimately improve public health through development of novel treatments targeted to populations with the greatest need. All specimens will be used by the Sponsor or those working for or with the Sponsor.

3. Summary of Procedures for Future Biomedical Research

a. Participants for Enrollment

All participants enrolled in the clinical study will be considered for enrollment in future biomedical research.

b. Informed Consent

Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained during screening for protocol enrollment from all participants or legal guardians, at a study visit by the investigator or his or her designate. Informed consent for future biomedical research should be presented to the participants on the visit designated in the SoA. If delayed, present consent at next possible Participant Visit. Consent forms signed by the participant will be kept at the clinical study site under secure storage for regulatory reasons.

A template of each study site's approved informed consent will be stored in the Sponsor's clinical document repository.

c. eCRF Documentation for Future Biomedical Research Specimens

Documentation of participant consent for future biomedical research will be captured in the eCRFs. Any specimens for which such an informed consent cannot be verified will be destroyed.

d. Future Biomedical Research Specimen(s)

Collection of specimens for future biomedical research will be performed as outlined in the SoA. In general, if additional blood specimens are being collected for future biomedical research, these will usually be obtained at a time when the participant is having blood drawn for other study purposes.

4. Confidential Participant Information for Future Biomedical Research

In order to optimize the research that can be conducted with future biomedical research specimens, it is critical to link participants' clinical information with future test results. In fact, little or no research can be conducted without connecting the clinical study data to the specimen. The clinical data allow specific analyses to be conducted. Knowing participant characteristics like sex, age, medical history and intervention outcomes are critical to understanding clinical context of analytical results.

To maintain privacy of information collected from specimens obtained for future biomedical research, the Sponsor has developed secure policies and procedures. All specimens will be single-coded per ICH E15 guidelines as described below.

At the clinical study site, unique codes will be placed on the future biomedical research specimens. This code is a random number which does not contain any personally identifying information embedded within it. The link (or key) between participant identifiers and this unique code will be held at the study site. No personal identifiers will appear on the specimen tube.

5. Biorepository Specimen Usage

Specimens obtained for the Sponsor will be used for analyses using good scientific practices. Analyses utilizing the future biomedical research specimens may be performed by the Sponsor, or an additional third party (eg, a university investigator) designated by the Sponsor. The investigator conducting the analysis will follow the Sponsor's privacy and confidentiality requirements. Any contracted third party analyses will conform to the specific scope of analysis outlined in future biomedical research protocol and consent. Future biomedical research specimens remaining with the third party after specific analysis is performed will be reported to the Sponsor.

6. Withdrawal From Future Biomedical Research

Participants may withdraw their consent for future biomedical research and ask that their biospecimens not be used for future biomedical research. Participants may withdraw consent at any time by contacting the investigator for the main study. If medical records for the main study are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@MSD.com). Subsequently, the participant's specimens will be flagged in the biorepository and restricted to main study use only. If specimens were collected from study participants specifically for future biomedical research, these specimens will be removed from the biorepository and destroyed. Documentation will be sent to the investigator confirming withdrawal and/or destruction, if applicable. It is the responsibility of the investigator to inform the participant of completion of the withdrawal and/or destruction, if applicable. Any analyses in progress at the time of request for withdrawal/destruction or already performed prior to the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received.

In the event that the medical records for the main study are no longer available (eg, if the investigator is no longer required by regulatory authorities to retain the main study records) or the specimens have been completely anonymized, there will no longer be a link between the participant's personal information and their specimens. In this situation, the request for withdrawal of consent and/or destruction cannot be processed.

7. Retention of Specimens

Future biomedical research specimens will be stored in the biorepository for potential analysis for up to 20 years from the end of the main study. Specimens may be stored for longer if a regulatory or governmental authority has active questions that are being answered. In this special circumstance, specimens will be stored until these questions have been adequately addressed.

Specimens from the study site will be shipped to a central laboratory and then shipped to the Sponsor-designated biorepository. If a central laboratory is not utilized in a particular study, the study site will ship directly to the Sponsor-designated biorepository. The specimens will be stored under strict supervision in a limited access facility which

operates to assure the integrity of the specimens. Specimens will be destroyed according to Sponsor policies and procedures and this destruction will be documented in the biorepository database.

8. Data Security

Databases containing specimen information and test results are accessible only to the authorized Sponsor representatives and the designated study administrator research personnel and/or collaborators. Database user authentication is highly secure, and is accomplished using network security policies and practices based on international standards to protect against unauthorized access.

9. Reporting of Future Biomedical Research Data to Participants

No information obtained from exploratory laboratory studies will be reported to the participant, family, or physicians. Principle reasons not to inform or return results to the participant include: Lack of relevance to participant health, limitations of predictive capability, and concerns regarding misinterpretation.

If important research findings are discovered, the Sponsor may publish results, present results in national meetings, and make results accessible on a public website in order to rapidly report this information to doctors and participants. Participants will not be identified by name in any published reports about this study or in any other scientific publication or presentation.

10. Future Biomedical Research Study Population

Every effort will be made to recruit all participants diagnosed and treated on Sponsor clinical studies for future biomedical research.

11. Risks Versus Benefits of Future Biomedical Research

For future biomedical research, risks to the participant have been minimized and are described in the future biomedical research informed consent.

The Sponsor has developed strict security, policies, and procedures to address participant data privacy concerns. Data privacy risks are largely limited to rare situations involving possible breach of confidentiality. In this highly unlikely situation, there is risk that the information, like all medical information, may be misused.

12. Questions

Any questions related to the future biomedical research should be emailed directly to clinical.specimen.management@MSD.com.

13. References

1. National Cancer Institute [Internet]: Available from <https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618>
2. International Council on Harmonisation [Internet]: E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. Available from <http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/definitions-for-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-and-sample-cod.html>
3. Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and Investigational Site Staff. Available at <http://i-pwg.org/>
4. Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at <http://i-pwg.org/>

10.7 Appendix 7: Country-specific Requirements

10.7.1 Argentina-specific Requirements

HBV, HCV, and HIV testing at screening is mandatory.

Section 1.3 Schedule of Activities - Screening and treatment Phase

Pregnancy testing must be performed at each cycle during treatment as well as at the end of study treatment.

Section 1.3 Schedule of Activities - Post-treatment Phase

Monthly urine pregnancy testing is required during study intervention as well as at the end of study intervention.

Section 1.3 Schedule of Activities - Long-term Follow-up Phase

Monthly urine pregnancy testing is required during study intervention as well as at the end of study intervention.

Section 10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing

Pregnancy testing must be performed at each cycle during treatment as well as at the end of study treatment.

10.7.2 France-specific Requirements

Section 1.3 Schedule of Activities

Pregnancy testing must be performed at each cycle during treatment as well as at the end of study treatment.

Section 1.3 Schedule of Activities - Post-treatment Phase

Pregnancy testing must be performed at each cycle during treatment as well as at the end of study treatment.

Section 1.3 Schedule of Activities - Long-term Follow-up Phase

Pregnancy testing must be performed at each cycle during treatment as well as at the end of study treatment.

Section 10.5 Appendix 5: Contraceptive Guidance

Pregnancy testing must be performed at each cycle during treatment as well as at the end of study treatment.

10.7.3 Germany-specific Requirements

Throughout the Protocol

Legally Acceptable Representative

In order for a participant to be eligible to participate in Germany, they must be capable of documenting the informed consent; therefore, all references to a participant's "legally acceptable representative" in the protocol are not applicable for participants in Germany.

Section 1.3 Schedule of Activities

Monthly urine pregnancy testing is required during study intervention as well as at the end of study intervention.

Section 1.3 Schedule of Activities - Post-treatment Phase

Monthly urine pregnancy testing is required during study intervention as well as at the end of study intervention.

Section 1.3 Schedule of Activities - Long-term Follow-up Phase

Monthly urine pregnancy testing is required during study intervention as well as at the end of study intervention.

Section 5.2 Exclusion Criteria

Exclusion Criterion: HIV testing is required for participants.

Exclusion Criterion: hepatitis B and C testing is required for participants.

Section 10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing

Monthly urine pregnancy testing after randomization is required during study intervention as well as at the end of study intervention.

10.8 Appendix 8: Eastern Cooperative Oncology Group Performance Status

Grade	Performance Status
0	Normal activity. Fully active, able to carry on all pre-disease performance without restriction.
1	Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).
2	In bed <50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours.
3	In bed >50% of the time. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
4	100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
5	Dead

[ECOG-ACRIN Cancer Research Group 2016]

10.9 Appendix 9: Abbreviations

Abbreviation	Expanded Term
1L	first-line
2L	second-line
ACCP	American College of Chest Physicians
ADA	antidrug antibodies
ADL	activities of daily living
AE	adverse event
AJCC	American Joint Committee on Cancer
ALK	anaplastic lymphoma kinase
ALT	alanine aminotransferase
APaT	All-Participants-as-Treated
AR	adverse reaction
ART	antiretroviral therapy
AST	aspartate aminotransferase
ATD	accelerated titration design
ATP	adenosine triphosphate
AUC	area under the curve
AxMP	auxiliary medicinal product
BCG	<i>Bacillus Calmette–Guérin</i>
BDS	blood drug screen
BICR	blinded independent central review
BID	twice daily
BMI	body mass index
BP	blood pressure
CAC	Clinical Adjudication Committee
CD28	cluster of differentiation 28
CD3ζ	CD3 zeta
CF	compact flash
CG	Cockcroft-Gault
CHS	cough hypersensitivity syndrome
CI	confidence interval
CNS	central nervous system
CONSORT	Consolidated Standards of Reporting Trials
COPD	chronic obstructive pulmonary disease
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
CL	clearance
CrCl	creatinine clearance
CR	complete response
CRF	Case Report Form
CRU	clinical research unit
CSD	Cough Severity Diary
C-SSRS	Columbia-Suicide Severity Rating Scale
CSR	Clinical Study Report
CT	computed tomography
CTCAE	Common Terminology Criteria for Adverse Events
CTCAE 5.0	Common Terminology Criteria for Adverse Events, Version 5.0
CTFG	Clinical Trial Facilitation Group
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
CXDY	Cycle X, Day Y
DC	discontinuation
DCR	disease control rate

Abbreviation	Expanded Term
DILI	drug-induced liver injury
DLT	dose-limiting toxicity
DMC	Data Monitoring Committee
DNA	deoxyribonucleic acid
DOR	duration of response
DRESS	drug reaction with eosinophilia and systemic symptoms
ECG	electrocardiogram
ECI	event of clinical interest
eCRF	electronic Case Report Form
eCTA	exploratory Clinical Trial Application
ECOG	Eastern Cooperative Oncology Group
EDC	electronic data collection
eDMC	External Data Monitoring Committee
EEA	European Economic Area
EGFR	epidermal growth factor receptor
eGFR	estimated glomerular filtration rate
ELISA	enzyme-linked immunosorbent assay
EMA	European Medicines Agency
EOC	Executive Oversight Committee
EOT	end of treatment
EU CTR	European Union Clinical Trial Regulation
FBR	future biomedical research
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Amendments Act
FEV1	forced expiratory volume in 1 second
FAS	Full Analysis Set
FFPE	formalin-fixed, paraffin embedded
FSH	follicle-stimulating hormone
FSR	First Site Ready
FVC	forced vital capacity
FWER	family-wise error rate
GCP	Good Clinical Practice
G-CSF	granulocyte colony-stimulating factor
GERD	gastroesophageal reflux disease
GI	gastrointestinal
GM-CSF	granulocyte macrophage colony-stimulating factor
Gy	gray
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCG	human chorionic gonadotropin
HCV	Hepatitis C virus
HIV	human immunodeficiency virus
HR	hazard ratio
HRT	hormone replacement therapy
IB	Investigator's Brochure
ICF	Informed Consent Form
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
iCRO	imaging CRO
IEC	Independent Ethics Committee
Ig	immunoglobulin
IgG	immunoglobulin G

Abbreviation	Expanded Term
IgV	immunoglobulin-variable
IHC	immunohistochemistry
IMP	Investigational Medicinal Product
IND	Investigational New Drug
IO	immuno-oncology
irAEs	immune-related AEs
IRB	Institutional Review Board
iRECIST	Response Evaluation Criteria in Solid Tumors 1.1 for immune-based therapeutics
IRT	interactive response technology
ITP	idiopathic thrombocytopenic purpura
ITT	intention-to-treat
IUD	intrauterine device
IUO	Investigational Use Only
IUS	intrauterine hormone-releasing system
IV	intravenous
IVD	in vitro diagnostic
IVRS	interactive voice response system
IWRS	integrated web response system
LAM	lactational amenorrhoea method
LCQ	Leicester Cough Questionnaire
mAb	monoclonal antibody
MAD	maximum administered dose
MDRD	Modification of Diet in Renal Disease
MedDRA	Medical Dictionary for Regulatory Activities
MRI	magnetic resonance imaging
mRNA	messenger RNA
MSI	microsatellite instability
MTD	maximum tolerated dose
mTPI	modified Toxicity Probability Interval
NCCN	National Comprehensive Cancer Network
NCI	National Cancer Institute
NCS	not clinically significant
NEAB	noneosinophilic bronchitis
NK	natural killer
NKT	natural killer T
NSCLC	non-small cell lung cancer
NDA	New Drug Application
NIMP	noninvestigational medicinal product
NOAEL	no observed adverse effect level
NSAID	nonsteroidal anti-inflammatory drug
OR	objective response
ORR	objective response rate
OS	overall survival
OSF	on-site formulation
OTC	over-the-counter
PBPK	physiologically based pharmacokinetics
PD	progressive disease
PD-1	programmed cell death 1
PD-L1	programmed cell death ligand 1
PD-L2	programmed cell death ligand 2
PET	positron emission tomography
PFS	progression-free survival

Abbreviation	Expanded Term
PGIC	Patient Global Impression Change
PK	pharmacokinetic
PKCθ	protein kinase C-theta
po	orally
PopPK	population pharmacokinetics
PP	per protocol
PQC	product quality complaint
PR	partial response
PS	performance status
PT	prothrombin time
PTT	partial thromboplastin time
QXW	every X weeks
QOL	quality of life
QP2	department of quantitative pharmacology and pharmacometrics
RBC	red blood cells
RCC	refractory chronic cough
RECIST	Response Evaluation Criteria in Solid Tumors
RNA	ribonucleic acid
ROS	reactive oxygen species
RP2D	recommended Phase 2 dose
SAC	Scientific Advisory Committee
SAE	serious adverse event
SAP	Statistical Analysis Plan
SD	stable disease
siDMC	Standing Internal Data Monitoring Committee
SIM	Site Imaging Manual
SJS	Stevens-Johnson Syndrome
SNP	single nucleotide polymorphism
SoA	schedule of activities
SOC	standard of care
SUSAR	suspected unexpected serious adverse reaction
T3	triiodothyronine
T4	thyroxine
Teffs	effector T-cells
TEA	treatment eligibility assessment
TEN	toxic epidermal necrolysis
TIGIT	T-cell immunoreceptor
TIL(s)	tumor-infiltrating lymphocyte(s)
TMDD	target-mediated drug disposition
TPS	tumor proportion score
TRAE(s)	treatment-related adverse event(s)
Tregs	regulatory T-cells
TSH	thyroid-stimulating hormone
UACS	upper airway cough syndrome
UCC	unexplained chronic cough
UDS	urine drug screen
Vc	volume of the central compartment
Vd	volume of distribution
VAS	Visual Analog Scale
VS	vital sign
WBC	white blood cell
WPAI	Work Productivity and Activity Impairment

Abbreviation	Expanded Term
WOCBP	woman/women of childbearing potential
ZAP70	zeta-chain-associated protein kinase

11 REFERENCES

- | | | |
|--|---|----------|
| [Arrieta, O., et al 2020] | Arrieta O, Barron F, Ramirez-Tirado LA, Zatarain-Barron ZL, Cardona AF, Diaz-Garcia D, et al. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. JAMA Oncol. In press 2020. | [05GXS8] |
| [Bai,S., et al 2012] | Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 2012;51(2):119-35. | [03T78B] |
| [Borghaei, H., et al 2015] | Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. | [049ZVM] |
| [Brahmer, J., et al 2015] | Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 May 31. [Epub ahead of print]. | [045YX3] |
| [Carlsten, M., et al 2007] | Carlsten M, Bjorkstrom NK, Norell H, Bryceson Y, van Hall T, Baumann BC, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007 Feb 1;67(3):1317-25. | [04GS8V] |
| [Chauvin, J. M., et al 2015] | Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8 ⁺ T cells in melanoma patients. J Clin Invest. 2015 May;125(5):2046-58. | [04GS9H] |
| [Clopper, C. J. and Pearson, E. S. 1934] | Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26(4):404-13. | [03Y75Y] |

[Collignon, O., et al 2020]	Collignon O, Gartner C, Haidich AB, James Hemmings R, Hofner B, Petavy F, et al. Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella, and platform trials. Clin Pharmacol Ther. 2020 May;107(5):1059-67.	[05H03X]
[Dardalhon, V., et al 2005]	Dardalhon V, Schubart AS, Reddy J, Meyers JH, Monney L, Sabatos CA, et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol. 2005 Aug 1;175(3):1558-65.	[04GS9P]
[Dirks, N. L. and Meibohm, B 2010]	Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49(10):633-59.	[058SQX]
[Disis, M. L. 2010]	Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28(29):4531-8.	[058SQL]
[Dostalek,M., et al 2012]	Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 2013;52:83-124.	[03T7LF]
[Dudley, M. E., et al 2005]	Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23(10):2346-57.	[00VMPR]
[ECOG-ACRIN Cancer Research Group 2016]	ECOG-ACRIN Cancer Research Group. ECOG Performance Status [Internet]. Philadelphia: ECOG-ACRIN Cancer Research Group; 2016. Available from: http://ecog-acrin.org/resources/ecog-performance-status .	[04JT28]
[Fossella, F. V., et al 2000]	Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [with Erratum]. J Clin Oncol 2000;18:2354-62.	[00VSVK]

[Freidlin, B., et al 2008]	Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res. 2008 Jul 15;14(14):4368-71.	[05H03V]
[Hanna, N., et al 2004]	Hanna N, Shepherd FA, Fossella FV, Pereira JR, de Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-97.	[00VSVM]
[Hendrikx, J. J. M. A., et al 2017]	Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22:1212-21.	[05JHQC]
[Herbst, R. S., et al 2016]	Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50.	[04F0YP]
[Hirota, T., et al 2005]	Hirota T, Irie K, Okamoto R, Ikeda W, Takai Y. Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway. Oncogene. 2005 Mar 24;24(13):2229-35.	[04GTZL]
[Howard, D. R., et al 2018]	Howard DR, Brown JM, Todd S, Gregory WM. Recommendations on multiple testing adjustment in multi-arm trials with a shared control group. Stat Methods Med Res. 2018;27(5):1513-30.	[05H03W]
[Hunder, N. N., et al 2008]	Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358(25):2698-703.	[00VMPX]
[International Agency for Research on Cancer 2018]	Global Cancer Observatory (GCO): Cancer Today [Internet]. Lyon (France): International Agency for Research on Cancer (IARC). Lung cancer: Globocan 2018; [cited 2019 Jul 11]. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf .	[058VGX]

[Johnston, R. J., et al 2014]	Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. <i>Cancer Cell</i> . 2014 Dec 8;26(6):923-37.	[04GS9T]
[Keizer,R.J., et al 2010]	Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. <i>Clin Pharmacokinet</i> 2010;49(8):493-507.	[03T7M7]
[Levin, S. D., et al 2011]	Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM, et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. <i>Eur J Immunol</i> . 2011 Apr;41(4):902-15.	[04GT88]
[Masson, D., et al 2001]	Masson D, Jarry A, Bauray B, Blanchardie P, Laboisie C, Lustenberger P, et al. Overexpression of the CD155 gene in human colorectal carcinoma. <i>Gut</i> . 2001 Aug;49(2):236-40.	[04GT8L]
[Metro, G., et al 2019]	Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, et al. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 $\geq 50\%$ who progress on first-line immunotherapy: real-world data from a European cohort. <i>J Thorac Dis</i> . 2019 Dec;11(12):4972-81.	[05JHL5]
[Miettinen, O. and Nurminen, M. 1985]	Miettinen O, Nurminen M. Comparative analysis of two rates. <i>Stat Med</i> 1985;4:213-26.	[00VMQY]
[National Cancer Institute 2020]	National Cancer Institute. SEER Cancer Statistics Review 1975-2017: cancer of the lung and bronchus (invasive). Bethesda (MD): National Cancer Institute (NCI); 2020.	[05HV4Z]
[National Cancer Institute 2020]	SEER*Stat [Internet]. Bethesda (MD): National Cancer Institute (NCI). 2020. Cancer stat facts: lung and bronchus cancer; [about 18 screens]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html .	[05HV55]

[National Comprehensive Cancer Network 2018]	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer: version 2.2018. Fort Washington, PA: National Comprehensive Cancer Network (NCCN); 2018.	[04V655]
[Niu, J., et al 2020]	Niu J, Nagrial A, Voskoboynik M, Chung HC, Lee DH, Ahn MJ, et al. Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC [abstract]. To be presented at: European Society for Medical Oncology (ESMO) Congress; 2020 Sep 18-22; Madrid (Spain).	[05HXB3]
[Rittmeyer, A., et al 2017]	Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-265.	[04P9V8]
[Shepherd, F. A., et al 2000]	Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.	[00VSVR]
[Soriani, A., et al 2009]	Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Galleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009 Apr 9;113(15):3503-11.	[04GT8W]
[Stanietsky, N., et al 2009]	Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63.	[04GTYX]
[Stanietsky, N., et al 2013]	Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol. 2013 Aug;43(8):2138-50.	[04GTZD]

[Sulpher, J. A., et al 2013]	Sulpher JA, Owen SP, Hon H, Tobros K, Shepherd FA, Sabri E, et al. Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma. Clin Lung Cancer. 2013 May;14(3):238- 44.	[040565]
---------------------------------	--	----------